

AD _____

Award Number: DAMD17-96-C-6093

TITLE: Hormonal Contraception, Body Water Balance and
Thermoregulation

PRINCIPAL INVESTIGATOR: Nina Stachenfeld, Ph.D.

CONTRACTING ORGANIZATION: The John B Pierce Laboratory
New Haven, Connecticut 06519

REPORT DATE: October 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010216 128

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 2000	3. REPORT TYPE AND DATES COVERED Annual (15 Sep 99 - 14 Sep 00)	
4. TITLE AND SUBTITLE Hormonal Contraception, Body Water Balance and Thermoregulation			5. FUNDING NUMBERS DAMD17-96-C-6093	
6. AUTHOR(S) Nina Stachenfeld, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The John B Pierce Laboratory New Haven, Connecticut 06519 E-MAIL: nstach@jbpierce.org			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) To test the hypothesis that estrogen enhances water and sodium retention, we compared the fluid regulatory responses to 150 min of exercise-induced dehydration, followed by 180 min of <i>ad libitum</i> drinking during the follicular and luteal phases of the menstrual cycle, and following treatment with an estrogen/progestin (OC EP) and a progestin-only (OC P) oral contraceptive in a double-blind, randomized, cross-over design. We found a downward shift in osmotic regulation of arginine vasopressin (AVP) during the luteal phase and OC EP compared to the follicular phase during exercise, which was not accompanied by plasma volume expansion or fluid retention. Overall fluid and electrolyte balance was similar across all trials. We also determined that the variability of the fluid regulatory hormones (renin, aldosterone and atrial natriuretic peptide) was high over the course of two menstrual cycles, but slopes and intercepts defining osmotic regulation of AVP were highly reliable. We also determined the estrogen and progesterone effects on thermoregulation. OC P increased core temperature and delayed the onset of sweating during exercise, but that OC E+P blocks these effects. This indicates that estrogen blocks the progestin-related changes in thermoregulation. We also found that all of these effects were independent of changes in plasma volume. In our third protocol, we have found that osmotic regulation of thirst is reduced in the luteal phase compared to the follicular phase and to men, without any effects of OC P or OC EP. Fluid balance was unaffected by phase or OCs. We have not completed analysis of the AVP at this point.				
14. SUBJECT TERMS Womens Health, estrogen, progesterone, body fluid regulation, thermoregulation, sodium regulation, ANP, AVP, PRA, aldosterone			15. NUMBER OF PAGES 138	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

TABLE OF CONTENTS

	<i>Page Numbers</i>
Front Cover	
Report Documentation Page	i
Table of Contents	ii
Introduction	1
Protocol A: Sex Hormone Effects on Body Water Regulation during Dehydration and Rehydration	
Introduction.....	1-2
Methods.....	2-6
Results & Discussion	6-12
Conclusions.....	12-13
Protocol A: Reliability of fluid regulation hormones	
Introduction.....	14
Methods.....	14-15
Results.....	15
Conclusions.....	15-16
Responses to technical issues regarding Progress Report from 1997 (9/15/96-9/14/97)	17
Protocol B:	
Sex Hormone Effects on Thermoregulation during Exercise in the Heat	18
Methods.....	19-22
Results (subject characteristics) & Discussion	22-26
Responses to comments regarding Progress Report from 1998 (9/15/97-9/14/98)	27-28
Protocol C:	
Sex Hormone Effects on Osmotic Regulation of Thirst and Arginine Vasopressin	29-30
Methods.....	30-34
Results (preliminary) & Discussion	34-39
(Men, preliminary)	40-42
Responses to comments regarding Progress Report from 1999 (9/15/99-9/14/00)	42
Text to Tables.....	43-46
Text to Figures	47-50
Key Research Accomplishments.....	51
Reportable Outcomes.....	52-53
Conclusions	54
References	55-62
Appendix A.....	63
(Tables 1-22).....	64-86
Appendix B.....	87
(Figures 2-20,22-27)	88-112

INTRODUCTION

Methods to regulate and suppress menstruation and provide contraception are needed as women take more active roles in the military. The administration of estrogen and progestin combinations in the form of the oral contraceptive pill has been proposed as a method to regulate menstruation in women during combat and field situations.

Alternatively, some contraceptive pills provide progestins only and contain no estrogen. Combined oral contraceptive pills contain synthetic estrogens, which exhibit 6-10 times the estrogenic activity provided by endogenous, circulating estrogens. Progestin-only pills not only contain no estrogen, but the unopposed progestin tends to down-regulate estrogen receptors. Thus, these two widely used oral contraceptive preparations differ significantly in their estrogenicity. Estrogens have potent effects on the regulation of body water balance (2, 9), so these two forms of oral contraceptive pills may differ in their effects on water regulation, and hence on physical performance under adverse environmental conditions.

Protocol A: Sex Hormone Effects on Body Water Regulation during Dehydration and Rehydration.

Sex hormone administration is accompanied by significant water and sodium retention (2, 9), which leads to plasma volume expansion (6, 8, 106, 115). In fact, variations in plasma volume at rest and during exercise that are observed following estrogen administration and during different phases of the menstrual cycle are comparable to the reported effects of posture, skin temperature and exercise intensity (43). Bilateral oophorectomy results in a 25% loss of blood volume and replacement of estrogen restores blood volume (37). Oral contraceptive agents, which deliver pharmacological levels of estrogens, increase total body water (9). Fortney et al. (34) demonstrated an attenuation of the blood volume loss associated with bed rest following estrogen (premarin) administration. Some investigators have shown that plasma volume is higher during the follicular phase, when estrogen levels are rising (95, 96).

The mechanism underlying the estrogen-mediated body water retention is unclear, but may be due to alterations in the release of arginine vasopressin (8, 16). No study has addressed the impact of sex hormone administration on body fluid restoration following dehydration, but arginine vasopressin measured during controlled rehydration returns to pre-dehydration levels more slowly in women (follicular phase) compared to men (89). This slower restoration of arginine vasopressin is associated with greater fluid retention in women suggesting the renal response to arginine vasopressin is unaffected by estrogen. These data also suggest a role for estrogen in the recovery of arginine vasopressin following dehydration. Prior to the present experimental series, no studies had evaluated systematically the impact of variable estrogen doses found in oral contraceptive pills on fluid regulation in women.

Our study was designed to test the hypothesis that oral contraceptive pills containing estrogen increase the thirst and arginine vasopressin response to plasma osmolality and plasma volume alterations during progressive dehydration to a greater degree than progestin-only pills. We expected that this increase in osmotic sensitivity

would result in enhanced fluid intake and water retention during a subsequent *ad libitum* rehydration period.

In addition to the changes in arginine vasopressin, plasma concentrations of the sodium and water retention hormones, renin and aldosterone, increase during pregnancy (84), during estrogen-dominant oral contraception (9, 114) and during ovarian stimulation (84). Elevations in plasma estrogen concentration increase sodium retention (2, 88), due either to changes in body sodium distribution (2, 9), renal sodium reabsorption (21), or renin and aldosterone actions (84). During the mid-luteal phase of the menstrual cycle however, PRA and aldosterone increase only when ovulation occurs (63), indicating that a functioning corpus luteum (and the progesterone it secretes) is necessary to augment the renin-angiotensin-aldosterone system. In young, cycling women, the mid-luteal phase increase in endogenous progesterone is accompanied by an increase in estrogen, which may enhance the progesterone effect on the renin-aldosterone system (84).

The impact of estrogen on the renin-aldosterone system and sodium regulation has not been studied during dehydration, a condition in which both sodium and water retention systems are stimulated. In this study, we used a dehydration-rehydration protocol during combined (estradiol and progestin) or progestin-only oral contraceptive pills in order to distinguish specific estrogen effects on the sodium regulating hormones. The synthetic progestin, norethindrone, does not possess antimineralocorticoid properties (112), and the progestin-only pills contain no estrogen, which down-regulates estrogen receptors. Thus, these two oral contraceptive preparations differ significantly in their estrogenicity, and as such, may differ in their effects on sodium and water regulation. We hypothesized that the estradiol contained in combined oral contraceptive pills would slow the rate of electrolyte loss during dehydrating exercise, and enhance fluid and sodium retention during rehydration relative to control (follicular and luteal phase), and progestin-only pills. We further hypothesized that the greater fluid and sodium retention would be related to an estrogen-mediated stimulation of the renin-aldosterone system.

METHODS

Study design:

Ten women volunteered to participate in the dehydration experiments. Subjects were non-smoking, healthy women, ages 21-31, with no contraindications to oral contraceptive use. All subjects were interviewed about their medical history, and had medical and gynecological examinations before admission to the study. During the month preceding the first dehydration/rehydration exposure, blood volume was determined by Evan's Blue dye dilution (procedures are described below). On the same day, following the blood volume assessment, maximal oxygen consumption (VO_{2peak}) was determined with an automated metabolic cart (Sensor Medics Corp, Yorba Linda, CA). The preliminary tests were all conducted in the follicular phase of the menstrual cycle.

Each woman served as her own control. Upon entering the study, the subjects were assigned (double-blind) to undergo experimental testing after four weeks of either continuous combined (estrogen/progestin) or progestin-only treatment (Fig.1). After

completing the studies on one treatment protocol, subjects crossed over to the other treatment following a 4-week "washout" period.




Figure 1. Oral contraception administration protocol

For estrogen/progestin combined treatment (OC E+P), subjects received 0.035 mg of ethinyl estradiol and 1 mg of the progestin norethindrone daily. For progestin-only treatment (OC P), subjects received norethindrone, 1 mg/day. All studies were begun within 2 hours of the daily pill ingestion when peak serum hormone levels occur (12).

Because sex hormones vary across the menstrual cycle, some variation in the dependent variables over the course of the menstrual cycle may exist. Therefore, the study design employed two dehydration baseline studies, carried out in the early-follicular phase (2-5 days after the beginning of menstrual bleeding) and mid-luteal phase of the menstrual cycle in the month preceding each oral contraception treatment. The two control tests were completed during the month before each 28-day pill treatment (Fig 1). The luteal phase was determined individually by the use of ovulation prediction kits (OvuQuick, Quidel Corp, San Diego, CA) that accurately identify the luteinizing hormone peak. To verify phase of the menstrual cycle, plasma levels of estrogen and progesterone were assessed from the control (pre-exercise) blood sample.

Dehydration experiments

Volunteers arrived at the laboratory between 7:00 - 8:00 am, after having eaten only a prescribed low fat breakfast (~ 300 kcal). The subjects refrained from alcohol and caffeine for 12 h prior to the experiment. Blood volumes were unmanipulated prior to each of the experiments, although subjects were well hydrated by drinking 7 ml/kg body weight of tap water at home before arrival at the laboratory. Upon arriving at the laboratory, the subjects gave a baseline urine sample, were weighed to the nearest 10 g on a beam balance and then sat on the contour chair of a cycle ergometer in the test chamber (27°C, 30% rh) for 60 min of control rest. During the control period, an indwelling catheter was placed in an arm vein. Electrodes and blood pressure cuff were placed and resting blood pressure (Colin Medical Instruments Corp, Komaki, Japan) and heart rate (EKG) were recorded at the end of the 60 min control period. At the end of the control period, a (20 ml) blood sample was drawn, control thirst tests (see below) were administered and

urine was collected. Hydration state was assessed from the specific gravity of the control (pre-exercise) urine sample (mean = 1.001).

Dehydration protocol

We have modified a Monark cycle ergometer by placement of an adjustable contour seat behind the pedals so that the subject was seated with legs nearly in a horizontal position. The exercise intensity was adjusted by changing the tension on the flywheel, and was normalized to each subject as determined by her individual $\text{VO}_{2\text{peak}}$ test.

Following the control period, the chamber temperature was increased to 35°C. The subjects exercised at 50% maximal power output without fluids for 150 min, with 5 min rest periods every 25 min. Blood samples (10-20 ml) were drawn immediately prior to the rest periods at 60, 120 and 150 min during exercise. Thirst ratings were also assessed immediately prior to rest periods at 30, 60, 90, 120 and 150 min of cycling. During exercise, sealed absorbent patches (Sudormed, Santa Anna, California) were placed on the thigh, forearm, chest, back and forehead for 20-40 min periods for sweat collection. The sweat patch consisted of 4.7 x 3.1 cm filter paper, sealed and affixed to the skin with tegaderm. The area used for the patch was cleaned with deionized water prior to placement and wiped with a clean dry towel. After sampling, the patches were transferred to plastic screw-capped bottles. Local sweat rate was determined by patch weight increase (to 0.0001 g) from the dry weight per min on the skin. The fluid in the patches was collected by centrifugation with nylon MicroFuge centrifuge filter tubes and analyzed for sodium and potassium concentrations. Heart rate and blood pressure were assessed every 10 min throughout exercise. Body weight was determined at 60, 120 and 150 min of exercise, and urine samples were collected at the end of exercise. At the end of exercise, the chamber temperature was reduced to 27° C for the 3.5 h recovery period.

Following dehydration, volunteers rested for 30 min in a contour chair without access to fluids to allow the body fluid compartments to stabilize, after which the subjects drank water *ad libitum* for 180 min. Heart rate and blood pressure were assessed every 10 min throughout stabilization and rehydration. Blood (10 ml) was sampled during the early period of rehydration (just prior to drinking, at 15 min of drinking) and at 30, 60, 120 and 180 min of rehydration (20 ml). Urine samples were collected at each 60 min of rehydration and body weight was measured every 60 min of rehydration.

All blood samples were analyzed for hematocrit, hemoglobin, total protein, osmolality, and the concentrations of creatinine, glucose, urea, sodium, potassium, and arginine vasopressin. The control and final blood samples were analyzed for 17-β-estradiol and progesterone. Blood samples at control, 60, 120 and 150 min of dehydration and at 0, 30, 60, 120 and 180 min of *ad libitum* drinking were also analyzed for the concentration of atrial natriuretic peptide, aldosterone, and plasma renin activity. All urine samples were analyzed for volume, osmolality, and sodium, potassium, and creatinine concentrations.

Blood sampling

All blood sampling was done via a 19 gauge Intracath catheter placed in an arm vein. Subjects were semi-recumbent during placement of the catheter and were seated for 60 min prior to sampling to ensure a steady state in plasma volume and constituents. Blood

samples were separated immediately into aliquots. The first was analyzed for hemoglobin and hematocrit. A second aliquot was transferred to a heparinized tube, and a third aliquot for the determination of serum sodium and potassium concentrations was placed into a tube without anticoagulant. All other aliquots were placed in tubes containing EDTA. The tubes were centrifuged and the plasma taken off the heparinized sample analyzed for sodium, potassium, osmolality, glucose, urea, creatinine and aldosterone. The EDTA samples were analyzed for concentrations of arginine vasopressin and atrial natriuretic peptide and plasma renin activity.

Blood volume

Absolute blood volume was measured by dilution of a known amount of Evan's blue dye. This technique involves injection of an accurately determined volume of dye (by weight, since the specific density is 1.0) into an arm vein and taking blood samples for determination of dilution after complete mixing has occurred (10, 20 and 30 min). Plasma volume was determined from the product of the concentration and volume of dye injected, divided by the concentration in plasma after mixing, taking into account 1.5% lost from the circulation within the 10 min. Blood volume is calculated from plasma volume and hematocrit concentration corrected for peripheral sampling.

Thirst ratings

The perception of thirst was assessed by asking the subject to make a mark on a line rating scale in response to the question 'How thirsty do you feel now?' The line is 175 mm in length and is marked 'not at all' on one end and 'extremely thirsty' at the 125 mm point. We tell subjects that they can mark beyond the 'extremely thirsty' point if they wish and may even extend the line if they feel it necessary. This method was developed by Marks et al. (62) and has been used with great success in the evaluation of several sensory systems.

Calculations

Total water loss due to dehydration was determined from body weight loss. Net fluid gain during rehydration was calculated by subtracting total urine loss from water intake, assuming that respiratory and sweat losses were negligible in the 27°C recovery condition. Electrolyte losses in sweat and urine during dehydration were calculated by multiplying the volume of water loss by the concentration of electrolyte in each fluid. Whole body sweat electrolyte concentration was calculated from sweat rate, local electrolyte concentration and body surface area using the following equation:

$$[E]_m = (0.07[E]_{fh}SR_{fh} + 0.36[E]_{tr}SR_{tr} + 0.13[E]_{fa}SR_{fa} + 0.32[E]_{th}SR_{th}) / (0.07SR_{fh} + 0.36SR_{tr} + 0.13SR_{fa} + 0.32SR_{th}) \quad (105)$$

where the subscripts m, fh, tr, fa and th are whole body mean, forehead, trunk, forearm and thigh; [E] is electrolyte concentration (sodium or potassium, mEq/l), and SR is local sweat rate ($\text{mg} \cdot \text{min}^{-1} \cdot \text{cm}^{-2}$); and the constants 0.07, 0.36, 0.13 and 0.32 represent the percent distribution of body surface in the head, trunk, arms and legs, respectively. Total electrolyte loss from sweat was calculated by multiplying $[E]_m$ and total body sweat loss,

calculated from the change in body weight during exercise. Electrolyte losses during rehydration were calculated by multiplying the volume of water loss by the concentration of electrolytes in the urine.

Changes in plasma volume were estimated from changes in hematocrit (hct) and hemoglobin (Hb) concentrations from the control (pre-exercise) sample according to the equation:

$$\% \Delta PV = 100 \left[\frac{[(Hb_b)/(Hb_a)][(1-hct_a \cdot 10^{-2})]}{[(1-hct_b \cdot 10^{-2})]} \right] - 100$$

where subscripts a and b denote measurements at time a and control, respectively. Hemoglobin was measured in triplicate by the cyanomethemoglobin technique and hematocrit in triplicate by the microhematocrit method.

Fractional excretions of water (FE_{H_2O}) and Na^+ (FE_{Na^+}) were calculated from the following equations:

$$FE_{H_2O} = (U_v/GFR) \cdot 100$$

$$FE_{Na^+} = (U_v \cdot [Na^+]_u / GFR \cdot [Na^+]_f) \cdot 100$$

$$[Na^+]_f = \text{the Donnan factor for cations } (0.95) \cdot [Na^+]_s$$

where the subscripts f and u are glomerular filtrate and urine respectively, U_v is urine flow rate, and $[Na^+]_s$ is $[Na^+]_s$ in protein-free solution (mEq/kg H_2O). Glomerular filtration rate (GFR) was estimated from creatinine clearance.

Blood analysis:

Plasma, sweat and urine sodium and potassium were measured by flame photometry (Instrumentation Laboratory model 943), plasma osmolality by freezing point depression (Advanced Instruments 3DII), and plasma proteins by refractometry. Plasma glucose, urea and creatinine concentrations were determined by colorimetric assay (Sigma Diagnostic Products). Plasma renin activity (PRA), plasma concentrations of aldosterone ($P_{[ALD]}$), atrial natriuretic peptide ($P_{[ANP]}$), arginine vasopressin ($P_{[AVP]}$), 17- β -estradiol ($P_{[E_2]}$) and progesterone ($P_{[P_4]}$) are measured by radioimmunoassay. Intra- and inter-assay coefficients of variation for the mid-range standard for AVP (4.52 pg/ml) were 6.0 % and 3.4 % (Immuno Biological Laboratories (IBL), Hamburg, Germany), for 17 β -estradiol (64.3 pg/ml) were 3.7 % and 4.0 % (Diagnostic Products, Los Angeles, CA), and for progesterone (3.7 pg/ml) were 2.1 % and 2.5 % (Diagnostic Products). The assay for AVP has a sensitivity of 0.8 pg/ml, which is necessary to detect small, but important, changes in this hormone.

RESULTS

Combined oral contraceptive administration caused severe nausea in one woman, and she did not complete dehydration testing while on this pill, so all of her control data for OC E+P have also been excluded. In addition, one subject dropped out for personal reasons after completing two of the control tests, so all of her data were excluded from the analysis. This analysis compares the dehydration test responses of 9 women on OC P with their two

control tests and 8 women on OC E+P with their control tests. There were no other significant adverse effects of oral contraceptive administration in any of the subjects.

Baseline (Pre-exercise). Pre-exercise body weight was similar for both phases of the menstrual cycle, and sex hormone administration (Table 1). Furthermore, $P_{[E_2]}$ and $P_{[P_4]}$ demonstrate that the subjects were tested in the early follicular phase and mid-luteal phase of the menstrual cycle during both trials. Finally, oral contraceptive administration suppressed the endogenous production of 17 β -estradiol and progesterone (Table 1).

Plasma osmolality was lower in both the luteal phase and following one month of OC E+P and OC P compared to the follicular phase (Fig. 2). Plasma glucose and urea concentrations were unaffected by menstrual phase or either oral contraceptive pill, indicating that the lower P_{Osm} was due to lower $S_{[Na^+]}$ (Table 2). Pre-exercise $P_{[AVP]}$ and thirst were unaffected by phase of the menstrual cycle or by oral contraceptive administration (Tables 3 & 4). Hematocrit and [Hb] were elevated during the luteal phase (Table 3), indicating a contraction of plasma volume when compared to the follicular phase (-7.8 ± 2.6 %) and OC E+P (-8.0 ± 3.4 %) and OC P (-5.7 ± 1.6 %). Combined oral contraceptive pills increased plasma volume only slightly (3.2 ± 2.1 %) and OC P did not change plasma volume (-2.3 ± 2.5 %) compared to the follicular phase. There was no effect of menstrual phase or oral contraceptive treatment on plasma protein concentration (Table 3).

Basal PRA and $P_{[ALD]}$ were elevated in both luteal phase tests compared to the follicular phase tests and to the OC E+P and OC P tests (Figs 3 & 4, $P < 0.05$). In contrast, $P_{[ANP]}$ was greatest at baseline in the follicular phase tests and in the OC E+P test (Fig. 5). There were no differences between the OC E+P and OC P tests in PRA, $P_{[ALD]}$ or $P_{[ANP]}$ at baseline. Pre-exercise urine flow, GFR, free water and osmolar clearances and renal electrolyte excretion were similar within subjects prior to each exercise test (Tables 5 & 6).

Heart rate and blood pressure were similar at baseline and dehydration within the follicular and luteal phase tests so the combined mean of the two series is given for the baseline values and for the dehydration tests. Baseline heart rate and mean blood pressure were unaffected by menstrual phase or by oral contraceptive treatment (Tables 7A and 7B).

Exercise. At the end of 150 min of exercise at 35°C, the women lost the same amount of body water through sweating in the early follicular phase (1.5 ± 0.2 and 1.5 ± 0.1 kg), the mid-luteal phase tests (1.4 ± 0.1 and 1.4 ± 0.1 kg), the OC E+P test (1.5 ± 0.1 kg) and the OC P test (1.3 ± 0.1 kg). Heart rate increased to similar levels during dehydrating exercise in the follicular and luteal phase tests and during the OC P test, but this increase was attenuated during the OC E+P test (Tables 7A and 7B). Mean blood pressure did not change during dehydration in any of the experimental conditions.

Exercise increased P_{Osm} and $P_{[AVP]}$, and decreased plasma volume similarly during the follicular and luteal phases, and during OC E+P and OC P (Fig. 2 & Table 3). Linear regression analysis of the individual subjects' data during dehydration indicated significant correlations between $P_{[AVP]}$ and P_{Osm} , with r values ranging from 0.82 to 0.98. The abscissal-intercepts of the linear $P_{[AVP]}$ - P_{Osm} relationship, or "theoretical osmotic threshold" for AVP release, was significantly lower in the mid-luteal phase and OC E+P than in the follicular phase (Table 1, $P < 0.05$). The slopes of this relationship were

unaffected by menstrual phase or oral contraceptive pills. Figure 6 shows the downward shift in the linear $P_{[AVP]}-P_{Osm}$ relationships during OC E+P and when $P_{[E_2]}$ and $P_{[P_4]}$ were increased during the luteal phase.

The data in Table 4 indicate that thirst increased similarly during dehydration in all conditions. Linear regression analysis of the individual subjects' P_{Osm} and thirst responses indicated significant correlations, with r values ranging from 0.73 to 0.99. Osmotic thirst stimulation was unaffected by menstrual phase and there were no effects of oral contraceptives on the slope or abscissal intercept of this relationship (Table 1).

Plasma renin activity, $P_{[ALD]}$ and $P_{[ANP]}$ increased during exercise in all conditions, with luteal phase values for PRA and $P_{[ALD]}$ remaining above the follicular phase, OC E+P and OC P (Figs. 3 & 4). For $P_{[ANP]}$, neither menstrual phase nor oral contraceptive treatment affected the magnitude of the exercise-induced increases (Fig. 5). Sweat sodium loss was greatest during exercise in the follicular phase tests (56.3 ± 7.0 and 59.4 ± 9.2 mEq, $P < 0.05$), but was similar between the luteal phase tests (45.2 ± 9.1 and 46.5 ± 7.8 mEq) compared to the OC E+P (47.1 ± 10.7 mEq) or OC P (46.7 ± 8.8 mEq) tests. Sweat potassium loss was unaffected by menstrual phase or oral contraception administration (5.32 ± 0.71 , 5.92 ± 0.59 and 5.35 ± 0.42 mEq for follicular and luteal phase tests and the OC E+P test, respectively) and (5.42 ± 0.57 , 4.47 ± 0.39 and 4.86 ± 0.62 , for follicular and luteal phase tests, and the OC P test, respectively). Renal sodium excretion increased during exercise in all conditions, and this increase was greatest during the follicular phase tests (Table 6, $P < 0.05$). The cumulative sodium (sweat + urine) loss was greatest during the follicular phase tests compared to the luteal phase tests, and the OC E+P and OC P tests (Fig. 7).

Rehydration. *Ad libitum* fluid intake was similar by the end of the 180 min of rehydration on all six experimental test days (Fig 8). At 180 min of *ad libitum* drinking, subjects had restored 41 ± 5 and 40 ± 10 % (follicular phase), 42 ± 7 and 39 ± 6 % (luteal phase), 38 ± 11 % (OC E+P) and 39 ± 7 % (OC P) lost during dehydration. Plasma osmolality was higher throughout the rehydration period in the follicular phase compared to the luteal phase, OC E+P and OC P tests (Fig. 2). Recovery of $P_{[AVP]}$ and thirst was rapid following the beginning of *ad libitum* drinking, and similar during all rehydration tests (Tables 3 & 4).

For the entire rehydration period, area under the curve for PRA (Fig. 3) was lower during the follicular phase tests ($P < 0.05$) compared to the luteal phase tests and the OC E+P test. Area under the curve for $P_{[ALD]}$ (Fig. 4) was significantly greater in the luteal phase tests compared to the follicular phase tests, and compared to the OC P test ($P < 0.05$). There were no effects of oral contraceptives or menstrual phase on $P_{[ANP]}$ during rehydration (Fig. 5).

Urine flow and renal free water clearance were lower at the end of drinking during OC E+P than in both the follicular and the luteal phase tests (Table 6, $P < 0.05$). Cumulative urine loss was greatest (Fig 8, $P < 0.05$) during the follicular phase relative to the other conditions, although overall fluid balance (i.e. fluid intake - urine output) was unaffected by either phase of the menstrual cycle or oral contraceptive administration. During rehydration, electrolyte excretion was unaffected by menstrual phase or oral

contraceptive administration (Table 6). However, because of the greater exercise sodium excretion during the follicular phase, cumulative sodium loss (exercise + rehydration) was greatest during the follicular phase (Fig. 7).

DISCUSSION

Osmotic regulation of AVP and fluid balance

We found that normally cycling young women have a reduction in the osmotic threshold for AVP release during the mid-luteal phase of the menstrual cycle (i.e. when estrogen and progesterone peak). Further, the osmotic threshold for AVP release is lowered during administration of oral contraceptives containing estrogen, but this reduction in threshold did not occur during progestin-only oral contraceptive use. Previously it was demonstrated that estrogen and progesterone upregulate thirst and AVP responses to an osmotic drive (28, 111), but the upregulation could not be attributed to specific estrogen or progesterone effects. Our data extend these early findings by demonstrating a reduction in the P_{Osm} threshold for AVP release during estrogen-containing oral contraception administration. This threshold shift did not occur when the oral contraceptive contained only progestin, implicating estrogen as the hormone mediating the changes in AVP regulation. Because the water intake during the rehydration phase was similar in all our studies, regardless of menstrual phase or oral contraceptive treatment, we are able to conclude that an elevated circulating estrogen alters the body tonicity around which the body regulates fluids.

Estrogen most likely modulates osmotic AVP regulation via its action within the central nervous system due to the fact that it readily crosses the blood-brain barrier. Studies in animals have demonstrated that estrogen acts directly on estrogen-binding neurons in the hypothalamus (3, 8, 25, 80), thereby affecting synthesis and release of AVP. Estradiol receptors have been identified in the nuclei of neurophysin- and AVP-producing cells in the mouse supraoptic nucleus (80), and osmotic stimulation of vasopressinergic neuronal activity is upregulated by estrogen in the supraoptic nucleus of brain slices of ovariectomized rats (8). Estrogen may also modulate hypothalamic AVP release indirectly through catecholaminergic (46) and/or angiotensinergic (100) neurons, which bind estrogen and project to the paraventricular and supraoptic nuclei. Using [3H]-labeled estradiol, Heritage et al. (46) identified estradiol binding sites in the nuclei of catecholamine neuronal systems, as well as the presence of catecholamine nerve terminals surrounding estradiol target sites in the paraventricular and supraoptic nuclei. Crowley et al. (26) noted parallel changes in brain norepinephrine and AVP in normally cycling rats, and that ovarian steroids modulated norepinephrine turnover in the paraventricular nucleus, indicating that estrogen may act on the osmoregulatory system through catecholamines. There also is evidence for cholinergic and angiotensinergic innervation of vasopressinergic cells in the paraventricular and supraoptic nuclei, both of which are modulated by sex steroids (100).

Peripheral mechanisms for the estrogen effect on osmotic stimulation of AVP are unlikely to participate in the response. For example, plasma volume reduction, such as that which occurred during the mid-luteal phase, could have contributed to the lower P_{Osm} threshold for AVP release because plasma volume is a potent AVP stimulus. However, this mechanism seems unlikely because the luteal phase-plasma volume contraction was not associated with a fall in blood pressure. Further, AVP was also upregulated during OC E+P administration, during which changes in pre-dehydration plasma volume did not occur. Atrial natriuretic peptide has also been shown to suppress the osmotically induced rise in AVP (22) but the follicular phase and OC E+P were both associated with greater plasma atrial natriuretic peptide levels, and had vastly different vasopressin responses.

Despite the lower osmotic threshold for AVP, there were no changes in water intake, which matched urine output, indicating a new set point for fluid regulation in the presence of high plasma estrogen levels. In addition to reducing the osmotic threshold for AVP release, estrogen may alter the renal sensitivity to AVP by attenuating renal antidiuretic activity. There is evidence that estrogen modulates AVP action in the rat collecting duct (26) at the receptor level (103). Our observation that the greater osmotic secretion of AVP in the mid-luteal phase of the menstrual cycle was not accompanied by increased water retention is consistent with these findings. In contrast, we also found that renal CH_2O was reduced during combined estrogen and progesterone administration despite similar $P_{[AVP]}$. Moreover, estrogen administration to postmenopausal women has been shown to increase renal concentrating response (U_{Osm}/P_{Osm}) to hypertonic saline infusion, despite similar $P_{[AVP]}$ responses (88). Future studies that determine the renal dose-response relationship of AVP are necessary to determine the impact of estrogen and progesterone on the kidney.

Finally, combined estrogen and progestin oral contraception administration increased plasma volume by as much as 12.4 % relative to the mid-luteal phase of the menstrual cycle. Estrogen-mediated increases in plasma volume are consistent with earlier findings in postmenopausal (2, 88) and young women (9, 34). The estrogen-mediated plasma volume expansion is not always accompanied by changes in water retention, and the mid-luteal phase plasma volume contraction not always associated with greater urine loss. A number of earlier studies demonstrated that high plasma levels of estrogen and progesterone alter Starling forces to favor protein and fluid movement out of the vasculature (55, 56, 107, 108). Therefore, these steroids may have their primary effect by altering body water distribution, rather than body water balance.

Sodium Regulation

Our experimental design enabled us to isolate estrogen effects on the renin-aldosterone system because norethindrone administered alone and with estradiol did not exhibit antimineralocorticoid properties. Our major finding was that neither estrogen dominant, nor progestin-only oral contraceptives increased PRA or $P_{[ALD]}$; rather, we found only the high endogenous estrogen and progesterone present in the luteal phase enhanced PRA and $P_{[ALD]}$. Sodium loss (sweat + urine) was attenuated during dehydration in the luteal phase and during OC E+P and OC P, but these losses were not

necessarily associated with increases in the sodium regulation hormones indicating that norethindrone inhibits sodium loss, but through a mechanism other than the renin-aldosterone system.

Combined oral contraceptive pills deliver pharmacological levels of ethinyl estradiol (11), which is almost identical in structure to the most biologically active form of endogenous estrogen, 17 β -estradiol, although with four times the potency (60). Our data do not support a role for estrogen in the stimulation of the renin-aldosterone system because OC E+P did not augment renin or aldosterone. Norethindrone, a progestational derivative of testosterone, differs in structure from endogenous progesterone. Endogenous progesterone inhibits aldosterone-dependent sodium reabsorption at distal sites in the nephron and produces a transient natriuresis (66) followed by a compensatory stimulation of the renin-aldosterone system (63, 104, 114). In contrast, norethindrone does not possess antimineralocorticoid properties because neither OC E+P nor OC P led to increases in PRA or $P_{[ALD]}$. Nonetheless, administration of norethindrone, with and without estrogen, enhanced sodium retention, suggesting this synthetic form of progesterone may act directly on the renal tubules.

Our data extend earlier findings demonstrating plasma volume contraction concomitant with enhanced PRA and $P_{[ALD]}$ during the mid-luteal phase of the menstrual cycle at rest, exercise and heat exposure (96, 98). The luteal phase was characterized by a baseline plasma volume contraction of ~220 ml compared to the follicular phase and of ~283 ml compared to OC E+P. Basal plasma sodium content also decreased in the luteal phase (377 ± 22 , 340 ± 26 , 388 ± 24 , 368 ± 22 mEq, $P < 0.05$, for the follicular and luteal phases, and OC E+P and OC P, respectively). However, although plasma volume and sodium content contraction are powerful stimuli to the renin-aldosterone system, they were not accompanied by changes in blood pressure so may not have contributed directly to the increases in PRA and $P_{[ALD]}$.

Progesterone and/or estrogen may modulate plasma volume and sodium content through inhibition of ANP release from cardiac myocytes. Atrial natriuretic peptide plays a role in the homeostatic feed back system that regulates sodium balance, that is, sodium- and volume-retaining stimuli increase ANP, which, in turn, antagonizes renin and aldosterone (11, 69, 85). Progesterone administration can suppress $P_{[ANP]}$ (113), so increases in circulating endogenous progesterone may inhibit ANP release during the luteal phase, and thus reduce sodium excretion. Furthermore, there is evidence that progesterone interferes with the inhibitory effects of ANP on aldosterone secretion (65, 69), suggesting that progesterone may enhance $P_{[ALD]}$ not only by attenuating ANP release, but by reducing the inhibitory actions of $P_{[ANP]}$ on the adrenal cortex. In our investigation, combined oral contraceptive pills increased $P_{[ANP]}$ at baseline and during dehydration, while OC P reduced $P_{[ANP]}$ to luteal phase levels, suggesting the estrogen in OC E+P may have modified a progesterone-modulated $P_{[ANP]}$ inhibition during dehydration. Alternatively, estrogen receptors are found in cardiac myocytes (102), so estradiol may stimulate ANP release directly.

Our findings also suggest that estrogen impacts water and protein distribution in the body. Despite the plasma volume contraction in the luteal phase, total protein concentrations were unchanged during the luteal phase tests, indicating that both water

and protein left the vasculature. Indeed, circulating plasma proteins (183.7 ± 11.3 , 175.6 ± 10.7 , 192.6 ± 13.1 and 184.8 ± 10.6 g, combined means for the follicular and luteal phase tests, and OC E+P and OC P, respectively) were lowest in the luteal phase tests compared to all other test conditions. Estrogen-mediated changes in body water and protein distribution are consistent with earlier studies in which the level of plasma volume expansion could not account for level of increases in overall body water retention (88). For example, during hypertonic saline infusion in estrogen-treated postmenopausal women, body water retention was increased by 31%, but plasma volume was unchanged (88). Finally, earlier studies have demonstrated that estrogen and/or progesterone alter transcapillary fluid dynamics to favor fluid and protein movement into the extravascular (interstitial) compartment (107, 108).

Any estrogen- or progesterone- mediated changes in transcapillary fluid dynamics may also have occurred via ANP. Atrial natriuretic peptide has important effects on body fluid dynamics, and may contribute to plasma volume regulation by inducing extravascularization (41, 77). Low-dose ANP infusions (to ~ 150 pg/ml) augment the capillary filtration coefficient (41), probably due to ANP-mediated changes in protein permeability. The increase in plasma protein permeability allows plasma proteins to escape from the circulation into the interstitial fluid, decreasing the rise in the colloid osmotic pressure of the microvasculature, opposing fluid reabsorption from the interstitium, and thus causing the extravascular efflux of proteins and fluid. Although estrogen and progesterone may increase ANP release, or impact its actions, the extent to which these hormones interact with ANP and modulate body water distribution has not been determined.

We used oral contraceptive pills to evaluate estrogen effects on the renin-aldosterone system and sodium regulation during dehydration and a subsequent rehydration period. During dehydration, we found that sodium loss was attenuated during the luteal phase and during administration of oral contraceptives containing estradiol and progestin, but these effects on sodium regulation were not mediated through the renin-aldosterone system. While estrogen does not appear to have direct effects on the renin-angiotensin-aldosterone system, this hormone may impact sodium regulation by modifying a progesterone-modulated inhibition of ANP release. In addition, the changes in sodium regulation may also have been influenced by the changes in resting plasma volume and sodium content.

CONCLUSIONS

We found that normally cycling young women have a reduction in the osmotic threshold for AVP release during the mid-luteal phase of the menstrual cycle (i.e. when estrogen and progesterone peak). Further, the osmotic threshold for AVP release is lowered during administration of oral contraceptives containing estrogen, but this reduction in threshold did not occur during progestin-only oral contraceptive use. Previously it was demonstrated that estrogen and progesterone upregulate thirst and AVP responses to an osmotic drive (28, 111), but the upregulation could not be attributed to specific estrogen or progesterone effects. Our data extend these early findings by

demonstrating a reduction in the P_{Osm} threshold for AVP release during estrogen-containing oral contraception administration. This threshold shift did not occur when the oral contraceptive contained only progestin, implicating estrogen as the hormone mediating the changes in AVP regulation. Because the water intake during the rehydration phase was similar in all our studies, regardless of menstrual phase or oral contraceptive treatment, we are able to conclude that an elevated circulating estrogen alters the body tonicity around which the body regulates fluids.

Regarding sodium regulation, we used oral contraceptive pills to evaluate estrogen effects on the renin-aldosterone system and sodium regulation. During dehydration, we found that sodium loss was attenuated during the luteal phase and during administration of oral contraceptives containing estradiol and progestin, but these effects on sodium regulation were not mediated through the renin-aldosterone system. While estrogen does not appear to have direct effects on the renin-angiotensin-aldosterone system, this hormone may impact sodium regulation by modifying a progesterone-modulated inhibition of ANP release. In addition, the changes in sodium regulation may also have been influenced by the changes in resting plasma volume and sodium content.

Reliability of fluid regulation hormones

INTRODUCTION

Despite the continued study of changes in the fluid and sodium regulating hormones, there were no studies examining their stability, or reliability within a given phase, over the course of two or more menstrual cycles. Differences in reported plasma concentrations of these hormones across different menstrual cycles can be affected by natural variations within a woman, by inaccurately choosing the day in each phase of the menstrual cycle to conduct physiological testing, by differences in water and/or sodium intake, or by difficulty with the hormone analysis techniques. We determined the reliability of the fluid and sodium regulating hormones, aldosterone, renin, arginine vasopressin and atrial natriuretic peptide, at rest and in response to dehydrating exercise over two menstrual cycles. Accordingly, we tested the reliability of the fluid regulating hormones in our subjects on the above-described dehydration testing days: twice during the early follicular phase (when estrogen and progesterone are low) and twice during the mid-luteal phase of the menstrual cycle (when estrogen and progesterone are high).

METHODS

Subjects were nine healthy, non-smoking women, ages 21-3. All subjects were interviewed about their medical history, and had medical and gynecological examinations before admission to the study. During the month preceding the first dehydration/rehydration exposure maximal oxygen consumption (VO_{2peak}) was determined with an automated metabolic cart (Sensor Medics Corp, Yorba Linda, CA). This preliminary test was conducted in the early-follicular phase of the menstrual cycle.

The study design employed four dehydration experiments, two conducted in the early-follicular phase (2-4 days (4 ± 1) after the beginning of menstrual bleeding) and two in the mid-luteal phase of the menstrual cycle (20-25 days (22 ± 2 days) after the start of menstrual bleeding). Specifically, for the mid-luteal phase tests, the subjects were tested between days 7-10 following the LH peak, and therefore approximately 6-9 days after ovulation. The dehydration protocol is described on pages 3-5 of this Progress Report (See "Dehydration experiments").

Statistical Analysis. Pearson's Product Moment Correlation on individual data was used to assess the slope and abscissal intercepts of the $P_{Osm} - P_{[AVP]}$ relationship during dehydration (28). The within-phase reliability of our most important dependent variables, fluid regulating hormones and osmotic regulation of AVP, measured at rest, dehydration and rehydration, was determined with Cronbach's α , assuming a value ≥ 0.80 as a acceptable level of reliability (10). Areas under the curve (AUC, trapezoid method) were calculated during the rehydration period for PRA, $P_{[ALD]}$ and $P_{[ANP]}$, and their reliability determined within a given menstrual using Cronbach's α . We used repeated measures ANOVA models, followed by Bonferoni's t , to test differences in the dependent variables both within and between menstrual phases. Data were analyzed using BMDP statistical

software (BMDP Statistical Software, Inc., Los Angeles, CA), and expressed as mean \pm SEM.

RESULTS

Within-phase reliability.

Early follicular phase. Within the follicular phase, there were no significant differences between the means of any of the variables during rest, dehydration and rehydration (Table 8). In fact, most of the hormonal responses demonstrated high reliability, attaining a Cronbach's α greater than 0.80 (Table 9). However, with the exception of $P_{[ANP]}$, none of the resting values of the fluid regulating hormones attained sufficiently high Cronbach's α to be considered reliable (Table 9). Reliability was improved following dehydrating exercise for $P_{[AVP]}$ and PRA; although it remained low for $P_{[ALD]}$ ($\alpha = 0.66$) and remained high for $P_{[ANP]}$ ($\alpha = 0.90$). During dehydration, both the slope and abscissal intercept of the $P_{Osm} - P_{[AVP]}$ relationship were highly reliable within the follicular phase, attaining Cronbach's α of 0.96 and 0.90, respectively. Again, $P_{[AVP]}$, $P_{[ALD]}$ and PRA were not reliably reproduced during rehydration, while Cronbach's α for $P_{[ANP]}$ was 0.93. Plasma estrogen concentration was highly reproducible within the follicular phase tests, attaining Cronbach's α of 0.85, but $P_{[P_4]}$ attained a Cronbach's α value of only 0.62 between tests in the follicular phase.

Mid-luteal phase. Similar to the follicular phase, there were no differences mean hormonal concentrations at rest, after dehydration or during rehydration within the mid-luteal phase (Table 8). Again, resting values for $P_{[AVP]}$, $P_{[ALD]}$ and PRA were not highly reproducible between the two mid-luteal phase tests (Table 9). Reliability for $P_{[ANP]}$ was greater compared to the other fluid regulating hormones, at rest and during exercise and rehydration, and again, despite high levels of reliability for osmotic regulation of AVP (Table 9), resting and rehydration levels of $P_{[AVP]}$ were not consistently correlated within the luteal phase tests. In contrast to the follicular phase however, both $P_{[E_2]}$ and $P_{[P_4]}$ were highly reliable between the two luteal phase tests, yielding Cronbach's α values of 0.93 and 0.93, respectively.

CONCLUSIONS

We examined the within-phase reliability of plasma concentration of fluid and sodium regulating hormone concentrations between two separate menstrual cycles at rest and in response to dehydration during the early follicular and mid-luteal phases. Resting and recovery plasma concentrations of AVP, aldosterone and PRA were not reproducible within each of the different menstrual phases; however, there were no statistical differences between the means of any of these hormone concentrations indicating that the within-subject inconsistency remains undetected when only the means are tested or reported. Nonetheless, our data indicate that between phase differences in the hormone

concentrations far exceed the variability within the phases, and therefore the low within-phase reliability does not prevent the detection of menstrual phase-related changes in these variables. In contrast, however, $P_{[AVP]}$, PRA and $P_{[ANP]}$ responses to dehydrating exercise were highly reliable within each menstrual phase indicating that hormonal responses to stress are more consistent in spite of the variability in baseline values.

Responses to technical issues regarding the Progress Report from 1997:

(1) We have attempted to clarify the timing the experiments in the text (Page 3) with the following *"Because sex hormones vary across the menstrual cycle, some variation in the dependent variables over the course of the menstrual cycle may exist. Therefore, the study design employed two dehydration baseline studies, carried out in the early-follicular phase (2-5 days after the beginning of menstrual bleeding) and mid-luteal phase of the menstrual cycle in the month preceding each oral contraception treatment."* In addition, we have added a figure to illustrate the protocol (See Figure 1).

(2) The letter "h" was changed to "hours" after the "2" in this sentence to clarify the timing on page three. The sentence now reads "All studies were begun within 2 hours of the daily pill ingestion when peak serum hormone levels occur (12)."

(3) The other major technical issue raised by the reviewers was regarding the long-term effect on these hormones on the variables we have measured. Of course we cannot answer this question from our data because our treatment only extends one month (28 days). However, there are a few studies that demonstrate that the effects on body water expansion (9), and body water distribution (107, 108) last at least as long as 6 months (107, 108) to one year (9). It has also been demonstrated that 2 months of oral contraceptive treatment leads to increases in blood volume at rest, as well as increases in stroke volume and cardiac output during exercise (57).

Protocol B: Sex Hormone Effects on Thermoregulation during Exercise in the Heat.

The regulation of body temperature in humans is known to interact with systems that regulate volume and osmotic pressure of the extracellular fluid (64). Blood volume expansion improves the efficiency of cardiovascular and thermoregulatory responses during physical activity. In a study in which we manipulated blood volume in young men by ~9% of normal (36), after 30 min of moderately heavy exercise in the heat, internal temperature rose to 38.6°C in the control condition, to 38.3°C in the volume-expanded condition and the 38.9°C in the volume-contracted condition. The likely reason for the dependence of heat transfer on absolute blood volume during exercise in the heat is that the ability of the heart to pump blood to the skin, and therefore provide increased convective heat transfer from the body core to the skin, is a function of preload. When blood volume is expanded, cardiac stroke volume increases, resulting in elevated cardiac output and improved ability to deliver blood to muscle and skin simultaneously where heat transfer takes place. Conversely, blood volume contraction results in a gradual fall in preload during exercise (109), a reduction in cardiac output and an associated increase in skin vascular resistance at any internal temperature, explaining the decrease in heat transfer. These observations imply that a reflex sensitive to changes in the filling pressure of the heart influences the distribution of blood flow (and thus the resident blood volume) and thereby affects the body's ability to dissipate the excess heat produced during exercise.

The temperature threshold for the onset of a thermoregulatory effector response, i.e. sweating and peripheral vasodilation, is defined as the core temperature above which the effector response is greater than that of baseline. A shift in the core temperature threshold is often referred to as a change in the set point for temperature regulation (97). A reduction in the set point for temperature regulation secondary to blood volume expansion has profound effects on performance of physical activity in the heat because core temperature is maintained at a lower level and strain on the cardiovascular system is reduced. Conversely, dehydration (plasma volume loss) elevates exercise core temperature (81, 83) and decreases exercise tolerance (82, 83).

Estrogen may alter the threshold for thermoregulation during exercise in the heat. Core temperature responses to passive heating and exercise in heat are reduced during the follicular phase of the menstrual cycle, the cycle phase characterized by rising estrogen levels (47, 48, 53, 73). Haslag and Hertzman (44) demonstrated that the onset of thermoregulatory sweating during whole body heating occurred at a lower core temperature in women during their follicular phase. Stephenson and Kolka reported lower core temperature thresholds of both sweating (53, 94, 95) and cutaneous vasodilation in a hot environment (94, 95) during the follicular phase. No studies have assessed directly the effect of oral contraceptives on thermoregulatory responses during exercise in the heat, but the thresholds for the onset of sweating and vasodilation were reduced by 0.47°C and 0.48°C, respectively following 2 weeks of estrogen replacement therapy in post-menopausal women (106), and was reduced during long term estrogen therapy (13). The plasma volume expansion that is an outcome of estrogen administration (106), and the follicular phase of the menstrual cycle (96) may play an important role in the improved thermoregulation in the presence of high plasma levels of estrogen. This phase

of the study was designed to determine the impact of estrogen-induced plasma volume expansion on thermoregulatory responses to exercise in the heat.

METHODS:

Study design:

Subjects were nine healthy, nonsmoking women (age 25 ± 1 y, range 22-31 y), with no contraindications to oral contraceptive use. All subjects were interviewed about their medical history, had medical and gynecological examinations and provided written confirmation of a negative Papanicolaou smear within one year of being admitted to the study. During the month (early follicular phase) preceding the first heat stress experiment, resting plasma volume was determined with Evan's blue dye dilution (see below) and peak oxygen consumption ($\text{VO}_{2\text{peak}}$) was determined from an incremental cycle ergometer test, using an automated metabolic cart (Sensor Medics Corp, Yorba Linda, CA).

Each woman participated in six baseline experiments, four baseline heat stress tests (2 in the follicular and 2 in the luteal phase of the menstrual cycle), and one heat stress test while taking each type of oral contraceptive (two total). Estrogen and progesterone vary across the menstrual cycle, so the study design employed a heat stress test conducted in the early-follicular phase, 2-4 days after the beginning of menstrual bleeding (low estrogen and progesterone), one for each pill treatment, and one conducted in the mid-luteal phase, 7-9 days after the luteinizing hormone peak (high estrogen and progesterone), determined individually by the use of ovulation prediction kits (OvuQuick, Quidel Corp, San Diego, CA). We report on two control tests per subject (one follicular, one luteal phase). Not all subjects had two ovulatory cycles. When only one ovulatory cycle occurred, data from only that menstrual cycle was used in the analysis. When both menstrual cycles were ovulatory, we randomly chose the first cycle to use in the analysis. When neither cycle was ovulatory, the subject was excluded from further analysis. To verify phase of the menstrual cycle, plasma levels of estrogen and progesterone were assessed from the pre-exercise blood sample prior to undertaking the temperature regulation protocol.

After completing the baseline heat stress tests, the subjects again performed heat stress protocols after four weeks of either continuous combined (estrogen-progestin, OC E+P) or progestin-only (OC P) oral contraceptive treatment (random assignment). Following a 4-week "washout" period, the subjects crossed over to the other pill treatment. During OC E+P, subjects received 0.035 mg of ethinyl estradiol and 1 mg of the progestin, norethindrone daily. During OC P treatment, subjects received 1 mg/day of the progestin, norethindrone.

Heat stress tests

Volunteers arrived at the laboratory between 7:00 - 8:00 am, after having eaten only a prescribed low fat breakfast (~ 300 kcal). The subjects refrained from alcohol and caffeine for 12 h prior to the experiment. Blood volumes were not manipulated prior to any of the experiments, although subjects pre-hydrated by drinking 7 ml/kg body weight of tap water at home before arrival at the laboratory. Upon arriving at the laboratory,

each subject gave a baseline urine sample, was weighed to the nearest 10 g on a beam balance, and was instrumented for the measurement of cardiac output (see below). The subject then sat on the contour chair of a semi-recumbent cycle ergometer in the test chamber (27°C, 30% rh) for 45 min of control rest. During the control period the subject was instrumented for the measurement of esophageal and skin temperatures, sweat rate, and blood pressure. An indwelling catheter (21 ga) was inserted into an arm vein for blood sampling, and a heparin block (20 U/ml) maintained catheter patency. Subjects were semi-recumbent during placement of the catheter and were seated for 45-min prior to sampling to ensure a steady state in plasma volume and constituents. Resting blood pressure (Colin Medical Instruments Corp, Komaki, Japan), heart rate (EKG) and cardiac stroke volume were recorded at the end of the 45-min control period. At the end of the control period, a blood sample (12 ml) was drawn and urine collected. Hydration state was assessed from the specific gravity of the pre-exercise urine sample (mean = 1.002 ± 0.001).

Following 20 min of control measurements, the chamber temperature was increased to 35°C and the subject sat quietly for 20 min of passive heating. Measurements were made of arterial blood pressure every 10 min, cardiac output every 15 min, esophageal temperature and mean skin temperature continuously. At the end of the passive heating, another blood sample (12 ml) was drawn.

Immediately following passive heating, the subjects exercised on a recumbent bicycle at 60 % of their individual $\text{VO}_{2\text{peak}}$ for 40 minutes. The subjects exercised with a fan positioned directly in front of the bike, with a fan speed 1.6 m/s to promote continuous evaporative sweating (1). Blood pressure was measured every 10 min, esophageal temperature and skin temperatures were monitored continuously and cardiac output estimates were obtained at 15 and 35 min during exercise. Sweating rate was also determined continuously throughout exercise. Blood was sampled at 10, 20 and 40 min of exercise.

Measurements

Body core temperature (T_{es}) was measured continuously from an esophageal thermocouple at the level of the left atrium. Skin temperatures were measured on the forehead, chest, upper arm, lateral flank, thigh and calf. T_{es} and T_{sk} were collected at a rate of 5 data points/s. Data were stored in a computer through an analog-to-digital converter system (ACRO 931, Daisylab, National Instruments, Austin, TX) as a mean value of every 30 seconds. Mean skin temperature was calculated from the following equation, which takes into consideration surface area (42) and the thermosensitivity of each skin area (67).

$$T_{\text{sk}} = 0.10 T_{\text{ch}} + 0.21 T_{\text{fh}} + 0.28 T_{\text{ab}} + 0.18 T_{\text{ua}} + 0.15 T_{\text{th}} + 0.18 T_{\text{ca}}$$

Where subscripts refer to mean skin (sk), chest (ch), forehead (fh), abdomen (ab) upper arm (ua), thigh (th) and calf (ca).

An automatic dew-point sensor enclosed in a ventilated, plexiglas capsule was placed on the forearm and secured with surgical glue to determine sweating rate (39). Cardiac stroke volume was measured noninvasively by impedance cardiography

(Minnesota Impedance Cardiograph, Model 304B), with two silver tape electrodes placed around the neck and two around the torso. The distance between the inner tapes was measured and made identical for all four experiments. Cardiac stroke volume was calculated using the equation of Kubicek et al. (54) and was averaged (ensemble averaging) over 25 seconds.

All blood samples were analyzed for hematocrit (Hct) and the concentrations of hemoglobin (Hb), total protein (TP), plasma osmolality (P_{Osm}) and serum concentrations of sodium ($S[Na^+]$) and potassium ($S[K^+]$). The control blood samples were also analyzed for 17 β -estradiol ($P[E_2]$) and progesterone ($P[P_4]$).

Blood and urine analysis:

An aliquot (1 ml) was removed for immediate assessment of Hct, [Hb], and [TP] in triplicate by microhematocrit, cyanomethemoglobin and refractometry respectively. A second aliquot was transferred to a heparinized tube, and a third aliquot was placed into a tube without anticoagulant for the determination of $S[Na^+]$ and $S[K^+]$. All other aliquots were placed in chilled tubes containing EDTA for analysis of $P[E_2]$ and $P[P_4]$. The centrifuged samples were frozen immediately and stored at $-80^\circ C$ until analysis. All urine samples were analyzed for volume, osmolality, creatinine, sodium and potassium concentrations.

Serum and urine sodium and potassium concentrations were measured by flame photometry (Instrumentation Laboratory, Model 943). Plasma and urine osmolality (U_{Osm}) were assessed by freezing point depression (Advanced Instruments 3DII). Plasma concentrations of $P[E_2]$ and $P[P_4]$ were measured by radioimmunoassay. Intra- and inter-assay coefficients of variation for the mid-range standard for $P[E_2]$ (58 ± 4 pg/ml) were 15 % and 4 % (Diagnostic Products, Los Angeles, CA), for $P[P_4]$ (1.7 pg/ml) were 14 % and 6 % (Diagnostic Products).

Blood volume

Absolute blood volume was measured by dilution of a known amount of Evan's blue dye dilution. This technique involves injection of an accurately determined volume of dye (by weight, since the specific density is 1.0) into an arm vein and taking blood samples for determination of dilution after complete mixing (10, 20 and 30 min). Plasma volume was determined from the product of the concentration and volume of dye injected divided by the concentration in plasma after mixing, taking into account 1.5% lost from the circulation within the first 10 min. Blood volume was calculated from plasma volume and hematocrit concentration corrected for peripheral sampling (40).

Changes in plasma volume (PV) were estimated from changes in Hct and [Hb] from the control (pre-exercise) sample according to the equation:

$$\% \Delta PV = 100 \left[\frac{(Hb_b)/(Hb_a)[(1-Hct_a \cdot 10^{-2})]/[(1-Hct_b \cdot 10^{-2})]}{(1-Hct_b \cdot 10^{-2})} \right] - 100$$

in which subscripts a and b denote measurements at time a and control, respectively. We used this equation to calculate both changes from baseline during exercise within a given experimental day, as well as changes between each experimental day versus the follicular phase.

Electrolyte losses in urine were calculated by multiplying the volume of water loss in each fluid by the concentration of the electrolyte within the fluid [Not reported]. Total body sweat loss, calculated from the change in body weight during exercise.

Statistics. Prior to statistical treatment, the independent variable (time) was partitioned into 5-min bins. Within each subject, the dependent variables were averaged for every other bin, so that each averaged time period was separated by a five-min partition. To determine individual T_{es} thresholds for the onset of sweating, each subject's sweating rate (30 second value) was plotted as a function of T_{es} (30 second value) during exercise, and the T_{es} threshold for sweating (i.e. the T_{es} above which the effector response is greater than that of baseline) was determined by two independent investigators. The average estimate was used for analysis, and the estimates had an inter-rater reliability of 0.95. We used repeated measures ANOVA models, followed by Bonferoni's t , to test differences in the sweating threshold and slopes due to menstrual phase or oral contraceptive treatment (24). Based on an alpha level of 0.05 and a sample size of 8, our beta level (power) was ≥ 0.80 for detecting effect sizes of 0.28°C . Data were analyzed using BMDP statistical software (BMDP Statistical Software, Inc., Los Angeles, CA) and expressed as mean \pm SEM.

RESULTS

Subject Characteristics

Two subjects did not have luteal phase progesterone peaks, so their data were excluded from further analysis. Therefore, all statistical analyses were performed on the remaining seven subjects and only their data are presented. On the pre-testing orientation day, the subjects weighed 53.0 ± 3.1 , were 162 ± 3 cm tall, and their plasma and blood volumes were 2642 ± 258 ml and 74.3 ± 6.6 ml/kg, respectively, and their $\text{VO}_{2\text{peak}}$ was 34.8 ± 2.1 ml/kg on the recumbent bicycle ergometer. Plasma levels of 17 β -estradiol and progesterone were consistent with expected values during the early follicular and mid-luteal phases of the menstrual cycle, and were suppressed during oral contraceptive treatment (Table 10).

Pre-exercise. During thermoneutral rest, T_{es} was greater during OC P compared to the follicular phase and OC E+P and was also greater during the luteal compared to the follicular phase (Table 10, $P < 0.05$). Mean T_{sk} was not affected by menstrual phase or oral contraceptive treatment. Relative to the follicular phase, plasma volume was decreased by $(-3.8 \pm 2.2 \%, (-115 \text{ ml}))$ during the luteal phase, increased by $7.3 \pm 3.4 \%$ (190 ml) during OC E+P treatment, but unchanged $(-0.7 \pm 1.8 \text{ ml } (-36 \text{ ml}))$ during OC P treatment (Fig 9).

Plasma osmolality and serum sodium concentrations were reduced before exercise during OC E+P relative to the follicular phase (Table 10, $P < 0.05$). Heart rate, stroke volume, cardiac output and blood pressure were unaffected by menstrual phase or oral contraceptive treatment prior to exercise (Table 11).

Passive heating. At the end of 20 min of passive heating, T_{es} during OC P was still greater relative to the follicular phase and OC E+P, but there were no differences between

the menstrual phases. Plasma volume (Fig 9), plasma osmolality and sodium concentrations during OC E+P remained below the other trials during passive heating (data are not shown). Passive heating did not increase heart rate, cardiac output or blood pressure under any of the four conditions (Table 11).

Exercise responses. Exercise increased T_{es} during all four trials, but increased the greatest during OC P (Fig. 10, $P < 0.05$), and T_{sk} changed little during exercise. (Fig 11) Exercise SR was similar across all trials for most of exercise (Fig 12), but the T_{es} threshold for sweating onset was greater during the luteal phase and OC E+P relative to the follicular phase (Fig. 13 and Table 12, $P < 0.05$). The changes in Hct and [Hb] (Fig 9) demonstrate that PV changes during exercise were similar across all trials. As with the other time periods, P_{Osm} and $S_{[Na+]}$ were reduced during OC E+P relative to the other trials (data not shown). Heart rate, stroke volume, cardiac out and blood pressure increased similarly across trials during exercise (Table 11).

DISCUSSION

Our major findings were that unopposed progestin administration increased the regulated body temperature as both core temperature and the core temperature threshold for sweating increased, similar to what occurred during the mid-luteal phase of the menstrual cycle, and these thermoregulatory changes were blocked by treatment with estrogen plus progestin. This is the first report to address potential modulating effects of estrogen on the pronounced progesterone-related increase in regulated body temperature. In addition, ours is the first investigation in which a within-subject design that allowed sufficient time for tissue washout of synthetic estrogens and progestins between trials was used to determine the effects of synthetic estrogen and progestin on thermoregulation. During OC E+P, the T_{es} threshold for sweating was $\sim 0.5^{\circ}\text{C}$ lower compared to the luteal phase indicating that synthetic estrogens and progestins do not elicit the same temperature responses as their endogenous counterparts. These differences may be due to differences in the direct or indirect actions of oral contraceptives on the CNS, to differences in the ratio or potency of the synthetic hormones, or to differential effects on peripheral influences on temperature regulation such as body fluid balance.

Charkoudian and Johnson (19) recently demonstrated that the core temperature threshold for active cutaneous vasodilation during passive heating was increased in women taking oral contraceptives containing estradiol [estrogen] and progestin compared to their responses after approximately 5 days of not taking the pill (19). This finding was consistent with earlier findings of an increased core temperature threshold for initiation of cutaneous vasodilation during exercise in the luteal phase (53, 95). Postmenopausal women taking combined progestin and estrogen did not exhibit the same reduction in the T_{es} threshold for vasodilation or sweating seen in women taking only estrogen during exercise (13) suggesting that progestin blocks some of the estrogen-related thermoregulatory effects. However, Chang et al. (95) failed to demonstrate a change in core temperature following three days of estrogen administration to young women in their early follicular phase, perhaps because three days of estrogen administration may not be long enough to elicit temperature changes. Conversely, another hormone, such as FSH, facilitates hypothalamic neuronal adaptation to estradiol. Nonetheless, these reports

indicate a disparity between chronic and acute effects of exogenous estrogens and progestins on temperature regulation.

Our data support earlier findings that estrogen with progestin administration does not alter the T_{es} threshold for thermoregulatory effector activation compared to the follicular phase (13). Moreover, we found that the estrogen component of the treatment reduced resting T_{es} by 0.58°C and the exercise T_{es} threshold for sweating by 0.68°C compared to progestin-only administration, indicating a profound modifying role for estrogen on the progesterone-induced core temperature increase. We suspect that the effects of these hormones occur via direct effects in the preoptic/anterior hypothalamus, the primary temperature-regulation area of the brain. Both estrogen and progesterone readily cross the blood-brain barrier, and may modulate thermoregulation via its action in the CNS, and sex steroid receptors have important effects on thermosensitive neurons in the brains of lower animals (68, 87). Progesterone inhibits warm-sensitive neuron activity, thus inhibiting heat loss mechanisms, and increasing body temperature (68). Conversely, estrogen inhibits cold and stimulates warm sensitive neurons (87), and should therefore inhibit heat-retaining mechanisms, excite heat loss mechanisms, and thus cause a decrease in the regulated body temperature.

To the extent that temperature is regulated by central mechanisms, estrogen and progesterone may exert their effects on the preoptic area and anterior hypothalamus by both transcription-dependent and transcription-independent mechanisms (30, 51). Various molecular mechanisms have been proposed to explain receptor-independent sex steroid action. Estrogens are metabolized to catechol estrogens, which, because of their structural similarity to catecholamines, may influence the metabolism and activity of these neurotransmitters in the hypothalamus (5, 7). In addition, A-ring reduced metabolites of progesterone influence the GABA-A-linked chloride ion channel, one of the most ubiquitous ion channels in the brain (61), thus allowing these ions to cross the membrane and regulate its excitability. However, extrapolation of basic mechanisms to predict physiological effects of estrogen and progesterone in humans has a number of limitations. These steroids and their metabolites have complex actions on different parts of the brain; indeed, a particular steroid may even have opposite effects on the same neurotransmitter system in different parts of the brain. This complexity makes it difficult to generalize findings from specific neuronal systems to other systems, or to predict how neuronal systems interact to regulate physiological systems, and to predict how the synthetic hormones found in oral contraceptives impact these receptors in humans.

Sex steroids may also act via a secondary mediator or pathway, such as cytokines (14) or heat shock proteins. However, these indirect mechanisms are less likely to be involved in thermoregulatory changes during oral contraceptive administration because neither IL-1 β nor IL-6 are elevated during OC E+P administration (79) and estrogen administration had no effect on heat shock proteins in young women given estrogen (17).

Our data conflict with other reports in which chronic administration of combined estrogen and progesterone to young women was associated with greater oral temperature responses to passive heating (18-20). The contrast in our findings may be due to the longer length of time between tests in our study (12-16 weeks) compared to the earlier studies (5-7 days). In addition, these earlier studies tested women taking chronic oral

contraceptives and compared them with the five to seven days in the cycle off the pills, while we provided an acute treatment to women not taking birth control pills. While this may have introduced more variability into our study, our design removed any effects of slow hormone washout or any adaptive response these previous studies may have invoked by performing the two studies so close together.

Our data together with earlier studies suggests that the effects on temperature regulation during sex hormone administration are more likely related to ratio of estrogen and progesterone, rather than the effects a single hormone. Endogenous progesterone and estrogen often have opposing effects on regulatory systems, and the presence of high levels of progesterones in the blood down-regulate estrogen receptors. This is consistent with the recent finding that the fall in the temperature thresholds for sweating onset of cutaneous vasodilation was related not only to the estrogen peak prior to ovulation, but also related to the ratio of E_2 to P_4 levels in the blood (94). The varying ratios of these hormones between the mid-luteal and OC E+P may explain the differing temperature responses in the present investigation. The ratio of progestin/estradiol *given* to each subject during OC E+P was 28.6, approximately 6-fold lower than the ratio of the progesterone/estradiol levels measured during the mid-luteal phase (151). However, we recognize that comparison of the different pill preparations is tenuous because the relative potency of synthetic estrogens and progestins found in oral contraceptives on the temperature regulation system is unknown. Furthermore, synthetic estrogens and progestins are metabolized at different rates among individual women so we cannot accurately predict the level of these hormones actually acting on tissue simply by knowing the quantity of the hormone administered.

While direct actions within the CNS may be a primary mechanism by which progesterone and estrogen exert their effects on the temperature regulation systems, the regulation of body temperature in humans is also interacts with systems that regulate volume and osmotic pressure of the extracellular fluid (64). Blood volume expansion improves the efficiency of cardiovascular and thermoregulatory responses during physical activity. When blood volume is expanded, cardiac stroke volume increases, resulting in elevated cardiac output and improved ability to deliver blood to muscle and skin simultaneously, where heat transfer takes place. High estrogen levels in the blood are associated with plasma volume expansion (88, 96, 106), and plasma volume was at its lowest during the mid-luteal phase of the menstrual cycle coinciding with the highest core temperature and delayed sweating onset during exercise. However, although OC E+P was associated with a large increase in plasma volume compared to the follicular phase, there were no differences in the thermoregulatory responses during exercise. In contrast, the greater plasma volume during OC E+P compared to OC P may have played a role in their contrasting temperature responses. Indeed, HR and cardiac output were slightly reduced only during OC E+P compared to the other three trials.

We found that oral contraceptive pills containing estrogen block the thermoregulatory effects of oral contraceptive pills that contained only progestin. These data extend earlier findings that estradiol may lower the thermoregulatory operating point, and also indicate that the synthetic hormones found in oral contraceptives do not elicit the same thermoregulatory responses as their endogenous counterparts. Differences in the ratio of the estrogen to progesterone or structural differences between the synthetic

and endogenous hormones may be the cause of this disparity. Finally, plasma volume differed during exercise between the two oral contraceptive treatments, and suggests plasma volume expansion as a possible mechanism for the lower temperature during OC E+P treatment.

We found that oral contraceptive pills containing estrogen with progestin did not produce the thermoregulatory effects of oral contraceptive pills that contained only progestin. This estrogen-related reversal of the thermoregulatory actions of progestin is most likely due to specific effects on thermosensitive neurons in the CNS. These findings confirm earlier findings that estrogen lowers the thermoregulatory operating point (94). Our findings differed from previous findings in young women taking chronic oral contraceptives in that we did not find that oral contraceptives containing both estrogen and progestin significantly increased core temperature at baseline or following passive heating (18-20). Finally, although estimated plasma volume was lower during progestin alone administration compared to combined estrogen and progestin administration, exercise stroke volume was unchanged, supporting earlier findings that plasma volume change is not a major contributor to altered temperature regulation during oral contraceptive administration (13).

Responses to comments regarding the Progress Report from 1998:

The subjects are recruited without bias to ethnicity, and we make every attempt to include minorities in our subject pool. Based on recent census figures, minority groups comprise approximately 16 % of the population of Connecticut (8% Black, 6 % Hispanic, and 2 % Asian, and people of other races) and these figures are consistent with those reported from admissions at Yale-New Haven Hospital. Up to this point, 40 % of our subjects are African American or people from other minority ethnic origins, so we have been successful at recruiting a diverse group of subjects, which represent young, healthy women in the general population, although primarily they are from upper to upper-middle class, educated backgrounds.

The subjects for all three protocols are recruited through posted advertisements at Yale School of Medicine, School Yale School of Epidemiology (18) and Public Health and Yale University (undergraduates), and by word of mouth (1).

Protocol A:

For this protocol, we recruited a total of eleven subjects: one Hispanic, three African Americans and seven white subjects. One of the white subjects dropped out of the study for personal reasons, and another of the white subjects completed 5 of the six tests because the combined birth control pill induced extreme, chronic nausea. This left us with one Hispanic, three African American and five white subjects for our final analysis.

Protocol B:

For the second protocol, we recruited eleven subjects: two Hispanics, two Asian Americans, one Asian, three African Americans, and three white subjects. One Hispanic subject did not participate because of prior medical problems, one black subject did not participate because of a positive Pap smear test, and two white and one black subject were not used in the final analysis because they did not have normal menstrual cycles. This left us with one Hispanic, one African American, two white subjects and two Asian Americans and one Asian (Chinese).

Protocol C:

We recruited ten women: two Hispanic, three African American, and six white subjects. One African American subject discontinued after the first hypertonic saline infusion experiment because of severe nausea, and another African American subject's data were excluded from final analysis because she did not have a normal menstrual cycle. This left us with two Hispanic, one African American, and five white subjects.

For the men, we recruited twelve men: whites, two African American, one Hawaiian, and three Hispanic subjects. One white subject and one Hispanic subject were not used in the final analysis because of dehydration on the morning of the infusion test.

A small subset of the population can be used to extrapolate to the larger population in these instances because the measurements we make are precise and reproducible. We cannot however, extrapolate to make conclusions about men, or about other population of women, such as older in women because aging has independent effects on all of these systems on the fluid regulatory and temperature regulatory systems.

We did see changes in dehydration and temperature responses to the oral contraceptive treatments, so one month is long enough to detect at least some important effects of the pills. In addition, there are cross-sectional studies comparing women on and off oral contraceptives on body water regulation (55-57, 79), that are consistent with our findings, suggesting that one month effects may be similar to chronic effects. However, our data cannot be extrapolated to indicate that the changes apparent after one month are similar to those during long-term oral contraceptive treatment.

Protocol C: Sex Hormone Effect on Osmotic Regulation of Thirst and Arginine Vasopressin

As discussed above, high estrogen states in women, such as occur around the time of ovulation (110) and during pregnancy (28), are associated with water retention and plasma volume expansion. As we saw during dehydration (92) the mechanism for this estrogen-associated plasma volume expansion may involve alterations in the osmotic control of arginine vasopressin release and thirst.

Arginine vasopressin, the primary hormone involved in renal reabsorption of free water, is highly sensitive to changes in plasma tonicity. A strong and positive correlation (~ 0.95) exists between plasma osmolality and plasma concentration of arginine vasopressin. The slope of this relationship is used to assess osmotic control of arginine vasopressin release; a steeper slope is interpreted as heightened sensitivity of central osmoreceptors that cause the release of arginine vasopressin. When a body water deficit exists, arginine vasopressin also is sensitive to decreases in plasma volume through unloading of low-pressure baroreceptors (peripheral mechanism). The sense of thirst is also sensitive to elevated plasma tonicity and decreased plasma volume, leading to increased fluid intake when water is available. Therefore, under conditions of high plasma tonicity and body water deficit, restoration of body water is achieved through a combination of thirst-induced drinking and vasopressin-mediated renal water retention.

Plasma arginine vasopressin concentration is elevated in the presence of a high concentration of plasma estrogens in humans (32, 33). Plasma concentration of arginine vasopressin is increased during the mid-follicular phase of the menstrual cycle in young women (32) and following the administration of exogenous estrogen in post-menopausal women (33), although these increases are inconsistent when progesterone is increased along with estrogen (32, 92). Late pregnancy, a state characterized by elevated sex hormone levels, is associated with an altered threshold for arginine vasopressin release due to normal AVP levels combined with reduced P_{Osm} . Using hypertonic saline infusion in pregnant women, Davison et al. (28) noted a 6 mosmol/kg H_2O fall in the plasma osmolality threshold for arginine vasopressin release and a 10 mm fall in the threshold for the onset of thirst, providing evidence for altered osmoregulatory control of arginine vasopressin and thirst responses in the presence of high plasma estrogen concentration.

It is likely that reproductive hormones act directly on the central nervous system to increase arginine vasopressin release. Estrogen can cross the blood brain barrier and gain access to hypothalamic sites (the paraventricular and supraoptic nuclei) that control arginine vasopressin release and some neurons in these sites bind estrogen (80, 87). In addition, estrogen may affect arginine vasopressin release indirectly through catecholaminergic and/or pro-opio melanocortin-immunopositive neurons which bind estrogen and project to the paraventricular and supraoptic nuclei (46), or by altering norepinephrine turnover (26).

This final protocol addressing female sex hormone effects on body fluid regulation was designed to explore the hypothesis that the mechanism for the expanded plasma volume associated with estrogen administration is increased responsiveness of thirst and arginine vasopressin to osmotic stimuli. At the time of this report, we have completed data collection, and the AVP and free cortisol analysis are ongoing.

In addition, for this final protocol, we also tested the responses of a group of men during hypertonic saline infusion. Men are generally at greater risk for cardiovascular disease than women, specifically with regard to the progression of hypertension and sodium regulation. There has been some discussion as to the roles of androgens in the onset of this disease, as opposed to simply the lack of estrogen protective effects. Our research design enabled us to examine potential sex differences under different estrogen/progesterone levels in the women. This design provided us with the opportunity to see whether estrogen and progesterone exerted effects on osmotic regulation of AVP and sodium regulation and whether androgens exerted independent effects in the men.

METHODS

Study design:

We have completed testing on nine subjects. Data on eight subjects will be presented because one subject did not have estrogen and progesterone peaks in the mid-luteal phase, so her data are excluded. In addition, one subject experienced severe nausea following hypertonic saline infusion, so she discontinued the study and her data are also excluded. In addition, we have tested 10 men under the same protocol as a control group, and compared their responses to those of the women during their follicular and luteal phases.

Subjects were healthy, nonsmoking women (age 29 ± 2 y, range 22-35 y) with no contraindications to oral contraceptive use. The men were also healthy and nonsmoking (age 24 ± 1 , range 20-33 y). All subjects were interviewed about their medical history. The women had medical and gynecological examinations and provided written confirmation of a negative Papanicolaou smear within one year of being admitted to the study. Each woman participated in four experiments, two baseline hypertonic saline infusion tests (one in the follicular and one in the luteal phase of the menstrual cycle), and one hypertonic saline infusion test while taking each type of oral contraceptive (two total). Estrogen and progesterone vary across the menstrual cycle. Therefore, as with our other protocols, the study design employed a hypertonic saline infusion test conducted in the early-follicular phase, 2-4 days after the beginning of menstrual bleeding (low estrogen and progesterone) and one conducted in the mid-luteal phase, 7-9 days after the luteinizing hormone peak (high estrogen and progesterone), determined individually by the use of ovulation prediction kits (OvuQuick, Quidel Corp, San Diego, CA). If the subject did not ovulate during a given cycle, she repeated the ovulation prediction test during the next cycle. Following two consecutive non-ovulatory cycles, the subject was excluded from further study. To verify phase of the menstrual cycle, plasma levels of estrogen and progesterone were assessed from the baseline blood sample prior to undertaking the infusion protocol. After completing the baseline hypertonic saline infusion tests, the women again underwent hypertonic saline infusions after four weeks of either continuous combined (estrogen-progestin, OC E+P) or progestin-only (OC P) oral contraceptive treatment (random assignment). Following a 4-week "washout" period, the subjects crossed over to the other pill treatment.

During OC E+P, the women received 0.035 mg of ethinyl estradiol and 1 mg of the progestin, norethindrone daily. During OC P treatment, subjects received 1 mg/day of the progestin, norethindrone.

Ten men underwent the hypertonic saline infusion test one time.

Infusion studies

For each experiment, the women and men arrived at the laboratory at approximately 9:00 am after eating a light (~ 300 kcal) breakfast. Upon reporting to the laboratory, the subject voided her/his bladder, entered an environmental chamber (27°C, 30 % rh), was weighed to the nearest 10 g on a beam balance, and rested seated for a 60-min control period. During this period, a 20-ga teflon catheter was placed in an antecubital or forearm vein in each arm and baseline arterial blood pressure and heart rate were recorded. A heparin block (20 U/ml) maintained catheter patency. At the end of the control period, a baseline blood sample was taken, thirst perception was assessed and a urine sample was collected. Following these control samples, hypertonic (3.0% NaCl) saline was infused at a rate of $0.1 \text{ ml} \cdot \text{min}^{-1} \cdot \text{kg}^{-1} \text{ BW}$ for 120 min into one of the catheters. Blood was sampled at 10, 20, 30, 40, 50, 60, 75, 105, and 120 min during the infusion from the other catheter, and a urine sample obtained at the end of infusion. Following a 30-min seated recovery period, the subject drank water (15 ml/kg BW) over the next 30 minutes. Thirty minutes after drinking was complete, plasma volume was determined with Evan's Blue dye procedure (see below). Blood samples were obtained at 30, 60, and 120 min following infusion. Urine was collected at 60 and 120 min of drinking. Thirst perception was assessed at all blood sampling times. The subjects were weighed at the end of the infusion period, after the drinking period, and again at the end of the protocol.

All blood samples were analyzed for hematocrit, hemoglobin, total protein, osmolality, and the concentrations of creatinine, glucose, urea nitrogen, sodium, potassium, cortisol (P_{CORT}) and arginine vasopressin. The control blood sample was also analyzed for 17- β -estradiol and progesterone. Blood samples at control, at the end of the infusion, and at 60 and 120 min following the infusion were analyzed for the concentrations of atrial natriuretic peptide, aldosterone, and plasma renin activity. Urine was analyzed for volume, osmolality, sodium, potassium, and creatinine concentrations.

Blood sampling

All blood sampling was done via a 20-ga Intracath catheter placed in an arm vein. Subjects were semi-recumbent during placement of the catheter and were seated for 60 min prior to sampling to ensure a steady state in plasma volume and constituents. Blood samples were separated immediately into aliquots. The first was analyzed for hemoglobin and hematocrit. A second aliquot was transferred to a heparinized tube, and a third aliquot for the determination of serum sodium and potassium concentrations was placed into a tube without anticoagulant. All other aliquots were placed in tubes containing EDTA. The tubes were centrifuged and the plasma taken off the heparinized sample analyzed for sodium, potassium, osmolality, glucose, urea creatinine and aldosterone. The EDTA samples were analyzed for concentrations of arginine vasopressin, cortisol and atrial natriuretic peptide and plasma renin activity.

Blood volume

Absolute blood volume was measured by dilution of a known amount of Evan's blue dye. This technique involves injection of an accurately determined volume of dye (by weight, since the specific density is 1.0) into an arm vein and taking blood samples for determination of dilution after complete mixing has occurred (10, 20 and 30 min). Plasma volume was determined from the product of the concentration and volume of dye injected, divided by the concentration in plasma after mixing, taking into account 1.5% lost from the circulation within the 10 min. Blood volume is calculated from plasma volume and hematocrit concentration corrected for peripheral sampling.

Thirst ratings

The perception of thirst was assessed by asking the subject to make a mark on a line rating scale in response to the question, 'How thirsty do you feel now?' The line is 175 mm in length and is marked 'not at all' on one end and 'extremely thirsty' at the 125 mm point. We tell subjects that they can mark beyond the 'extremely thirsty' point if they wish and may even extend the line if they feel it necessary. This method was developed by Marks et al. (62) and has been used with great success in the evaluation of several sensory systems. We have found an extraordinarily good relationship between the perception of thirst and plasma osmolality during hypertonic saline infusion and dehydration in young volunteers (91, 92).

Calculations

Changes in plasma volume were estimated from changes in hemoglobin (Hb) and hematocrit (Hct) concentrations from the control (pre-HSI) sample according to the equation:

$$\% \Delta PV = 100 \left[\frac{[(Hb_b)/(Hb_a)][(1-hct_a \cdot 10^{-2})]}{[(1-hct_b \cdot 10^{-2})]} \right] - 100$$

where subscripts a and b denote measurements at time a and control, respectively. Hemoglobin was measured in triplicate by the cyanomethemoglobin technique and hematocrit in triplicate by the microhematocrit method.

Fractional excretions of water (FE_{H_2O}) and Na^+ (FE_{Na^+}) were calculated from the following equations:

$$FE_{H_2O} = (U_v/GFR) \cdot 100$$

$$FE_{Na^+} = (U_v \cdot [Na^+]_u / GFR \cdot [Na^+]_f) \cdot 100$$

$$[Na^+]_f = \text{the Donnan factor for cations } (0.95) \cdot [Na^+]_s$$

where the subscripts f and u are glomerular filtrate and urine respectively, U_v is urine flow rate, and $[Na^+]_s$ is $[Na^+]_s$ in protein-free solution (mEq/kg H_2O). Glomerular filtration rate (GFR) was estimated from creatinine clearance.

Blood analysis:

Plasma and urine sodium and potassium were measured by flame photometry (Instrumentation Laboratory model 943), plasma osmolality by freezing point depression (Advanced Instruments 3DII), and plasma proteins by refractometry. Plasma glucose, urea and creatinine concentrations were determined by colorimetric assay (Sigma Diagnostic Products). Plasma renin activity, plasma concentrations of aldosterone, cortisol, atrial natriuretic peptide, arginine vasopressin, 17- β -estradiol and progesterone were measured by radioimmunoassay. The assay for AVP has a sensitivity of 0.6 pg/ml, which is necessary to detect small, but important, changes in this hormone.

Data analysis:

For each subject, osmotic regulation of thirst was determined by plotting thirst as a function of plasma osmolality during hypertonic saline infusion. The sensitivity of thirst to changes in plasma osmolality provides the slope of this relationship, and the intercept provides the threshold for thirst onset. Body water handling was determined through the assessment of overall fluid balance and the renal clearance of free water, osmols and sodium. Plasma concentrations of the fluid and sodium-regulating hormones, aldosterone, atrial natriuretic peptide and plasma renin activity were assessed to help determine the mechanisms by which renal water and osmoregulatory function were altered by changes in sex hormone status.

Statistics. The variables over time (control tests, hormone intervention tests) were analyzed by conditions (combined estrogen, progestin vs. progestin-only) ANOVA for repeated measures. When significant differences were found, post hoc testing was applied to determine differences between means. Differences were considered statistically significant when $P < 0.05$.

Sample size calculation. The primary variables used to determine changes in body water regulation and the osmotic regulation of arginine vasopressin are plasma concentrations of arginine vasopressin and thirst. Expected plasma arginine vasopressin and thirst responses within and between groups are derived from data from our laboratory using subjects of the same age (35, 91). In an earlier study, during hypertonic saline infusion, plasma arginine vasopressin increased by 5.29 pg/ml, and thirst perception by 88 mm on a visual analog scale. An estimate of the pooled standard deviation for the group was 1.81 pg/ml and 23 mm, for arginine vasopressin and thirst respectively.

The desired statistical test is two-sided at the 5% significance level, with 80% power to detect a difference. Based on our previous work, 80% power is sufficient to detect a significant alteration in plasma arginine vasopressin concentration and fluid balance. For a two-sided test, $Z_{(\alpha)} = 1.96$, and for 80% power, $Z_{(\beta)} = 0.84$. The formula for calculating sample size for continuous response variables is (24):

$$N = 2[(Z_{(\alpha)} + Z_{(\beta)})^2 (s)^2 / (d)^2]$$

Substituting the values, the sample size is 8 subjects per group.

RESULTS (preliminary).

We have completed data collection on all women and men in the protocol. Most blood analysis is also complete, however analyses of arginine vasopressin and free versus bound cortisol levels are still ongoing. Therefore, the data presented here are from all subjects, but exclude these variables.

Effects of menstrual cycle and oral contraceptive pills on osmotic regulation of thirst, water balance and sodium regulation (women only).

Subject characteristics.

Subjects were 29 ± 2 years old, were 164 ± 5 cm tall and weighed 59.9 ± 2.3 kg at the time of their first (follicular phase) test. There were no changes in baseline body weight across menstrual phases or due to either oral contraceptive pill (Table 13). Blood and plasma volumes were significantly reduced during the luteal phase compared to the follicular phase and to OC E+P. Neither OC P nor OC E+P were associated with changes in blood or plasma volume relative to the follicular phase (Table 13).

Baseline (pre-infusion).

Plasma osmolality was reduced (Fig 14), and Hct and [Hb] increased during the luteal phase (Table 14) compared to the follicular phase, however there were no significant differences between phases in $S_{[Na^+]}$ prior to the infusion. In addition, there were no baseline differences in thirst ratings across menstrual phase or oral contraceptive treatments (Table 14, Fig 15).

Baseline PRA was lower in the follicular phase compared to the other four conditions, although $P_{[ALD]}$ was greater than the follicular phase only in the luteal phase (Fig 16, $P < 0.05$). There were no differences between any of the four conditions at baseline in $P_{[ANP]}$ (Fig 16). Baseline $P_{[CORT]}$ was greater during OC E+P administration, but unaffected by menstrual phase or OC P treatment (Fig.17, $P < 0.05$). Urine flow, osmolality and renal sodium excretion and free water (C_{H_2O}) and osmotic (C_{Osm}) clearances were also unaffected by phase or pill treatment, indicating baseline hydration levels were similar among the treatment days (Tables 15-16). Baseline heart rate and mean blood pressure were unaffected by menstrual phase or by oral contraceptive treatment (Table 17).

Hypertonic saline infusion.

Despite the increases, P_{Osm} during the luteal phase and OC E+P remained significantly below that of the follicular phase during the early part of infusion, although despite a strong trend, these differences were no longer significant after 50 minutes and 60 minutes (for OC E+P and luteal phase, respectively) of infusion. Hypertonic saline infusion-related increases in thirst were similar under all four conditions.

Hypertonic saline infusion increased P_{Osm} , plasma volume and thirst similarly during the follicular and luteal phases, and during OC E+P and OC P (Figs. 14 and 15). Linear regression analysis of the individual subjects' data during hypertonic saline infusion indicated significant correlations between thirst and P_{Osm} (mean $r = 0.90 \pm 0.02$). Linear regression analysis of the individual subjects' P_{Osm} and thirst responses indicated significant correlations (mean $r = 0.90 \pm 0.02$). Figure 18 and Table 13 shows the downward shift in the abscissal intercept of the linear thirst- P_{Osm} relationship during hypertonic saline infusion when endogenous $P_{\text{[E}_2]}$ and $P_{\text{[P}_4]}$ were increased in the luteal phase. The slopes of this relationship were unaffected by menstrual phase or oral contraceptive pills.

Plasma renin activity and $P_{\text{[ALD]}}$ decreased during hypertonic saline infusion in all conditions, with luteal phase values for $P_{\text{[ALD]}}$ remaining above the follicular phase, OC E+P and OC P (Fig. 16, $P < 0.05$). Plasma cortisol concentration fell steadily in all conditions, but remained greater in the OC E+P treatment (Fig 17, $P < 0.05$). Renal sodium and potassium excretion increased during hypertonic saline infusion in all conditions, and there were no differences among the different menstrual phases or oral contraceptive pill treatments (Table 16 and Fig. 19).

Recovery.

Plasma osmolality was similar among conditions during recovery from hypertonic saline infusion as were percent changes in plasma volume and $S_{\text{[Na+]}}$ (Fig. 14). In addition, absolute plasma volume as measured by Evan's blue was greatest during the follicular phase (3028 ± 188 , 2917 ± 166 , 2910 ± 188 and 2901 ± 177 ml for follicular and luteal phase and OC P and OC E+P respectively). Plasma [ANP] and PRA were not affected by menstrual phase or oral contraceptive treatment, but $P_{\text{[ALD]}}$ was significantly greater in the luteal phase compared to the follicular phase, and compared to OC P and OC E+P (Fig 16, $P < 0.05$). Plasma [CORT] fell slightly during recovery in all conditions and remained significantly elevated during OC E+P treatment (Fig 17, $P < 0.05$).

During recovery, neither renal function nor electrolyte excretion were affected by menstrual phase or oral contraceptive administration (Tables 15 and 16 and Fig.19), and overall fluid balance (i.e. fluid intake - urine output) was unaffected by either phase of the menstrual cycle or oral contraceptive administration (Fig. 20). Heart rate and mean blood pressure remained unchanged throughout recovery and was unaffected by menstrual phase or oral contraceptive treatment (Table 17).

DISCUSSION

Osmotic regulation of thirst and fluid balance

We found that normally cycling young women have a reduction in the osmotic threshold for thirst onset during the mid-luteal phase of the menstrual cycle (i.e. when estrogen and progesterone peak). However, the osmotic threshold for thirst onset was unaffected by either oral contraceptive pill, suggesting these changes may be specific to the endogenous forms of estrogen and progesterone.

Our findings regarding the thirst- P_{Osm} relationship during hypertonic saline infusion with OC E+P appear in contrast to the thirst- P_{Osm} relationship during dehydration. It is difficult to explain why the method of inducing osmotic stimulation would have a strong impact on the sex hormone effects, but the primary difference between hypertonic saline infusion and dehydration is the effect on plasma volume. Hypertonic saline infusion causes a large (~19 %) increase in plasma volume while dehydration leads to a large decrease (~7.9 %) in plasma volume. In addition, only during the luteal phase is there a large baseline fall in plasma volume, so the plasma volume reduction could have contributed to the lower P_{Osm} threshold for thirst onset because plasma volume is a potent thirst stimulus. However, this mechanism seems unlikely because the luteal phase plasma volume contraction was not associated with a fall in blood pressure, so would not have stimulated high-pressure baroreceptors (50). Low-pressure baroreceptors may certainly have been loaded during hypertonic saline infusion and may exert their own influence on thirst perception. Changes in brain angiotensin II are also a potent thirst stimulus, and PRA increased in the luteal versus follicular phase, although this trend was also apparent during both oral contraceptive treatments. At this point, it is difficult to speculate because we do not have the data from the $P_{[\text{AVP}]}$, but it may be that thirst ratings, which are a relatively insensitive measure of body fluid regulation, may simply be unable to demonstrate changes during OC E+P.

Combined estrogen and progestin oral contraception administration increased plasma volume by as much as 11.6 % relative to the mid-luteal phase of the menstrual cycle. The fact that estrogen and progesterone are both elevated under these conditions may seem difficult to reconcile. However the plasma estrogen/progesterone ratio, or simply the greater (pharmacological) levels of estrogen present in the plasma and tissues during OC E+P administration, are important factors in determining body water effects. Estrogen-mediated plasma volume expansion (2, 9, 34, 88) is not always accompanied by changes in water retention, and the mid-luteal phase plasma volume contraction is not always associated with greater urine loss (92). A number of earlier studies demonstrated that high plasma levels of estrogen and progesterone alter Starling forces to favor protein and fluid movement out of the vasculature (55, 56, 107, 108). We recently found (90) that administration of estrogen during ANP infusion prevented plasma volume loss, while combined estrogen with progesterone administration designed to achieve luteal phase plasma levels reversed these protective effects. However, there were no changes in sodium loss between the two conditions, while capillary filtration coefficient increased during estrogen administration and fell during combined treatment. These findings support the hypothesis that the primary effects of estrogen and progesterone are to regulate water distribution, rather than overall water balance.

Sodium Regulation

Neither estrogen dominant, nor progestin-only oral contraceptives increased $P_{[\text{ALD}]}$; rather, we found only the high endogenous estrogen and progesterone present in the luteal phase enhanced $P_{[\text{ALD}]}$, despite increases in PRA during OC treatments. Urine sodium loss was unaffected during hypertonic saline infusion, despite these changes in the sodium regulation hormones.

Combined oral contraceptive pills deliver pharmacological levels of ethinyl estradiol (11), which is almost identical in structure to the most biologically active form of endogenous estrogen, 17 β -estradiol, although with four times the potency (60). As with dehydration, our data do not support a role for estrogen in the stimulation of the renin-aldosterone system because the small increases in PRA led to only minor (nonsignificant) increases in $P_{[ALD]}$. Norethindrone, a progestational derivative of testosterone, differs in structure from endogenous progesterone. Endogenous progesterone inhibits aldosterone-dependent sodium reabsorption at distal sites in the nephron and produces a transient natriuresis (66) followed by a compensatory stimulation of the renin-aldosterone system (63, 104, 114). In contrast, norethindrone does not possess antimineralocorticoid properties because neither OC E+P nor OC P led to increases in $P_{[ALD]}$. Nonetheless, administration of norethindrone, with and without estrogen, enhanced PRA and to some minor extent aldosterone (Fig 16), suggesting norethindrone may stimulate the renin-angiotensin-aldosterone system, perhaps indirectly through changes in renal sodium retention, or through subtle effects on blood pressure. Our earlier findings demonstrated that norethindrone administration increased sodium retention slightly during dehydration, suggesting this synthetic form of progesterone may act directly on the renal tubules.

Cortisol responses


We also used oral contraceptive pills to evaluate estrogen and progesterone effects on the hypothalamic-pituitary-adrenal axis by measuring cortisol responses to hypertonic saline infusion under the different reproductive hormone conditions. We chose this system in an attempt to evaluate any independent effects the hormones may have on pituitary release of arginine vasopressin. In addition, this system controls the release of cortisol, one of the most vital hormones released in response to physiological and psychological stress. Cortisol has important effects on carbohydrate and lipid metabolism and serves as the primary physiological antagonist to insulin.

Two pathways accomplish Hypothalamic control of the pituitary: direct connections between the posterior pituitary and hypothalamic neurosecretory neurons through nerve fibers in the pituitary stalk, and hypothalamic hormones reaching the anterior pituitary through pituitary portal circulation [Fig. 21, (75)] Hypothalamic control of the pituitary and adrenal hormones (HPA axis) begins with corticotrophin-releasing hormone (CRH) which, like AVP, is synthesized and released by the PVN (Fig 21).

Corticotrophin-releasing hormone, in response to stress and other physiologic stimuli, stimulates the release of adrenocortico releasing hormone (ACTH) from the anterior pituitary. This hormone is released into the circulation and stimulates cortisol release from the adrenal cortex.

It has long been accepted that AVP has important effects on the HPA axis, and that the HPA axis has important effects on AVP. Older studies have demonstrated that cortisol increases osmotic threshold for AVP release in humans (4) and other primates (101). In conscious monkeys cortisol introduced into the supraoptic nucleus significantly lowered plasma osmolality prior to infusion, so that a larger amount of 5% saline was required to reach the osmotic threshold for AVP release (101). Arginine vasopressin is a weak corticotrophic factor and is found in high concentrations in the long portal blood vessels (i.e. access from PVN to anterior pituitary) where it amplifies the effect of CRH on ACTH secretion (78). In addition, AVP is found in high concentrations in the short

Fig. 21. AVP and HPA axis interaction.
Adapted from Raff et al. (75)



portal vessels (those that connect the anterior and posterior pituitaries) suggesting direct control of ACTH release by AVP. In fact, AVP modulation of ACTH release may predominate in some instances, such as insulin-induced hypoglycemia (15, 31, 74). Finally, modulation of AVP release by the posterior pituitary is a part of the negative feedback control of ACTH secretion.

In the present study we demonstrated elevated cortisol levels during administration of oral contraceptives containing estradiol and progestin relative to the early follicular and mid-luteal phases, although this increase did not occur during administration with progestin alone. We did not observe changes in blood glucose concentrations, and the cortisol increase was likely due to increases in cortisol-binding globulin (CBG, or transcortin) which can increase as much as 240% during oral contraceptive administration (71). This increase occurs only during oral administration of estradiol, likely due to hepatic interactions as transcortin is produced in the liver where ethynl-estradiol is metabolized. In fact, the cortisol available for biologically active functions may have even been reduced during the OC administration if the CBG levels were increased at a higher rate than the free cortisol, as cortisol binding can increase from as low as 84% to as high as 99% during OC administration. Thus, it is difficult to determine if the elevations in cortisol have any functional or biological significance. The greater cortisol levels without concomitant changes in glucose metabolism may indicate a compensatory role to transient changes in glucose metabolism occurring early in the administration of OC E+P, or may simply be a biochemical manifestation of the greater CBG levels and CBG-cortisol binding. Finally, the cortisol binding to CBG is very weak to serve the biological function of making cortisol readily available in times of stress. At this point, we are measuring using filters to separate the free versus bound cortisol.

We cannot know the impact of changes in cortisol levels on osmotic AVP regulation until our AVP data are analyzed.

We suspect that the effects on cortisol were due to increases in estradiol because they did not occur when progestin was administered alone. However, progesterone likely modulates estrogen-mediated changes in HPA function because progestin administration along with estrogen obliterates the improvement of insulin resistance in both pre- and postmenopausal women. In addition to its effects on AVP, estrogen also has important effects on the HPA axis. The HPA axis is activated in a number of stressful situations and can have negative effects on the reproductive system. For example, excess ACTH or cortisol can inhibit luteinizing hormone (LH) release and/or ovulation in animals (99) and humans (27). On the other hand, sex hormones have important effects on the HPA. In rats, basal and stress-stimulated HPA hormone concentrations differ between males and females (58). Ovariectomy reduces basal levels and stress-induced levels of corticoids which are restored to normal by administration of estrogens (52, 72). In humans, ACTH reductions have been observed after CRH administration to women on oral contraceptives (49) and basal ACTH and cortisol are highest in the mid-follicular phase and during ovulation (38). On the other hand, cortisol levels are lowest when progesterone levels are high (45), and an acute fall in estrogen following ovariectomy in young women induced changes in the HPA axis characterized by inhibition of ACTH and cortisol secretion during CRH stimulation (29).

RESULTS (Men, preliminary)

Sex differences in body fluid regulation

Subject characteristics

The men in this study were taller (174 ± 2 cm), weighed more (75 ± 2 kg) and were younger (24 ± 1 y, range 20-33) than the women. In addition, their blood and plasma volumes were greater (Table 18, $P < 0.05$)

Baseline (pre-infusion).

Plasma osmolality was reduced (Fig. 22), and Hct and [Hb] increased during the luteal phase (Table 19) compared to the men, however there were no significant differences between phases in $S_{[Na^+]}$ prior to the infusion. In addition, there were no baseline differences in thirst ratings between men and women in either menstrual phase (Table 19, Fig 2).

Baseline PRA and $P_{[ALD]}$ were elevated in the luteal phase compared to the follicular phase and compared to the men (Fig 23, $P < 0.05$). In contrast, there were no differences between the men and women at baseline in $P_{[ANP]}$ (Fig 23). Likewise, baseline $P_{[CORT]}$ was unaffected by menstrual phase or sex (Fig. 24). Urine flow, osmolality and sodium excretion as well as C_{H_2O} and C_{Osm} were also unaffected by phase or sex, indicating baseline hydration levels were similar among the treatment days and between the men and women (Tables 20 and 21). Baseline heart rate was unaffected by menstrual phase or sex, but baseline systolic, diastolic and mean arterial pressure were greater in the men (Table 22).

Hypertonic saline infusion.

Plasma osmolality in the women during the luteal phase remained significantly below that of the follicular phase and the men during the early part of infusion (Fig 22). Further, despite a strong trend, these differences were no longer significant after 50 min of infusion. Hypertonic saline infusion-related increases in thirst were similar between the phases and between the men and women in both menstrual phases (Fig. 22)

Hypertonic saline infusion increased P_{Osm} , plasma volume and thirst similarly during the follicular and luteal phases, and the men (Fig. 22 and Table 19). Linear regression analysis of the individual subjects' data during hypertonic saline infusion indicated significant correlations between thirst and P_{Osm} (mean $r = 0.90 \pm 0.02$ for women, mean $r = 0.85 \pm 0.04$ for the men). Figure 25 and Table 18 shows the downward shift in the abscissal intercept of the linear thirst- P_{Osm} relationship during hypertonic saline infusion when endogenous $P_{[E_2]}$ and $P_{[P_4]}$ were increased in the luteal phase relative to the women in the follicular phase, and relative to the men. The slope of this relationship, however, was unaffected by menstrual phase or sex.

Plasma renin activity and $P_{[ALD]}$ decreased during hypertonic saline infusion in all conditions, with luteal phase values for $P_{[ALD]}$ remaining above the follicular phase, but not the men (Fig. 23, $P < 0.05$). Plasma cortisol concentration fell steadily in the women during both phases, but began to increase in the men at 75 min of infusion (Fig. 24, $P < 0.05$). The

increases continued over time throughout the end of the infusion, and were greater than the women at all time points after 75 min all conditions. Renal sodium excretion increased during hypertonic saline infusion all conditions, and there were no differences between the two menstrual phases, but sodium excretion was lower in the men compared to the women in both menstrual phases (Fig. 26, $P < 0.05$). Although heart rate did not increase during hypertonic saline infusion in the either group, blood pressure increased during the infusion in men (Table 22, $P < 0.05$).

Recovery

Plasma osmolality was similar among conditions and between men and women during recovery from hypertonic saline infusion (Fig. 22), as were percent changes in plasma volume and $S_{[Na^+]}$. In addition, absolute plasma volume as measured by Evan's blue was greater during the follicular (3028 ± 188 ml) compared to the luteal (2917 ± 166 ml, $P < 0.05$) phase, although both phases were lower than the men (4495 ± 92 ml, $P < 0.05$). Again, $P_{[ANP]}$ and PRA were similar between men and women, but $P_{[ALD]}$ was significantly greater in the luteal phase compared to the follicular phase (Fig 23, $P < 0.05$). Plasma cortisol concentration fell slightly during recovery in all conditions in the women, but significantly in the men, although $P_{[CORT]}$ remained greater in the men until 120 min following the infusion (Fig. 24 $P < 0.05$).

During recovery, neither renal function, electrolyte excretion (Tables 20 and 21, Fig. 25) nor overall fluid balance (i.e. fluid intake - urine output) were affected by either phase of the menstrual cycle or sex (Fig. 27). Due to the greater sodium retention during the infusion in the men, cumulative sodium retention was greater in men than in women by the end of recovery (Fig. 25, $P < 0.05$). This greater sodium retention is accounted for primarily in the plasma, as the increase in plasma sodium content was greater in the men (566 ± 35 to 642 ± 14 mEq, $P < 0.05$) compared to the women in either the follicular (349 ± 27 to 419 ± 28 mEq or the luteal (334 ± 18 to 405 ± 9 mEq). Heart rate and mean blood pressure remained unchanged throughout recovery in the women and was unaffected by menstrual phase. However, blood pressure remained elevated throughout recovery in the men, and was greater than the women throughout (Table 22, $P < 0.05$).

DISCUSSION

Previous data on Danish men and women using 24-hour ambulatory monitoring have demonstrated that men have higher blood pressure than pre-menopausal women (116). In addition, a number of studies, including meta-analysis, have demonstrated that men have higher blood pressure until age 70 years (93). In addition, the rate of development of renal disease is also greater in men (59, 86). Our study examined the way in which the male sex as a predisposing factor affected the response to a sodium load in young, healthy men and women.

The men in this study were not hypertensive (Table 17), but their blood pressure was still significantly higher at baseline than the women. In addition, in contrast to the women, their blood pressure increased during hypertonic saline infusion. In fact, the blood pressure response was similar in the women regardless of the level of estrogen and

progesterone, suggesting that the changes in blood pressure were due to androgen, not estrogen or progesterone effects. The mechanisms by which androgens may increase blood pressure are not known, but a number of studies have demonstrated a shift in the pressure-natriuresis curve in spontaneously hypertensive male versus female rats (76), and a similar shift in when ovariectomized female rats are given testosterone (23, 70). The cause for these shifts is unknown, but Reckelhoff and Granger (76) speculate in their excellent review, that differences in the renin-angiotensin system (RAS) may be involved. Plasma renin activity is reported to be higher in men than women, but without these studies are observational in design and did not control for phase of the menstrual cycle. Our findings do not support sex differences in the RAS as a mechanism for the differences in blood pressure and sodium regulation between men and women. Plasma renin activity was greater in the men compared to women only in the follicular phase, but was similar to the women during the luteal phase, whereas sodium retention was greater between the men and women regardless of menstrual phase. Therefore, the sex differences may have to do more with direct effects of androgens on the kidney to increase proximal tubule reabsorption of sodium.

Another system that may be brought into play is the HPA axis, in which the end result is the release of the hormone cortisol. Cortisol release is often an indicator of stress, and may be indicative of the release of other stress-related hormones, such as catecholamines. We did not measure catecholamines, but perhaps the blood pressure increases during hypertonic saline infusion were related to a greater overall stress response to the sodium load that led to sympathetic nervous system activation and consequent increases in blood pressure. Sympathetic nervous system activity cannot be determined because we did not measure catecholamines, but may be part of an overall stress response leading to the greater blood pressure at baseline, and the greater blood pressure response to hypertonic saline infusion.

In contrast to the effects on sodium retention and blood pressure, osmotic regulation of thirst was different between menstrual phases, and different between men and women only during the luteal phase when estrogen and progesterone are increased. These data are consistent with our earlier data during dehydration, and also the changes in osmotic regulation during OC E+P, indicating that this relationship is shifted downward only when estrogen and progesterone are elevated. Whether or not the relationship remains for the osmotic regulation of AVP will be evaluated when the plasma AVP concentration has been analyzed.

Responses to comments regarding the Progress Report from 1999:

No technical issues were raised regarding the Progress Report from 1999. We have attempted to remove grammatical and typographical errors from this report.

Text to tables

Table 1. Subject characteristics and responses to dehydration. Pre-exercise body weight (BW) and plasma concentrations of endogenous 17- β estradiol ($P_{[E_2]}$) and progesterone ($P_{[P_4]}$) in the early follicular and mid-luteal phases of the menstrual cycle and during administration of combined (estradiol + progestin, OC E+P) and (progestin only, OC P) oral contraceptive pills. Slopes and abscissal intercepts of the individual subjects' plasma arginine vasopressin concentration ($P_{[AVP]}$)-plasma osmolality (P_{Osm}) and thirst- P_{Osm} relationships during dehydration in the early follicular and mid-luteal phases of the menstrual cycle and OC E+P and OC P. *Difference between the follicular and luteal phases. #Difference between follicular phase and OC E+P. Differences were considered statistically significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 2. Blood responses at rest, and during dehydration and *ad libitum* drinking. Serum concentrations of sodium ($S_{[Na^+]}$) and potassium $S_{[K^+]}$, and total protein concentration (TP).

*Difference between the follicular and luteal phases. #Difference between follicular phase and OC E+P, §Difference between follicular phase and OC P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 3. Blood responses at rest, and during dehydration and *ad libitum* drinking. Hematocrit (Hct), blood hemoglobin concentration (Hb), plasma volume (PV), plasma arginine vasopressin concentration ($P_{[AVP]}$) and total protein (TP).. *Difference between the follicular and luteal phases. #Difference between follicular phase and OC E+P, †Difference between luteal phase and OC E+P. §Difference between follicular phase and OC P. ††Difference between luteal phase and OC P. §Difference between OC E+P and OC P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 4. Thirst ratings (analog-rating scale) at rest, and during dehydration and *ad libitum* drinking.

Table 5. Renal osmoregulatory responses at rest, and during dehydration and *ad libitum* drinking. Urine flow (U_v), urine osmolality (U_{Osm}), plasma osmolality (P_{Osm}), free water clearance (C_{H_2O}), osmolar clearance (C_{Osm}). #Difference between follicular phase and OC E+P, †Difference between luteal phase and OC E+P. Data are expressed as mean \pm SEM.

Table 6. Renal function and electrolyte excretion at rest, during dehydration and *ad libitum* drinking. Glomerular filtration rate (GFR), fractional excretion of sodium (FE_{Na^+}), urine excretion of sodium (U_{Na^+}) and potassium (U_{K^+}), and ratio of urine sodium and potassium concentrations ($[Na^+]_u/[K^+]_u$). *Difference between the follicular and luteal phases. #Difference between follicular phase and OC E+P. §Difference between follicular

phase and OC P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 7A. Cardiovascular responses to dehydration. Heart rate (HR), mean (MAP), systolic (SBP), diastolic (DBP) and pulse (PP) blood pressures at rest and in response to 150 min dehydrating exercise and 180 of *ad libitum* rehydration in the follicular and luteal phases, and during combined estradiol/progestin oral contraception administration OC E+P, $n=8$). Data are expressed as mean \pm SEM.

Table 7B. Cardiovascular responses to dehydration. Heart rate (HR), mean (MAP), systolic (SBP), diastolic (DBP) and pulse (PP) blood pressures at rest and in response to 150 min dehydrating exercise and 180 of *ad libitum* rehydration in the follicular and luteal phases, and during progestin-only oral contraception administration ($n=9$). Data are expressed as mean \pm SEM.

Table 8. Fluid regulation hormones over two menstrual cycles. Trial A and Trial B are the first and second trials within the specified menstrual phase. Plasma renin activity (PRA) and plasma concentrations of aldosterone ($P_{[ALD]}$), arginine vasopressin ($P_{[AVP]}$) and atrial natriuretic peptide ($P_{[ANP]}$) in response to dehydrating exercise and 180 min of *ad libitum* rehydration in the early follicular and mid-luteal phases of the menstrual cycle.

*Difference between the follicular and luteal phases. † Area under the curve (AUC, trapezoid). Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 9. Reliability of fluid regulation hormones over two menstrual cycles. Cronbach's α for reliability within two follicular and two luteal phase tests. † Cronbach's $\alpha \geq 0.80$ was considered reliable.

Table 10. Subject characteristics (27°C) and responses to passive heating (35°C) and exercise in the heat (35°C). Pre-exercise body weight (BW), plasma concentrations of endogenous 17- β estradiol ($P_{[E_2]}$) and progesterone ($P_{[P_4]}$), hematocrit (Hct), blood hemoglobin concentration ($[Hb]$), plasma osmolality ($P_{[Osm]}$) and serum sodium concentration ($S_{[Na+]}$). Esophageal (T_{es}) and skin (T_{sk}) temperatures in the early follicular and mid-luteal phases of the menstrual cycle and during administration of combined (estradiol + progestin, OC E+P) and (progestin only, OC P) oral contraceptive pills, and following 40-min of exercise at 35°C. *Difference from follicular. † Difference from OC E+P. Differences were considered statistically significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 11. Cardiovascular responses to passive heat and exercise. Heart rate (HR), stroke volume (SV), cardiac output (CO) mean (MAP), systolic (SBP), diastolic (DBP) and pulse (PP) blood pressures at rest (27°C) and in response to 20 min of passive heating (35°C) and 40 min of exercise (35°C) in the follicular and luteal menstrual phases. Data are expressed as mean \pm SEM.

Table 12. Esophageal temperature for sweating during 40 min of exercise (35°C) in the early follicular and mid-luteal phases of the menstrual cycle and during administration of combined (estradiol + progestin, OC E+P) and (progestin only, OC P) oral contraceptive pills. *Difference from follicular. †Difference from OC E+P. Differences were considered statistically significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 13. Subject characteristics and thirst responses during hypertonic saline infusion. Pre-infusion body weight (BW) and plasma concentrations of endogenous 17- β estradiol ($P[E_2]$) and progesterone ($P[P_4]$) in the early follicular and mid-luteal phases of the menstrual cycle and during administration of combined (estradiol + progestin, OC E+P) and (progestin only, OC P) oral contraceptive pills. Slopes and abscissal intercepts of the individual subjects' and thirst-plasma osmolality (P_{Osm}) relationships during hypertonic saline infusion in the early follicular and mid-luteal phases of the menstrual cycle and OC E+P and OC P. *Different from the follicular phase. †Different from OC P. ‡Different from OCE+P. Differences were considered statistically significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 14. Blood and thirst responses at rest, and during hypertonic saline infusion and recovery. Hematocrit (Hct), blood hemoglobin concentration (Hb), and plasma volume (PV). . *Different from the follicular phase. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 15. Renal osmoregulatory responses at rest, and during hypertonic saline infusion and recovery. Urine flow (U_v), urine osmolality (U_{Osm}), plasma osmolality (P_{Osm}), renal free water clearance (C_{H_2O}), and renal osmolar clearance (C_{Osm}). Data are expressed as mean \pm SEM.

Table 16. Renal electrolyte excretion at rest, during hypertonic saline infusion and recovery. Glomerular filtration rate (GFR), fractional excretion of sodium (FE_{Na+}), urine excretion of sodium (U_{Na+}) and potassium (U_{K+}), and ratio of urine sodium and potassium concentrations ($[Na^+]_u/[K^+]_u$). Data are expressed as mean \pm SEM.

Table 17. Cardiovascular responses at rest, and during hypertonic saline infusion and recovery. Heart rate (HR), mean (MAP), systolic (SBP), diastolic (DBP) and pulse (PP) blood pressures at rest and in response to 120 min hypertonic saline infusion in the follicular and luteal phases, and during combined estradiol/progestin oral contraception administration OC E+P). Data are expressed as mean \pm SEM.

Table 18. Subject characteristics and thirst responses during hypertonic saline infusion in men and women. Pre-infusion body weight (BW) and plasma concentrations of endogenous 17- β estradiol ($P[E_2]$) and progesterone ($P[P_4]$) in the early follicular and mid-luteal phases of the menstrual cycle. Slopes and abscissal intercepts of the individual thirst-plasma osmolality (P_{Osm}) relationships during dehydration in the early follicular and

mid-luteal phases of the menstrual cycle. *Different from the follicular phase. #Different from the men. Differences were considered statistically significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 19. Blood and thirst responses at rest, and during hypertonic saline infusion and recovery in men and women. Hematocrit (Hct), blood hemoglobin concentration (Hb), and plasma volume (PV). . *Different from the follicular phase. #Different from the men. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Table 20. Renal osmoregulatory responses at rest, and during hypertonic saline infusion and recovery. Urine flow (U_v), urine osmolality (U_{Osm}), plasma osmolality (P_{Osm}), renal free water clearance (C_{H_2O}), and renal osmolar clearance (C_{Osm}). Data are expressed as mean \pm SEM.

Table 21. Renal electrolyte excretion at rest, during hypertonic saline infusion and recovery in men and women. Glomerular filtration rate (GFR), fractional excretion of sodium (FE_{Na^+}), urine excretion of sodium (U_{Na^+}) and potassium (U_{K^+}), and ratio of urine sodium and potassium concentrations ($[Na^+]_u/[K^+]_u$). Data are expressed as mean \pm SEM.

Table 22. Cardiovascular responses at rest, and during hypertonic saline infusion and recovery in men and women. Heart rate (HR), mean (MAP), systolic (SBP), diastolic (DBP) and pulse (PP) blood pressures at rest and in response to 150 min dehydrating exercise and 180 of *ad libitum* rehydration in the follicular and luteal phases and in men. Differences were considered statistically significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Text to figures

Figure 1. Time line for sex hormone administration. (Figure embedded in text).

Figure 2. Plasma osmolality (P_{Osm}) at rest, and in response to dehydrating exercise and 180 min of *ad libitum* rehydration in the follicular and luteal phases, and during combined estradiol/progestin (OC E+P, n=8) and progestin-only oral contraception administration (OC P, n=9). *Difference between the follicular and luteal phases. #Difference between follicular phase and OC E+P. §Difference between follicular phase and OC P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 3. Plasma renin activity (PRA) at rest, and in response to dehydrating exercise and 180 min of *ad libitum* rehydration in the follicular and luteal phases, and during combined estradiol/progestin (OC E+P n=8) and progestin-only oral contraception administration (OC P, n=9). *Difference between the follicular and luteal phases. #Difference between follicular phase and OC E+P. †Difference between luteal phase and OC E+P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 4. Plasma aldosterone concentration ($P_{\text{[ALD]}}$) at rest, and in response to dehydrating exercise and 180 min of *ad libitum* rehydration in the follicular and luteal phases, and during combined estradiol/progestin (OC E+P n=8) and progestin-only oral contraception administration (OC P, n=9). *Difference between the follicular and luteal phases. †Difference between luteal phase and OC E+P. ††Difference between luteal phase and OC P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 5. Plasma atrial natriuretic peptide ($P_{\text{[ANP]}}$) at rest, and in response to dehydrating exercise and 180 min of *ad libitum* rehydration in the follicular and luteal phases, and during combined estradiol/progestin (OC E+P n=8) and progestin-only oral contraception administration (OC P, n=9). *Difference between the follicular and luteal phases. †Difference between luteal phase and OC E+P. §Difference between follicular phase and OC P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 6. Mean plasma arginine vasopressin concentration ($P_{\text{[AVP]}}$) responses to increases in plasma osmolality (P_{Osm}) during dehydration in the follicular and luteal phases, and during combined estradiol/progestin (OC E+P, n=8) and progestin-only oral contraception administration (OC P, n=9). Data are expressed as mean \pm SEM.

Figure 7. Cumulative renal sodium (Na^+) in response to dehydrating exercise and 180 min of *ad libitum* rehydration in the follicular and luteal phases, and during combined

estradiol/progestin (OC E+P n=8) and progestin-only oral contraception administration (OC P, n=9). *Difference between the follicular and luteal phases. #Difference between follicular phase and OC E+P. §Difference between follicular phase and OC P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 8. Body fluid balance after dehydrating exercise and during 180 min of *ad libitum* rehydration in the follicular and luteal phases, and during combined estradiol/progestin (OC E+P, n=8) and progestin-only oral contraception administration (OC P, n=9). #Difference between the follicular and OC E+P. †Difference between luteal phase and OC E+P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 9. Plasma volume changes during exercise and percent changes at baseline relative to follicular phase. *Different from follicular phase. †Different from luteal phase. § Different from OC P.

Figure 10. Esophageal (T_{es}) during 40-minutes of semirecumbent cycle exercise in the heat (35°C). *Different follicular phase from OC P, and follicular phase from luteal phase. †Different luteal phase from OCE+P, and OC P from OCE+P.

Figure 11. Weighted skin temperature (T_{sk}) during 40-minutes of semirecumbent cycle exercise in the heat (35°C).

Figure 12. Arm sweat rate during exercise in the heat (35°C). *Different follicular phase from OC P. †Different luteal phase from OC P. ‡Different OC P from luteal phase.

Figure 13. Arm sweat rate as a function of temperature changes during exercise at 35°C .

Figure 14. Plasma osmolality (P_{osm}), Serum sodium (Na^+) concentration and % plasma volume (PV) change at rest, and in response to hypertonic saline infusion and recovery in the follicular and luteal phases, and during combined estradiol/progestin and progestin-only oral contraception administration. *Different from the follicular phase. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 15. Thirst perception at rest, and in response to hypertonic saline infusion and recovery in the follicular and luteal phases, and during combined estradiol/progestin and progestin-only oral contraception administration. Data are expressed as mean \pm SEM.

Figure 16. Plasma renin activity (PRA), plasma aldosterone ($P_{[ALD]}$) and plasma atrial natriuretic peptide ($P_{[ANP]}$) concentrations at rest, and in response to hypertonic saline infusion and recovery in the follicular and luteal phases, and during combined estradiol/progestin and progestin-only oral contraception administration. *Different from

the follicular phase. [†]Different from OC P. [‡]Different from OCE+P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 17. Plasma cortisol ($P_{[CORT]}$) concentrations at rest, and in response to hypertonic saline infusion and recovery in the follicular and luteal phases, and during combined estradiol/progestin and progestin-only oral contraception administration. ^{*}Different from the follicular phase. [§]Different from luteal phase. [†]Different from OC P. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 18. Mean thirst responses to increases in plasma osmolality (P_{Osm}) during infusion in the follicular and luteal phases, and during combined estradiol/progestin and progestin-only oral contraception administration. Data are expressed as mean \pm SEM.

Figure 19. Cumulative renal sodium (Na^+) and potassium (K^+) excretion in response to hypertonic saline infusion and recovery in the follicular and luteal phases, and during combined estradiol/progestin and progestin-only oral contraception administration. Data are expressed as mean \pm SEM.

Figure 20. Body fluid balance in response to hypertonic saline infusion and recovery in the follicular and luteal phases, and during combined estradiol/progestin and progestin-only oral contraception administration. Data are expressed as mean \pm SEM.

Figure 22. Plasma osmolality (P_{Osm}), % plasma volume (PV) change and thirst perception at rest, and in response to hypertonic saline infusion and recovery in the follicular and luteal phases in women, and in men. ^{*}Different from the follicular phase. [#]Different from the men. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 23. Plasma renin activity (PRA), plasma aldosterone ($P_{[ALD]}$) and plasma atrial natriuretic peptide ($P_{[ANP]}$) concentrations at rest, and in response to hypertonic saline infusion and recovery in the follicular and luteal phases in women, and in men. ^{*}Different from the follicular phase. [#]Different from the men. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 24. Plasma cortisol ($P_{[CORT]}$) concentrations at rest, and in response to hypertonic saline infusion and recovery in the follicular and luteal phases in women, and in men. ^{*}Different from the follicular phase. [§]Different from luteal phase. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

Figure 25. Mean thirst responses to increases in plasma osmolality (P_{Osm}) during infusion in the follicular and luteal phases in women, and in men. Data are expressed as mean \pm SEM.

Figure 26. Cumulative renal sodium (Na^+) and potassium (K^+) excretion at rest, and in response to hypertonic saline infusion and recovery in the follicular and luteal phases in women, and in men. *Different from the follicular phase. §Different from luteal phase. Differences were accepted as significant at $P < 0.05$. Data are expressed as mean \pm SEM.

KEY RESEARCH ACCOMPLISHMENTS

Protocol A

1. Body fluid tonicity is regulated lower when both endogenous 17 β -estradiol and administered ethinyl estradiol are elevated.
2. Body fluid balance is unaffected by the estrogen-related change in osmotic regulation of arginine vasopressin and thirst.
3. Renal sodium and water regulation is unaffected during the luteal phase despite large increases in sodium regulating hormones such as aldosterone, renin and atrial natriuretic peptide.

Protocol B

1. Estrogen reverses progesterone-related increases in core temperature.
2. Estrogen reverses progesterone-related delays in sweat onset during exercise, leading to lower exercise core temperature.

Protocol C

1. In women, osmotic regulation of thirst is reduced when both endogenous 17 β -estradiol and administered ethinyl estradiol are elevated.
2. In women, cortisol is elevated during oral contraceptive treatment with ethinyl estradiol administration compared to the follicular and luteal menstrual phases and compared to treatment with norethindrone.
3. Body fluid balance and sodium regulation are unaffected by menstrual phase or oral contraceptive treatment during and following hypertonic saline infusion.
4. Osmotic regulation of thirst is lower in women compared to men only when both endogenous 17 β -estradiol and administered ethinyl estradiol are elevated.
5. Cortisol responses to osmotic stimulation are greater in men than women at both phases of the menstrual cycle.
6. Sodium retention following a sodium load is greater in men compared to women at both phases of the menstrual cycle.

REPORTABLE OUTCOMES

Published papers:

Stachenfeld, N. S., L. DiPietro, C. A. Kokoszka, C. Silva, D. Keefe and E. R. Nadel. Physiological reliability of fluid regulation hormones in young women. *J. Appl. Physiol.* 86: 1092-1096, 1999.

Stachenfeld, N. S., C. Silva, D. L. Keefe and E. R. Nadel. Estrogen and progesterone effects on body fluid regulation. *J. Appl. Physiol.* 87: 1061-1025, 1999.

Stachenfeld, N. S., C. Silva, and D. L. Keefe. Estrogen modifies the temperature effects of progesterone. *J. Appl. Physiol.* 88: 1643-1649, 2000.

Papers in preparation:

Calzone, W.L., C. Silva, D.L. Keefe, N.S. Stachenfeld. Estrogen effects on osmotic regulation of AVP and cortisol. *Am J. Physiol.* (in preparation).

Stachenfeld, N.S., Splenser, A., Calzone, W.L., C. Silva, D.L. Keefe. Sex differences in cortisol responses during hypertonic saline infusion. *Am J. Physiol.* (in preparation).

Abstracts:

Stachenfeld, N.S., C. Silva, C. Kokoszka, E.R. Nadel. Sex hormones lower the operating point for body fluid tonicity. *Med. Sci. Sports. Exerc.* 30: S230, 1998.

Stachenfeld, N. S., C. Silva, D. Keefe, C. Kokoszka and E. R. Nadel. Natriuretic effects of progesterone do not influence water balance. *FASEB J.* 12: A684, 1998.

Stachenfeld, N.S., C. Silva, D.L. Keefe. Temperature effects of progesterone are blocked by estrogen. *Med. Sci. Sports. Exerc.* 32: S116, 2000.

Calzone, W.L., C. Silva, D.L. Keefe, N.S. Stachenfeld. Progestin effects on adrenal sodium regulation. *Med. Sci. Sports. Exerc.* 32: S198, 2000.

REPORTABLE OUTCOMES (cont)

Funding:

“Sex Hormones and Body Fluid Regulation”

Principal Investigator: Nina Stachenfeld, Ph.D.

Agency: National Heart, Lung and Blood Institute

Type: RO1 HL62240

Period: 5/30/00-4/30/04

“Sex Hormone Effects on Plasma Volume Regulation”

Principal Investigator: Nina Stachenfeld, Ph.D.

Agency: National Heart, Lung and Blood Institute

Type: RO1

Submitted 10/1/00

CONCLUSIONS

Protocol A

We found that normally cycling young women have a reduction in the osmotic threshold for AVP release during the mid-luteal phase of the menstrual cycle (i.e. when estrogen and progesterone peak). Further, the osmotic threshold for AVP release is lowered during administration of oral contraceptives containing estrogen, but this reduction in threshold did not occur during progestin-only oral contraceptive use. Our data demonstrated a reduction in the P_{Osm} threshold for AVP release during estrogen-containing oral contraception administration. Because the water intake during the rehydration phase was similar in all our studies, regardless of menstrual phase or oral contraceptive treatment, we are able to conclude that an elevated circulating estrogen alters the body tonicity around which the body regulates fluids. In addition, during dehydration, we found that sodium loss was attenuated during the luteal phase and during administration of oral contraceptives containing estradiol and progestin, but these effects on sodium regulation were not mediated through the renin-aldosterone system. While estrogen does not appear to have direct effects on the renin-angiotensin-aldosterone system, this hormone may impact sodium regulation by modifying a progesterone-modulated inhibition of ANP release.

The use of oral contraceptives during deployment has been proposed as a method of controlling pregnancy and temporarily suppressing menstruation. Dehydration during field training or combat can have significant effects on performance. The effects of sex hormones on the regulation of body fluids are important because the systems that regulate body temperature interact with the fluid regulatory systems. This study demonstrated that oral contraceptives lowered the osmotic operating point for body fluid balance and that the women maintained normal body fluid levels. These data demonstrate that oral contraceptives do not have a negative effect on body fluid regulation, and may attenuate sodium loss.

Protocol B

We found that oral contraceptive pills containing estrogen with progestin did not produce the thermoregulatory effects of oral contraceptive pills that contained only progestin, which confirms earlier findings that estrogen lowers the thermoregulatory operating point. Our findings differed from previous findings in young women taking chronic oral contraceptives in that we did not find that oral contraceptives containing both estrogen and progestin significantly increased core temperature at baseline or following passive heating. The data in this study provide important new information for women who may want to take oral contraceptives during field training and combat. Our studies were conducted using a longitudinal design in which the women began taking oral contraceptives while in the study, and demonstrated improved temperature regulation while taking pills that contain estrogen. In addition, our study demonstrated reduced sweating and higher core temperature when the progestin-only pill was taken indicating this pill is likely not recommended for women deployed in hot environments.

Protocol C

This will be included in the final report, when all data have been collected and analyzed.

REFERENCES

1. Adams, W. C., G. W. Mack, G. W. Langhans, and E. R. Nadel. Effects of varied air velocity on sweating and evaporative rates during exercise. *J. Appl. Physiol.* 73: 2668-2674, 1992.
2. Aitken, J. M., R. Lindsay, and D. M. Hart. The redistribution of body sodium in women on long-term oestrogen therapy. *Clin. Sci. Mol. Med.* 47: 179-187, 1974.
3. Akaishi, T., and Y. Sakuma. Estrogen-induced modulation of hypothalamic osmoregulation in female rats. *Am. J. Physiol.* 258 (Regulatory Integrative Comp. Physiol. 27): R924-R929, 1990.
4. Aubrey, R. H., H. R. Nankin, A. M. Moses, and D. H. Streeten. Measurement of the osmotic threshold for vasopressin release in human subjects, and its modifications by cortisol. *J. Clin. Endocrinol. Metab.* 25: 1481-1492, 1965.
5. Axelrod, J., and R. Tomchick. Enzymatic *o*-methylation of epinephrine and other catechols. *J. Biol. Chem.* 233: 702-705, 1958.
6. Baker, M. A., D. D. Dawson, C. E. Peters, and A. M. Walker. Effects of estrogen on thermoregulatory evaporation in rats exposed to heat. *Am. J. Physiol.* 267 (Regulatory, Integrative, Comp. Physiol. 36): R673-R677, 1994.
7. Ball, P., M. Haupt, and R. Knuppen. Comparative studies on the metabolism of oestradiol in the brain, the pituitary and the liver of the rat. *Acta Endocrinol.* 87: 1-11, 1978.
8. Barron, W. M., J. Schreiber, and M. D. Lindheimer. Effect of ovarian sex steroids on osmoregulation and vasopressin secretion in the rat. *Am. J. Physiol.* 250 (Endocrinol. Metab. 13): E352-E361, 1986.
9. Bland, W. H., M. A. Lederer, and E. T. Tyler. Effects of oral contraceptives on body water and electrolytes. *J. Reprod. Med.* 13: 223-225, 1974.
10. BMDP. BMDP Statistical Software Manual. (7 ed.). Los Angeles, CA: BMDP Statistical Software, Inc, 1992.
11. Brenner, B. M., B. J. Ballerman, M. E. Gunning, and M. L. Zeidel. Diverse biological actions of atrial natriuretic peptide. *Physiol. Rev.* 70: 665-699, 1990.
12. Brenner, P. F., D. R. Mishell, and F. Z. Stanczyk. Serum levels of d-norgestrel, luteinizing hormone, follicle stimulating hormone, estradiol and progesterone in women during and following ingestion of combination oral contraceptive containing dl levonorgestrel. *Am. J. Obstet. Gynecol.* 129: 133, 1972.
13. Brooks, E. M., A. L. Morgan, J. M. Pierzga, S. L. Wladkowski, J. T. Gorman, J. A. Derr, and W. L. Kenney. Chronic hormone replacement therapy alters thermoregulatory and vasomotor function in postmenopausal women. *J. Appl. Physiol.* 83: 477-484, 1997.
14. Cannon, J. G., and C. A. Dinarello. Increased plasma interleukin-1 activity in women after ovulation. *Science* 227: 1247-1249, 1985.
15. Caraty, A., M. Grino, V. Locatelli, F. Guillaume, B. Boudouresque, Conte-Devolx B., and C. Oliver. Insulin-induced hypoglycemia stimulates corticotropin-releasing factor and arginine vasopressin secretion in hypophyseal portal blood of conscious, unrestrained rams. *J. Clin. Invest.* 85: 1716-1721, 1990.

16. Carlberg, K. A., M. J. Fregley, and M. Fahey. Effects of chronic estrogen treatment on water exchange in rats. *Am. J. Physiol.* 247 (Endocrinol. Metab. 10): E101-E110, 1984.
17. Chang, R. T., G. P. Lambert, P. L. Moseley, F. K. Chapler, and C. V. Gisolfi. Effect of estrogen supplementation on exercise thermoregulation on premenopausal women. *J. Appl. Physiol.* 85: 2082-2088, 1998.
18. Charkoudian, N., and J. Johnson. Altered reflex control of cutaneous circulation by female sex steroids in independent of prostaglandins. *Am. J. Physiol.* 276 (Heart Circ Physiol. 45): H1634-H1640, 1999.
19. Charkoudian, N., and J. M. Johnson. Modification of active cutaneous vasodilation by oral contraceptive hormones. *J. Appl. Physiol.* 83: 2012-2018, 1997.
20. Charkoudian, N., and J. M. Johnson. Reflex control of cutaneous vasoconstrictor system is reset by exogenous female reproductive hormones. *J. Appl. Physiol.* 87: 381-385, 1999.
21. Christie, N. P., and J. C. Shaver. Estrogens and the kidney. *Kidney Int.* 6: 366-376, 1974.
22. Clark, B. A., D. Elahi, L. Fish, M. McAloon-Dyke, K. Davis, K. L. Minaker, and F. H. Epstein. Atrial natriuretic peptide suppresses osmostimulated vasopressin release in young and elderly humans. *Am. J. Physiol.* 261: (Endocrinol. Metab. 24): E252-E256, 1991.
23. Colby, H. D., F. R. Skelton, and A. C. Brownie. Testosterone-induced hypertension in the rat. *Endocrinology* 86: 1093-1101, 1970.
24. Colton, T. *Statistics in Medicine*. U.S.A.: Little, Brown and Company (Inc.), 1974.
25. Crowley, R. S., and J. A. Amico. Gonadal steroid modulation of oxytocin and vasopressin gene expression in the hypothalamus of the osmotically stimulated rat. *Endocrinol.* 133: 2711-2718, 1993.
26. Crowley, W. R., T. L. O'Donohue, J. M. George, and D. M. Jacobowitz. Changes in pituitary oxytocin and vasopressin during the estrous cycle and after ovarian hormones: evidence for mediation by norepinephrine. *Life Sci.* 23: 2579-2586, 1978.
27. Cunningham, G. R., J. W. Goldzieher, A. de La Pena, and M. Oliver. The mechanism of ovulation inhibition by triamcnolone acetonide. *J. Clin. Endocrinol. Metab.* 46: 8-14, 1978.
28. Davison, J. M., E. A. Gilmore, J. Durr, G. L. Robertson, and M. D. Lindheimer. Altered osmotic thresholds for vasopressin secretion and thirst in human pregnancy. *Am. J. Physiol.* 246 (Renal Fluid Electrolyte Physiol. 15): F105-F109, 1984.
29. De Leo, V., A. la Marca, B. Talluri, D. D'Antona, and G. Morgante. Hypothalamo-pituitary-adrenal axis and adrenal function before and after ovariectomy in premenopausal women. *Eur. J. Endocrinol.* 138: 430-435, 1998.
30. Dluzen, D. E., and V. D. Ramirez. Progesterone effects on dopamine release from the corpus stratum of female rats. II Evidence for membrane site of action and the role of albumin. *Brain Res.* 476: 338-344, 1989.

31. Engler, D., T. Pham, G. Fullerton, G. Ooi, J. W. Funder, and I. J. Clarke. Studies of the secretion of corticotropin-releasing factor and arginine vasopressin into the hypophyseal-portal circulation of the conscious sheep. *Neuroendocrinol.* 49: 367-381, 1989.
32. Forsling, M. L., M. Akerlund, and P. Stromberg. Variations in plasma concentrations of vasopressin during the menstrual cycle. *J. Endocrinol.* 89: 263-266, 1981.
33. Forsling, M. L., P. Stromberg, and M. Akerlund. Effect of ovarian steroids on vasopressin secretion. *J. Endocrinol.* 95: 147-151, 1982.
34. Fortney, S. M., W. S. Beckett, A. J. Carpenter, J. Davis, H. Drew, N. D. LaFrance, J. A. Rock, C. G. Tankersley, and N. B. Vroman. Changes in plasma volume during bed rest: effects of menstrual cycle and estrogen administration. *J. Appl. Physiol.* 65: 525-533, 1988.
35. Fortney, S. M., C. B. Wenger, J. R. Bove, and E. R. Nadel. Effect of hyperosmolality on control of blood flow and sweating. *J. Appl. Physiol.* 57(Respirat. Environ. Exercise Physiol. 6): 1688-1695, 1984.
36. Fortney, S. M., C. B. Wenger, J. R. Bove, and E. R. Nadel. Effects of plasma volume on forearm venous and cardiac stroke volumes during exercise. *J. Appl. Physiol.* 55: 884-890, 1983.
37. Friedlander, M., N. Laskey, and S. Silbert. Effect of estrogenic substance on blood volume. *Endocrinol.* 20: 329-332, 1936.
38. Genazzani, A. R., T. H. Lemarchand-Beraud, M. L. Aubert, and J. P. Felber. Pattern of ACTH, hGh, and cortisol during the menstrual cycle. *Clin. Endocrinol. Metab.* 41: 431-436, 1975.
39. Graichen, H., R. Rascati, and R. R. Gonzalez. Automated dew-point temperature sensor. *J. Appl. Physiol.* 52: 1658-1660, 1982.
40. Greenleaf, J. E., V. A. Convertino, and G. R. Mangseth. Plasma volume during stress in man: osmolality and red cell volume. *J. Appl. Physiol.* 47: 1031-1038, 1979.
41. Groban, L., A. W. Cowley, and T. J. Ebert. Atrial natriuretic peptide augments forearm capillary filtration in humans. *Am. J. Physiol.* 256 (Heart Circ. Physiol. 28): H258-H263, 1990.
42. Hardy, J. D. Heat transfer. In: *Physiology of Heat Regulation and Science of Clothing*, edited by L. H. Newburgh. Philadelphia, PA: Saunders, 1949, p. 78-108.
43. Harrison, M. H. Effects of thermal stress and exercise on blood volume in humans. *Physiol. Rev.* 65: 149-209, 1985.
44. Haslag, S. W. M., and A. B. Hertzman. Temperature regulation in young women. *J. Appl. Physiol.* 20: 1283-1288, 1965.
45. Hellman, L., K. Yoshida, and Z. Barnett. The effect of medroxyprogesterone on the pituitary adrenal axis. *J. Clin. Endocrinol. Metab.* 42: 912-916, 1976.
46. Heritage, A. S., W. E. Stumpf, M. Sar, and L. D. Grant. Brainstem catecholamine neurons are target sites for sex steroid hormones. *Science* 207: 1377-1379, 1980.

47. Hirata, K., T. Nagasaka, M. Hirashita, T. Takahata, and T. Nuriomura. Effects of human menstrual cycle on thermoregulatory vasodilation during exercise. *Euro. J. Appl. Physiol.* 54: 559-565, 1986.
48. Horvath, S., and B. Drinkwater. Thermoregulation and the menstrual cycle. *Aviat. Space Environ. Med.* 53: 790-790, 1982.
49. Jacobs, A. J., M. J. Odom, R. A. Word, and B. R. Carr. Effect of oral contraceptives on adrenocorticotropin and growth hormone secretion following CRH and GHRH administration. *Contraception* 40: 690-699, 1989.
50. Johnson, A. K. Brain mechanisms in the control of body fluid balance. In: *Fluid Homeostasis During Exercise*, edited by C. V. Gisolfi and D. T. Lamb. Carmel, Indiana: Brown and Benchmark, 1990, p. 347-424.
51. Keefe, D. L., D. Michelson, S. H. Lee, and F. Naftolin. Astrocytes within the hypothalamic arcuate nucleus contain estrogen-sensitive peroxidase, bind fluorescein-conjugated estradiol and may mediate synaptic plasticity in the rat. *Am. J. Obstet. Gynecol.* 164: 959-66, 1991.
52. Kitay, J. I. Pituitary-adrenal function in the rat after gonadectomy and gonadal hormone replacement. *Endocrinol.* 73: 253-260, 1963.
53. Kolka, M., and L. Stephenson. Control of sweating during the human menstrual cycle. *Eur. J. Appl. Physiol.* 58: 890-895, 1989.
54. Kubicek, W. G., J. N. Karnegis, R. P. Patterson, D. A. Witsoe, and R. H. Mattson. Development and evaluation of an impedance cardiac output system. *Aero. Med.* 37: 1208-1212, 1966.
55. Lehtovirta, P. Haemodynamic effects of combined oestrogen/progestogen oral contraceptives. *J. Obstet. Gynecol. Brit. Commonwealth* 81: 517-252, 1974.
56. Lehtovirta, P. Peripheral haemodynamic effects of combined oestrogen/progestogen oral contraceptives. *J. Obstet. Gynecol.* 81: 526-534, 1974.
57. Lehtovirta, P., J. Kuikka, and T. Pyorala. Hemodynamic effects of oral contraceptives during exercise. *Int. J. Gynaecol. Obstet.* 15: 35-37, 1977.
58. Lesniewska, B., B. Miskowiak, M. Nowak, and L. K. Malendowicz. Sex differences in adrenocortical structure and function. XXVII. The effect of ether stress on ACTH and corticosterone in intact, gonadectomized, and testosterone- or estradiol-replaced rats. *Res. Exper. Med.* 190: 95-103, 1990.
59. Lindeman, R. D., and R. Goldman. Anatomic and physiological age changes in the kidney. *Exp. Gerontol.* 21: 379-386, 1986.
60. Machchak, C. A., R. A. Lobo, R. Dozono-Takano, P. Eggena, R. M. Nakamura, P. F. Brenner, and D. R. Mishell. Comparison of pharmacodynamic properties of various estrogen formulations. *Am. J. Obstet. Gynecol.* 144: 511-514, 1982.
61. Majewska, M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* 232: 1,004, 1986.
62. Marks, L. E., J. C. Stevens, L. M. Bartoshuk, J. F. Geny, B. Rifkin, and V. K. Stone. Magnitude-matching: the measurement of taste and smell. *Chem. Senses* 13: 66-87, 1988.
63. Michelakis, A. M., H. Yoshida, and J. C. Dormois. Plasma renin activity and plasma aldosterone during the normal menstrual cycle. *Am. J. Obstet. Gynecol.* 123: 724-726, 1975.

64. Morimoto, T. Thermoregulation and body fluids: role of blood volume and central venous pressure. *Jpn J. Physiol.* 40: 165-179, 1990.
65. Mulay, S., S. D'Sylva, and D. R. Varma. Inhibition of the aldosterone-suppressant activity of atrial natriuretic factor by progesterone and pregnancy in rats. *Life Sciences* 52: 1121-8, 1993.
66. Myles, K., and J. W. Funder. Progesterone binding to mineralocorticoid receptors: in vitro and vivo studies. *Am. J. Physiol.* 270 (Endocrinol. Metab. 33): E601-E607, 1996.
67. Nadel, E. R., J. W. Mitchell, and J. A. J. Stolwijk. Differential thermal sensitivity in the human skin. *Phluegers Arch.* 340: 71-76, 1973.
68. Nakayama, T., M. Suzuki, and N. Ishizuka. Action of progesterone on thermosensitive neurons. *Nature* 258: 80, 1975.
69. Ohashi, M., N. Fujio, K. Kato, H. Nawata, H. Ibayashi, and H. Matsuo. Effect of human α -atrial natriuretic polypeptide on adrenocortical function in man. *J. Endocrinol.* 110: 287-292, 1986.
70. Oudar, O., M. Elgar, L. Bankir, U. Gnaten, and W. Kriz. Differences in rat kidney morphology between males, females and testosterone-treated females. *Renal Physiol. Biochem.* 14: 93-102, 1991.
71. Petak, S. M., and Steinberger. The Adrenal Gland. In: *Pharmacology of Contraceptive Steroids*, edited by J. W. Goldzieher. New York: Raven Press, 1994, p. 233-242.
72. Phillips, J. G., and W. Poolsanguan. A method to study temporal changes in adrennal activity in relation to sexual status in the female laboratory rat. *Endocrinol.* 77: 283-291, 1978.
73. Pivarnik, J., C. Marichal, T. Spillman, and J. Morrow. Menstrual cycle phase affects temperature regulation during endurance exercise. *J. Appl. Physiol.* 72: 542-548, 1992.
74. Plotsky, P. M., T. O. Bruhn, and W. Vale. Hypophsiotropic regulation of adrenocorticotropin secretion in response to insulin-induced hypoglycemia. *Endocrinol.* 117: 323-329, 1985.
75. Raff, H. Interactions between neurohypophysial hormones and the ACTH adrenocortical axis. *Annals NY Acad. Sci.* 689: 411-425, 1993.
76. Reckelhoff, J. F., and J. P. Granger. Role of androgens in mediating hypertension and renal injury. *Clin. Experimental Pharmacol. Physiol.* 26: 127-131, 1999.
77. Renkin, E. M., and V. L. Tucker. Atrial natriuretic peptide as a regulator of transvascular fluid balance. *News Physiol. Sci.* 11: 138-143, 1995.
78. Rittmaster, R. S., G. B. Cutler Jr., P. W. Gold, D. D. Brandon, T. Tomai, D. L. Loriaux, and G. P. Chrousos. The relationship of saline-induced changes in vasopressin secretion to basal and cortotropin-releasing hormone-stimulated adrenocorticotropin and cortisol secretion in man. *J. Clin. Endocrinol. Metab.* 64: 371-376, 1987.
79. Rogers, S. M., and M. A. Baker. Thermoregulation during exercise in women who are taking oral contraceptives. *Eur. J. Appl. Physiol.* 75: 34-38, 1997.

80. Sar, M., and W. E. Stumpf. Simultaneous localization of [³H]estradiol and neurophysin I or arginine vasopressin in hypothalamic neurons demonstrated by a combined technique of dry-mount autoradiography and immunohistochemistry. *Neuroscience Letters* 17: 179-184, 1980.
81. Sawka, M. N., and K. B. Pandolf. Effects of body water loss on exercise performance and physiological functions. In: *Perspectives in Exercise Science and Sports Medicine. Fluid Homeostasis During Exercise*, edited by C. V. G. a. D. R. Lamb. Indianapolis, IN: Benchmark, 1990, p. 1-38.
82. Sawka, M. N., and C. B. Wenger. Physiological responses to acute exercise heat stress. In: *Human Performance Physiology and Environmental Medicine at Terrestrial Extremes*, edited by M. N. S. a. R. R. G. K.B. Pandolf. Indianapolis, IN: Benchmark, 1988, p. 97-151.
83. Sawka, M. N., A. J. Young, W. A. Latzka, P. D. Neufer, M. D. Quigley, and K. B. Pandolf. Human tolerance to heat strain during exercise: influence of hydration. *J. Appl. Physiol.* 73: 368-375, 1992.
84. Sealy, J. E., J. Itskovitz-Eldor, S. Rubattu, G. D. James, P. August, I. Thaler, J. Levron, and J. H. Laragh. Estradiol- and progesterone-related increases in the renin-aldosterone system: studies during ovarian stimulation and early pregnancy. *J. Clin. Endocrinol. Metab.* 79: 258-264, 1994.
85. Shenker, Y. Atrial natriuretic hormone and aldosterone in salt-depleted state. *Am. J. Physiol.* 257: E583-E587, 1989.
86. Silbiger, S. R., and J. Neugarten. The impact of gender on the progression of chronic renal disease. *Am. J. Kidney Dis.* 25: 515-533, 1995.
87. Silva, N. L., and J. A. Boulant. Effects of testosterone, estradiol, and temperature on neurons in preoptic tissue slices. *Am. J. Physiol.* 250 (Regulatory, Integrative, Comp. Physiol. 19): R625-R632, 1986.
88. Stachenfeld, N. S., L. DiPietro, S. F. Palter, and E. R. Nadel. Estrogen influences osmotic secretion of AVP and body water balance in postmenopausal women. *Am. J. Physiol.* 274 (Regulatory Integrative Comp. Physiol. 43): R187-R195, 1998.
89. Stachenfeld, N. S., G. W. Gleim, P. M. Zabetakis, and J. A. Nicholas. Fluid balance and renal response following dehydrating exercise in well-trained men and women. *Eur. J. Appl. Physiol.* 72: 468-477, 1996.
90. Stachenfeld, N. S., D. L. Keefe, and S. F. Palter. Effects of estrogen and progesterone on transcapillary fluid dynamics. *Am. J. Physiol.* in review, 2000.
91. Stachenfeld, N. S., G. W. Mack, A. Takamata, L. DiPietro, and E. R. Nadel. Thirst and fluid regulatory responses to hypertonicity in older adults. *Am. J. Physiol.* 271 (Regulatory, Integrative, Comp. Physiol. 40): R757-R765, 1996.
92. Stachenfeld, N. S., C. S. Silva, D. L. Keefe, C. A. Kokoszka, and E. R. Nadel. Effects of oral contraceptives on body fluid regulation. *J. Appl. Physiol.* 87: 1016-1025, 1999.
93. Staessen, J., R. Fagard, P. Lijen, R. Van Hoof, and A. Amery. Reference values for ambulatory blood pressure: a meta analysis. *J. Hypertens.* 8 (Suppl 6): S57-S64, 1990.

94. Stephenson, L. A., and M. A. Kolka. Esophageal temperature threshold for sweating decreases before ovulation in premenopausal women. *J. Appl. Physiol.* 86: 22-28, 1999.
95. Stephenson, L. A., and M. A. Kolka. Menstrual cycle phase and time of day alter reference signal controlling arm blood flow and sweating. *Am. J. Physiol.* 249: (Regulatory Integrative Comp. Physiol. 18): R186-R191, 1985.
96. Stephenson, L. A., and M. A. Kolka. Plasma volume during heat stress and exercise in women. *Eur. J. Appl. Physiol.* 57: 373-381, 1988.
97. Stephenson, L. A., and M. A. Kolka. Thermoregulation in women. In: *Exercise and Sports Science Reviews*, edited by J. O. Holloszy. Philadelphia: Williams and Wilkins, 1993, p. 231-262.
98. Stephenson, L. A., M. A. Kolka, R. Francesconi, and R. R. Gonzalez. Circadian variations in plasma renin activity, catecholamines and aldosterone during exercise in women. *Eur. J. Appl. Physiol.* 58: 756-764, 1989.
99. Stoebel, D. P., and G. P. Moberg. Effect of ACTH and cortisol on estrous behavior and the luteinizing hormone surge in the cow. *Federation Proc.* 38: 1250-1254, 1979.
100. Stone, J. D., J. T. Crofton, and L. Share. Sex differences in central adrenergic control of vasopressin release. *Am. J. Physiol.* 257 (Regulatory, Integrative, Comp. Physiol. 26): R1040-R1045, 1989.
101. Streeten, D. H., M. Souma, G. S. Ross, and M. Miller. Action of cortisol introduced into the supraoptic nucleus, on vasopressin release and antidiuresis in conscious monkeys. *Acta Endocrinol.* 98: 195-204, 1981.
102. Stumpf, W. E., M. Sar, and G. Aumuller. The heart: a target organ for estradiol. *Science* 196: 319-320, 1977.
103. Stumpf, W. E., M. Sar, R. Narbaitz, F. A. Reid, H. F. DeLuca, and Y. Tanaka. Cellular and subcellular localization of 1,25-(OH)₂-vitamin D₃ in rat kidney: comparison with localization of parathyroid hormone and estradiol. *Proc. Natl. Acad. Sci.* 77: 1149-1153, 1980.
104. Sundsfjord, J. A. Plasma renin activity and aldosterone excretion during prolonged progesterone administration. *Acta Endocrinol.* 67: 486-490, 1971.
105. Takamata, A., G. W. Mack, C. M. Gillen, and E. R. Nadel. Sodium appetite, thirst and body fluid regulation in humans during rehydration without sodium replacement. *Am. J. Physiol.* 266: R1493-R1502, 1994.
106. Tankersley, C. G., W. C. Nicholas, D. R. Deaver, D. Mikita, and W. L. Kenney. Estrogen replacement therapy in middle-aged women: thermoregulatory responses to exercise in the heat. *J. Appl. Physiol.* 73: 1238-1245, 1992.
107. Tollan, A., N. Holst, F. Forsdahl, H. O. Fadnes, P. Oian, and J. M. Maltau. Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization. *Am. J. Obstet. Gynecol.* 162: 554-558, 1990.
108. Tollan, A., K. Kvenild, H. Strand, P. Oian, and J. M. Maltau. Increased capillary permeability for plasma proteins in oral contraceptive users. *Contraception* 45: 473-481, 1992.

109. Tripathi, A., G. W. Mack, and E. R. Nadel. Cutaneous vascular reflexes during exercise in the heat. *Med. Sci. Sports Exercise* 22: 796-803, 1990.
110. Veille, J. C., M. J. Morton, K. Burry, M. Nemeth, and L. Speroff. Estradiol and hemodynamics during ovulation induction. *J. Clin. Endocrinol. Metab.* 63: 721-724, 1986.
111. Vokes, T. J., N. M. Weiss, J. Schreiber, M. B. Gaskill, and G. L. Robertson. Osmoregulation of thirst and vasopressin during normal menstrual cycle. *Am. J. Physiol.* 254 (Regulatory Integrative Comp. Physiol. 23): R641-R647, 1988.
112. Wambach, G., J. R. Higgins, D. C. Kem, and W. Kaufmann. Interaction of synthetic progestagens with renal mineralocorticoids. *Acta Endocrinol.* 92: 560-567, 1979.
113. Watanabe, H., D. C. Lau, H. L. Guyn, and N. L. Wong. Effect of progesterone therapy on arginine vasopressin and atrial natriuretic factor in premenstrual syndrome. *Clin. Invest. Med.* 20: 211-23, 1997.
114. Weinberger, M. H., N. J. Kramer, C. E. Grim, and L. P. Petersen. The effect of posture and saline loading on plasma renin activity and aldosterone concentration in pregnant, non-pregnant and estrogen-treated women. *J. Clin. Endocrinol. Metab.* 44: 69-77, 1977.
115. Whitten, C. L., and J. T. Bradbury. Hemodilution as a result of estrogen therapy. Estrogenic effects in the human female. *Proc. Soc. Exp. Biol.* 78: 626-629, 1951.
116. Winberg, N., A. Hoeghom, and H. R. Christensen. 24-h Ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. *Am.J. Hyperten.* 8: 978-986, 1995.

APPENDIX A
Tables 1-22

	Follicular	Luteal	OC E+P	Follicular	Luteal	OC P
BW, kg	61.4 ± 4.1	61.8 ± 4.1	61.6 ± 3.8	60.7 ± 3.7	61.1 ± 3.4	60.0 ± 3.5
P[E ₂], pg/ml (range)	27.3 ± 5.6 (12.3-40.8)	105.1 ± 26.2 (63.6-189.6)	> 12.0	26.1 ± 6.7 (13.1-36.2)	146.7 ± 38.3 (61.1-222.0)	25.1 ± 5.3 (6.4-26.7)
P[P ₄], ng/ml (range)	1.3 ± 0.6 (0.3-2.2)	8.7 ± 3.1 (5.2-19.1)	> 0.02	0.49 ± 1.0 (0.4-0.8)	9.8 ± 2.2 (5.2-18.3)	> 0.02
P _{Osm} -P _[AVP] slope (pg·ml ⁻¹)·mOsm ⁻¹	0.47 ± 0.11	0.51 ± 0.18	0.49 ± 0.12	0.49 ± 0.14	0.55 ± 0.17	0.46 ± 0.14
P _{Osm} -P _[AVP] x-intercept, mOsm/kg H ₂ O	282 ± 1	278 ± 1*	276 ± 2 [#]	283 ± 1	279 ± 1*	280 ± 2
P _{Osm} -thirst slope, mm/mOsm	13.7 ± 3.5	14.0 ± 2.7	13.3 ± 3.7	12.8 ± 1.7	12.9 ± 2.9	13.7 ± 2.1
P _{Osm} -thirst x-intercept, mm	280 ± 3	278 ± 2	276 ± 2	280 ± 1	279 ± 2	280 ± 2

Table 1. Subject characteristics and responses to dehydration.

	Pre-exercise		Exercise		Rehydration			
	0 min	150 min	0 min	60 min	120 min	180 min		
S[Na⁺], mEq/l								
Follicular	137.9 ± 0.5 ^{*#}	141.3 ± 0.9 ^{*#}	140.5 ± 0.9 [#]	137.1 ± 0.5 ^{**#}	136.2 ± 0.5 ^{**#}	136.1 ± 0.5 ^{**#}		
Luteal	136.7 ± 0.6	139.6 ± 0.9	139.2 ± 0.8	136.2 ± 0.7	135.3 ± 0.5	134.9 ± 0.4		
OC E + P	136.2 ± 0.6	139.9 ± 0.7	138.9 ± 0.7	135.9 ± 0.4	135.7 ± 0.4	134.8 ± 0.7		
S[K⁺], mEq/l								
Follicular	3.85 ± 0.10	4.75 ± 0.11	4.18 ± 0.06	4.31 ± 0.05	4.19 ± 0.08	4.03 ± 0.08		
Luteal	3.90 ± 0.10	4.77 ± 0.08	4.18 ± 0.07	4.35 ± 0.01	4.28 ± 0.08	4.14 ± 0.08		
OC E + P	4.03 ± 0.10	4.82 ± 0.10	4.31 ± 0.07	4.42 ± 0.12	4.29 ± 0.07	4.17 ± 0.06		
TP, g/l								
Follicular	6.7 ± 0.1	7.4 ± 0.2	7.0 ± 0.1	6.6 ± 0.1	6.7 ± 0.1	6.6 ± 0.1		
Luteal	6.8 ± 0.1	7.4 ± 0.2	7.0 ± 0.1	6.8 ± 0.1	6.7 ± 0.1	6.7 ± 0.1		
OC E + P	6.7 ± 0.1	7.3 ± 0.2	6.9 ± 0.1	6.7 ± 0.1	6.7 ± 0.1	6.6 ± 0.2		
	Pre-exercise	Exercise	Pre-exercise	Exercise	Rehydration			
	0 min	150 min	0 min	60 min	120 min	180 min		
S[Na⁺], mEq/l								
Follicular	137.7 ± 0.4 ^{*\$}	141.3 ± 0.9 ^{*\$}	140.4 ± 0.6 ^{*\$}	137.2 ± 0.8 ^{*\$}	136.8 ± 0.6 ^{*\$}	136.3 ± 0.5 ^{*\$}		
Luteal	136.8 ± 0.4	140.2 ± 0.9	139.1 ± 0.8	136.2 ± 0.6	135.5 ± 0.7	134.7 ± 0.5		
OC P	136.6 ± 0.5	140.6 ± 1.5	139.4 ± 0.8	136.5 ± 0.7	136.5 ± 0.8	136.0 ± 0.6		
S[K⁺], mEq/l								
Follicular	3.86 ± 0.08	4.68 ± 0.11	4.14 ± 0.08	4.21 ± 0.07	4.09 ± 0.06	3.98 ± 0.04		
Luteal	3.97 ± 0.08	4.94 ± 0.13	4.25 ± 0.06	4.41 ± 0.05	4.31 ± 0.07	4.02 ± 0.06		
OC P	3.87 ± 0.11	4.70 ± 0.15	4.26 ± 0.13	4.12 ± 0.14	4.05 ± 0.08	3.90 ± 0.07		
TP, g/l								
Follicular	6.7 ± 0.1	7.3 ± 0.2	6.8 ± 0.2	6.6 ± 0.2	6.6 ± 0.1	6.5 ± 0.1		
Luteal	6.9 ± 0.1	7.5 ± 0.2	7.0 ± 0.2	6.9 ± 0.2	6.8 ± 0.2	6.8 ± 0.2		
OC P	6.8 ± 0.1	7.3 ± 0.2	6.9 ± 0.1	6.7 ± 0.1	6.7 ± 0.1	6.6 ± 0.2		

Table 3. Blood responses at rest, and during dehydration and *ad libitum* drinking.

	Pre-exercise	Exercise	Rehydration			
	0 min	150 min	0 min	60 min	120 min	180 min
Hct, %						
Follicular	36.3 ± 0.8 ^{*#}	38.1 ± 0.9 [‡]	36.6 ± 0.7	36.3 ± 0.8 ^{*#}	36.3 ± 0.7 ^{*#}	36.2 ± 0.8 [*]
Luteal	36.8 ± 1.0 [†]	39.7 ± 0.8	37.7 ± 0.9 [†]	37.1 ± 0.9 [†]	37.0 ± 0.9 [†]	37.0 ± 1.0 [†]
OC E + P	35.7 ± 0.6 ^δ	38.0 ± 0.8 ^δ	36.4 ± 0.9 ^δ	35.8 ± 0.9 ^δ	35.6 ± 0.8 ^δ	35.2 ± 0.7 ^δ
Hb, g/dl						
Follicular	12.2 ± 0.2	13.0 ± 0.3	12.5 ± 0.3	12.1 ± 0.3	12.1 ± 0.3	12.1 ± 0.3
Luteal	12.5 ± 0.4	13.5 ± 0.4	12.8 ± 0.4	12.4 ± 0.4	12.4 ± 0.4	12.4 ± 0.4
OC E + P	11.9 ± 0.3 ^δ	12.8 ± 0.3 ^δ	12.1 ± 0.2 ^δ	11.9 ± 0.2 ^δ	11.7 ± 0.2 ^δ	11.7 ± 0.2 ^δ
PV, % change						
Follicular	---	-8.6 ± 1.3	-2.6 ± 1.6	1.3 ± 1.6	1.2 ± 1.7	2.5 ± 1.8
Luteal	---	-9.5 ± 2.6	-3.3 ± 2.0	0.2 ± 1.4	0.7 ± 1.6	0.5 ± 1.5
OC E + P	---	-7.9 ± 1.2	-0.5 ± 1.2	1.9 ± 1.3	3.6 ± 1.0	5.1 ± 1.7
P_[AVP], pg/ml						
Follicular	1.3 ± 0.2	4.0 ± 0.8	3.3 ± 0.9	1.7 ± 0.4	1.6 ± 0.3	1.6 ± 0.3
Luteal	1.2 ± 0.2	3.8 ± 0.7	3.0 ± 0.7	1.5 ± 0.4	1.3 ± 0.3	1.5 ± 0.4
OC E + P	1.6 ± 0.3	3.1 ± 0.4	3.1 ± 0.4	2.7 ± 0.7	1.9 ± 0.4	2.3 ± 0.4
TP, g/l						
Follicular	6.7 ± 0.1	7.4 ± 0.2	7.0 ± 0.1	6.6 ± 0.1	6.7 ± 0.1	6.6 ± 0.1
Luteal	6.8 ± 0.1	7.4 ± 0.2	7.0 ± 0.1	6.8 ± 0.1	6.7 ± 0.1	6.7 ± 0.1
OC E + P	6.7 ± 0.1	7.3 ± 0.2	6.9 ± 0.1	6.7 ± 0.1	6.7 ± 0.1	6.6 ± 0.2

	Pre-exercise	Exercise	Rehydration			
	0 min	150 min	0 min	60 min	120 min	180 min
Hct, %						
Follicular	36.4 ± 0.7	37.5 ± 0.8	36.2 ± 0.7	35.8 ± 0.5	35.8 ± 0.5	35.4 ± 0.6
Luteal	37.9 ± 0.9 ^{††}	40.0 ± 1.2 ^{††}	38.4 ± 1.0 ^{††}	37.8 ± 0.9 ^{††}	37.9 ± 1.1 ^{††}	37.6 ± 1.0 [†]
OC P	37.1 ± 0.9	39.0 ± 0.9	37.2 ± 1.1	36.1 ± 0.9	36.3 ± 1.0	36.4 ± 0.8
Hb, g/dl						
Follicular	12.3 ± 0.4	13.2 ± 0.5	12.4 ± 0.4	12.1 ± 0.4	12.1 ± 0.4	11.9 ± 0.4
Luteal	13.0 ± 0.4	13.7 ± 0.5	12.9 ± 0.4	12.6 ± 0.4	12.6 ± 0.4	12.6 ± 0.4
OC P	12.6 ± 0.4	13.3 ± 0.4	12.5 ± 0.4	12.2 ± 0.3	12.2 ± 0.4	12.4 ± 0.4
PV, % change						
Follicular	---	-7.5 ± 1.2	0.0 ± 1.4	2.3 ± 1.1	3.1 ± 1.1	5.0 ± 0.7
Luteal	---	-7.4 ± 1.0	0.1 ± 1.1	3.2 ± 0.1	0.8 ± 1.2	1.6 ± 1.1
OC P	---	-6.5 ± 1.0	0.4 ± 0.9	4.7 ± 1.4	4.5 ± 1.3	5.2 ± 1.6
P_[AVP], pg/ml						
Follicular	1.2 ± 0.4	3.7 ± 1.0	2.5 ± 0.5	1.8 ± 0.6	1.8 ± 0.6	1.6 ± 0.4
Luteal	1.1 ± 0.3	4.8 ± 1.4	2.3 ± 0.6	2.0 ± 0.5	1.9 ± 0.6	1.9 ± 0.6
OC P	1.0 ± 0.2	4.0 ± 1.2	2.7 ± 0.7	1.8 ± 0.7	2.2 ± 0.7	1.5 ± 0.4
TP, g/l						
Follicular	6.7 ± 0.1	7.3 ± 0.2	6.8 ± 0.2	6.6 ± 0.2	6.6 ± 0.1	6.5 ± 0.1
Luteal	6.9 ± 0.1	7.5 ± 0.2	7.0 ± 0.2	6.9 ± 0.2	6.8 ± 0.2	6.8 ± 0.2
OC P	6.8 ± 0.1	7.3 ± 0.2	6.9 ± 0.1	6.7 ± 0.1	6.7 ± 0.1	6.6 ± 0.2
	Pre-exercise	Exercise	Rehydration			

	0 min	150 min	0 min	60 min	120 min	180 min
Thirst, mm						
Follicular	18 ± 9	101 ± 10	100 ± 10	21 ± 8	24 ± 11	13 ± 5
Luteal	29 ± 11	100 ± 11	97 ± 12	12 ± 5	23 ± 8	7 ± 3
OC E + P	29 ± 10	94 ± 13	101 ± 12	19 ± 6	22 ± 8	17 ± 6
Thirst, mm						
Follicular	18 ± 9	101 ± 10	100 ± 10	21 ± 8	24 ± 11	13 ± 5
Luteal	29 ± 11	100 ± 11	97 ± 12	12 ± 5	23 ± 8	7 ± 3
OC P	29 ± 10	94 ± 13	101 ± 12	19 ± 6	22 ± 8	17 ± 6

Table 4. Thirst responses to dehydrating exercise.

Table 5. Renal osmoregulatory responses at rest, and during dehydration and *ad libitum* drinking.

	Pre-Exercise 0 min	End-exercise 150 min	60 min	Rehydration 120 min	180 min
U_v ml/min					
Follicular	3.6 ± 1.1	1.1 ± 0.2	0.7 ± 0.1	2.0 ± 0.6	2.7 ± 0.8
Luteal	4.4 ± 0.9	1.5 ± 0.2	0.5 ± 0.1	1.1 ± 0.4	1.7 ± 0.5
OC P + E	3.3 ± 0.7	0.9 ± 0.2	0.5 ± 0.0	0.6 ± 0.1	0.9 ± 0.3
U_{Osm}, mosmol/kg H₂O					
Follicular	290 ± 123	509 ± 79	790 ± 95	577 ± 135	451 ± 152
Luteal	148 ± 29	339 ± 57	833 ± 52	633 ± 125	481 ± 124
OC P + E	274 ± 97	502 ± 86	889 ± 48	792 ± 94	675 ± 120
U_{Osm}/P_{Osm}					
Follicular	1.0 ± 0.4	1.8 ± 0.3	3.0 ± 0.3	2.2 ± 0.5	1.8 ± 0.6
Luteal	0.5 ± 0.1	1.1 ± 0.2	3.0 ± 0.2	1.9 ± 0.5	1.9 ± 0.5
OC P + E	1.1 ± 0.4	1.7 ± 0.3	3.2 ± 0.2	2.5 ± 0.5	2.3 ± 0.5
C_{H₂O}, ml/min					
Follicular	1.7 ± 1.1	-0.5 ± 0.2	-1.0 ± 0.2	-0.4 ± 0.3	1.0 ± 0.6
Luteal	2.5 ± 0.8	0.0 ± 0.3	-1.0 ± 0.1	-0.5 ± 0.3	0.1 ± 0.5
OC P + E	1.5 ± 0.7	-0.4 ± 0.2	-1.0 ± 0.1	-1.0 ± 0.1	-0.6 ± 0.2
C_{Osm}					
Follicular	1.9 ± 0.2	1.6 ± 0.2	1.7 ± 0.2	1.7 ± 0.2	1.7 ± 0.2
Luteal	1.8 ± 0.2	1.6 ± 0.2	1.5 ± 0.2	1.6 ± 0.1	1.6 ± 0.1
OC P + E	1.7 ± 0.1	1.3 ± 0.1	1.5 ± 0.1	1.5 ± 0.2	1.4 ± 0.1
	Pre-Exercise 0 min	End-exercise 150 min	60 min	Rehydration 120 min	180 min
U_v ml/min					
Follicular	5.0 ± 1.2	1.3 ± 0.3	0.6 ± 0.1	1.3 ± 0.4	1.7 ± 0.5
Luteal	4.6 ± 0.8	3.5 ± 0.5	0.9 ± 0.1	1.4 ± 0.5	1.7 ± 0.5
OC P + E	4.4 ± 0.6	3.7 ± 0.7	0.8 ± 0.7	1.5 ± 0.5	2.0 ± 0.5
U_{Osm}, mosmol/kg H₂O					
Follicular	171 ± 48	410 ± 81	876 ± 77	662 ± 132	486 ± 128
Luteal	166 ± 43	406 ± 77	837 ± 55	635 ± 137	567 ± 139
OC P	125 ± 23	387 ± 58	799 ± 39	553 ± 130	415 ± 109
U_{Osm}/P_{Osm}					
Follicular	0.6 ± 0.2	1.4 ± 0.3	2.7 ± 0.5	2.6 ± 0.5	1.8 ± 0.5
Luteal	0.6 ± 0.2	1.4 ± 0.3	3.0 ± 0.2	2.2 ± 0.5	1.9 ± 0.5
OC P	0.4 ± 0.1	1.4 ± 0.2	2.8 ± 0.2	1.6 ± 0.5	1.6 ± 0.4
C_{H₂O}, ml/min					
Follicular	3.0 ± 1.0	-0.1 ± 0.2	-1.1 ± 0.1	-0.5 ± 0.5	0.1 ± 0.5
Luteal	2.4 ± 0.9	-0.2 ± 0.2	-1.0 ± 0.1	-0.2 ± 0.4	0.1 ± 0.6
OC P	2.6 ± 0.6	-0.4 ± 0.2	-0.9 ± 0.1	0.1 ± 0.5	0.4 ± 0.5
C_{Osm}					
Follicular	2.0 ± 0.3	1.4 ± 0.3	1.6 ± 0.2	1.8 ± 0.2	1.6 ± 0.2
Luteal	2.0 ± 0.2	1.5 ± 0.1	1.5 ± 0.1	1.6 ± 0.1	1.5 ± 0.1
OC P	1.8 ± 0.2	1.6 ± 0.3	1.4 ± 0.2	1.5 ± 0.1	1.5 ± 0.3

	Pre-Exercise	End-exercise	Rehydration		
	0 min	150 min	60 min	120 min	180 min
GFR, ml/min					
Follicular	113 ± 8	83 ± 10	74 ± 10	92 ± 12	83 ± 9
Luteal	119 ± 5	94 ± 7	72 ± 9	84 ± 8	91 ± 11
OC E + P	111 ± 6	89 ± 13	86 ± 9	88 ± 12	91 ± 9
FE_{Na}+, %					
Follicular	0.49 ± 0.09	0.66 ± 0.16	0.93 ± 0.14	0.60 ± 0.05	0.54 ± 0.05
Luteal	0.32 ± 0.06	0.37 ± 0.09	0.65 ± 0.14	0.51 ± 0.06	0.49 ± 0.08
OC E + P	0.36 ± 0.07	0.42 ± 0.11	0.66 ± 0.10	0.62 ± 0.12	0.78 ± 0.31
U_{Na}+, mEq					
Follicular	5.2 ± 0.8	13.4 ± 2.8*#	9.3 ± 1.3	5.7 ± 0.9	4.0 ± 0.4
Luteal	3.3 ± 0.6	7.2 ± 1.5	6.0 ± 0.8	5.0 ± 1.5	4.8 ± 1.5
OC E + P	3.6 ± 0.6	7.4 ± 1.6	6.7 ± 0.8	4.3 ± 0.6	4.2 ± 0.9
U_K+, mEq					
Follicular	2.2 ± 0.4	10.30 ± 2.1	7.2 ± 1.4	5.2 ± 1.4	3.3 ± 0.4
Luteal	4.1 ± 1.9	11.5 ± 2.0	5.2 ± 1.2	3.4 ± 0.9	2.8 ± 0.6
OC E + P	1.9 ± 0.4	8.7 ± 1.6	5.8 ± 1.1	4.1 ± 1.1	4.1 ± 0.8
[Na⁺]_u/[K⁺]_u					
Follicular	2.2 ± 0.2	1.0 ± 0.2	2.5 ± 0.8	4.2 ± 2.1	1.3 ± 0.3
Luteal	1.8 ± 0.6	0.7 ± 0.2	2.4 ± 0.9	6.5 ± 4.9	1.7 ± 0.4
OC E + P	2.5 ± 0.8	0.8 ± 0.2	1.5 ± 0.3	1.2 ± 0.2	1.1 ± 0.2

	Pre-Exercise	End-exercise	Rehydration		
	0 min	150 min	60 min	120 min	180 min
GFR, ml/min					
Follicular	119 ± 9	89 ± 9	82 ± 9	85 ± 5	96 ± 4
Luteal	115 ± 8	96 ± 5	93 ± 8	111 ± 9	103 ± 9
OC P	120 ± 8	87 ± 7	79 ± 7	87 ± 6	90 ± 6
FE_{Na}+, %					
Follicular	0.36 ± 0.09	0.43 ± 0.10	0.71 ± 0.14	0.57 ± 0.11	0.46 ± 0.12
Luteal	0.35 ± 0.05	0.42 ± 0.12	0.55 ± 0.19	0.35 ± 0.07	0.33 ± 0.05
OC P	0.35 ± 0.05	0.47 ± 0.14	0.58 ± 0.10	0.44 ± 0.08	0.41 ± 0.09
U_{Na}+, mEq					
Follicular	4.5 ± 1.1	10.7 ± 2.5*§	7.6 ± 1.9	6.7 ± 1.6	4.8 ± 1.0
Luteal	4.3 ± 0.7	8.7 ± 1.8	5.9 ± 1.3	3.5 ± 0.6	3.3 ± 0.5
OC P	3.6 ± 0.8	8.5 ± 3.3	6.1 ± 1.3	3.1 ± 0.7	2.8 ± 0.6
U_K+, mEq					
Follicular	2.1 ± 0.7	8.0 ± 1.7	6.2 ± 1.6	4.0 ± 1.2	2.6 ± 0.4
Luteal	2.1 ± 0.5	11.2 ± 1.4	5.5 ± 0.8	3.3 ± 0.3	3.2 ± 0.5
OC P	2.0 ± 0.5	8.8 ± 2.1	3.6 ± 0.4	2.5 ± 0.5	3.0 ± 0.6
[Na⁺]_u/[K⁺]_u					
Follicular	2.9 ± 0.9	1.3 ± 0.5	2.9 ± 1.2	2.2 ± 0.6	2.1 ± 0.4
Luteal	2.6 ± 0.8	0.9 ± 0.3	1.2 ± 0.4	1.1 ± 0.3	1.0 ± 0.2
OC P	2.2 ± 0.8	0.9 ± 0.5	1.8 ± 0.7	1.7 ± 0.6	1.8 ± 0.6

Table 6. Renal electrolyte excretion at rest, during dehydration and *ad libitum* drinking.

	Exercise		Rehydration		
	Pre-	End-			
	0 min	150 min	0 min	120 min	180 min
HR, beats/min					
Follicular	77 ± 4	144 ± 6	86 ± 4	76 ± 3	75 ± 4
Luteal	75 ± 5	142 ± 5	88 ± 4	75 ± 6	80 ± 5
OC E+P	78 ± 3	135 ± 6	85 ± 6	77 ± 4	76 ± 4
MAP, mm Hg					
Follicular	83 ± 2	85 ± 3	77 ± 2	80 ± 2	79 ± 1
Luteal	82 ± 2	82 ± 3	76 ± 2	79 ± 2	78 ± 2
OC E+P	83 ± 1	84 ± 4	77 ± 2	77 ± 2	79 ± 1
SBP, mm Hg					
Follicular	113 ± 3	141 ± 7	110 ± 2	106 ± 2	108 ± 2
Luteal	115 ± 3	137 ± 6	109 ± 3	109 ± 4	109 ± 2
OC E+P	118 ± 2	145 ± 8	111 ± 2	109 ± 1	112 ± 1
DBP, mm Hg					
Follicular	69 ± 2	57 ± 2	61 ± 2	67 ± 3	64 ± 1
Luteal	66 ± 2	52 ± 3	60 ± 2	65 ± 3	62 ± 3
OC E+P	66 ± 1	54 ± 3	61 ± 2	61 ± 3	63 ± 2
PP, mm Hg					
Follicular	44 ± 3	84 ± 5	49 ± 2	39 ± 5	44 ± 2
Luteal	49 ± 5	83 ± 7	49 ± 4	44 ± 6	47 ± 4
OC E+P	52 ± 3	91 ± 6	50 ± 3	48 ± 3	49 ± 2

Table 7A. Cardiovascular responses to dehydration.

	Exercise		Rehydration		
	Pre	End			
	0 min	150 min	0 min	120 min	180 min
HR, beats/min					
Follicular	79 ± 3	145 ± 3	88 ± 4	73 ± 2	74 ± 4
Luteal	80 ± 4	142 ± 5	88 ± 4	75 ± 6	80 ± 5
OC P	81 ± 4	141 ± 7	92 ± 4	82 ± 4	81 ± 3
MAP, mm Hg					
Follicular	86 ± 2	82 ± 4	81 ± 4	78 ± 1	78 ± 2
Luteal	82 ± 2	84 ± 3	78 ± 3	79 ± 2	77 ± 2
OC P	81 ± 2	83 ± 3	78 ± 2	80 ± 2	79 ± 2
SBP, mm Hg					
Follicular	116 ± 2	140 ± 6	114 ± 4	109 ± 2	110 ± 2
Luteal	115 ± 3	137 ± 6	109 ± 3	109 ± 4	109 ± 2
OC P	116 ± 3	136 ± 4	110 ± 2	111 ± 2	110 ± 3
DBP, mm Hg					
Follicular	71 ± 3	53 ± 3	65 ± 4	62 ± 2	62 ± 3
Luteal	66 ± 2	58 ± 3	64 ± 5	63 ± 3	63 ± 2
OC P	64 ± 2	57 ± 4	62 ± 3	65 ± 2	64 ± 2
PP, mm Hg					
Follicular	45 ± 4	87 ± 5	48 ± 4	47 ± 3	49 ± 3
Luteal	42 ± 3	80 ± 5	42 ± 7	48 ± 3	43 ± 3
OC P	52 ± 4	79 ± 5	48 ± 3	47 ± 2	46 ± 3

Table 7B. Cardiovascular responses to dehydration.

	Follicular Phase		
	Pre-exercise	Exercise	Rehydration
	0 min	150 min	AUC [‡]
P_[ALD], pg/ml			
Trial A	78 ± 12	275 ± 65	228·10 ² ± 37·10 ²
Trial B	96 ± 19	198 ± 47	166·10 ² ± 30·10 ²
PRA, ng·ml⁻¹ ANG·hr⁻¹			
Trial A	0.8 ± 0.2	3.9 ± 1.0	287 ± 60
Trial B	0.9 ± 0.2	3.4 ± 1.1	267 ± 62
P_[AVP], pg/ml			
Trial A	1.3 ± 0.2	3.7 ± 0.8	399 ± 72
Trial B	1.2 ± 0.4	3.5 ± 0.8	374 ± 106
P_[ANP], pg/ml			
Trial A	33.0 ± 3.9	88.1 ± 11.7	78·10 ² ± 8·10 ²
Trial B	38.0 ± 5.3	87.9 ± 12.1	76·10 ² ± 8·10 ²

	Luteal Phase		
	Pre-exercise	Exercise	Rehydration
	0 min	150 min	AUC [‡]
P_[ALD], pg/ml			
Trial A	156.8 ± 21.8*	388.1 ± 43.1*	330·10 ² ± 47·10 ² *
Trial B	154.9 ± 20.6*	499.8 ± 51.0*	460·10 ² ± 52·10 ² *
PRA, ng·ml⁻¹ ANG·hr⁻¹			
Trial A	1.8 ± 0.4*	6.1 ± 1.7*	471 ± 113*
Trial B	1.7 ± 0.2*	4.2 ± 0.9*	653 ± 121*
P_[AVP], pg/ml			
Trial A	1.2 ± 0.2	3.2 ± 0.6	347 ± 79
Trial B	1.1 ± 0.3	3.7 ± 1.1	496 ± 125
P_[ANP], pg/ml			
Trial A	49.6 ± 5.6	109.2 ± 14.5	94·10 ² ± 9·10 ²
Trial B	54.6 ± 9.2	114.8 ± 22.2	101·10 ² ± 14·10 ²

Table 8. Fluid regulation hormones over two menstrual cycles.

	Cronbach's α	
	Follicular Phase	Luteal Phase
Resting $P_{[AVP]}$	0.49	0.25
Exercise $P_{[AVP]}$	0.81 [†]	0.98 [†]
Rehydration $P_{[AVP]}$	0.58	0.96 [†]
$P_{[AVP]}-P_{Osm}$ slope	0.96 [†]	0.81 [†]
$P_{[AVP]}-P_{Osm}$ intercept	0.90 [†]	0.86 [†]
Resting $P_{[ANP]}$	0.80 [†]	0.80 [†]
Exercise $P_{[ANP]}$	0.90 [†]	0.87 [†]
Rehydration $P_{[ANP]}$	0.93 [†]	0.80 [†]
Resting PRA	0.49	0.51
Exercise PRA	0.72	0.89 [†]
Rehydration PRA	0.67	0.95 [†]
Resting $P_{[ALD]}$	0.55	0.66
Exercise $P_{[ALD]}$	0.66	0.82 [†]
Rehydration $P_{[ALD]}$	0.64	0.76
Resting $P_{[E_2]}$	0.85 [†]	0.93 [†]
Resting $P_{[P_4]}$	0.62	0.92 [†]

Table 9. Reliability of fluid regulation hormones over two menstrual cycles.

	Follicular	Luteal	OC P	OC E+P
BW, kg	53.8 ± 3.3	53.2 ± 3.0	53.3 ± 2.9	52.1 ± 3.1
P[E₂], pg/ml	21 ± 6	104.5 ± 20.0	31.3 ± 10.0	10.0 ± 2.9
P[P₄], ng/ml	0.7 ± 0.1	12.0 ± 1.8	0.6 ± 0.1	0.7 ± 0.1
Hct, %	38.3 ± 0.7	39.3 ± 0.5	38.9 ± 0.5	37.8 ± 0.7
[Hb], g/dl	13.1 ± 0.3	13.4 ± 0.2	13.1 ± 0.2	12.3 ± 0.3
P_{Osm}, mOsmol/kg	284 ± 1	283 ± 1	285 ± 1	282 ± 1*
S_[Na⁺], mEq/l	137.8 ± 0.8	137.4 ± 0.5	138.0 ± 0.7	136.8 ± 0.9
P[P₄]/ P[E₂]	85.8 ± 51.6	151.3 ± 50.1		
Tes °C at 27°C	36.66 ± 0.21	37.11 ± 0.20*	37.61 ± 0.31*	37.03 ± 0.23
Tsk °C at 27°C	31.27 ± 0.38	31.66 ± 0.16	31.12 ± 0.22	31.82 ± 0.27
Tes °C at 35°C pre-exercise	36.98 ± 0.30	37.15 ± 0.32	37.54 ± 0.27**†	36.64 ± 0.13
Tsk °C at 35°C pre-exercise	35.08 ± 0.29	35.04 ± 0.14	35.21 ± 0.16	35.61 ± 0.24
Tes °C at 35°C 40-min of exercise	37.86 ± 0.16	38.31 ± 0.27	38.74 ± 0.35	37.75 ± 0.21
Tsk °C at 35°C 40-min of exercise	34.82 ± 0.26	34.99 ± 0.41	34.84 ± 0.24	35.01 ± 0.20

Table 10. Baseline subject characteristics.

	Rest 27°C	Rest 35°C	exercise 35°C 20 min	exercise 35°C 40 min
Heart rate, bpm				
Follicular	67 ± 3	69 ± 3	132 ± 8	140 ± 8
Luteal	67 ± 3	69 ± 4	127 ± 7	137 ± 7
OC P	66 ± 3	68 ± 3	131 ± 6	141 ± 7
OC E+P	64 ± 4	67 ± 4	126 ± 10	135 ± 9
Stroke volume, ml				
Follicular	81 ± 8	80 ± 7	98 ± 10	99 ± 10
Luteal	88 ± 8	88 ± 7	111 ± 11	111 ± 10
OC P	87 ± 6	87 ± 6	113 ± 10	110 ± 11
OC E+P	99 ± 7	95 ± 8	112 ± 8	115 ± 15
Cardiac output, l/min				
Follicular	5.3 ± 0.4	5.5 ± 0.4	12.9 ± 1.1	13.6 ± 1.2
Luteal	5.8 ± 0.5	6.0 ± 0.3	13.9 ± 1.2	14.9 ± 1.4
OC P	5.8 ± 0.4	6.0 ± 0.3	14.4 ± 0.9	15.2 ± 1.4
OC E+P	6.4 ± 0.5	6.2 ± 0.5	13.6 ± 1.0	15.1 ± 1.4
Mean arterial pressure, mm Hg				
Follicular	80 ± 4	81 ± 4	90 ± 4	92 ± 5
Luteal	80 ± 3	78 ± 3	92 ± 4	90 ± 5
OC P	78 ± 2	76 ± 2	88 ± 2	89 ± 2
OC E+P	77 ± 2	78 ± 2	93 ± 5	96 ± 5

Table 11. Cardiovascular responses during exercise in the heat.

	Follicular	Luteal	OC P	OC E+P
T_{es} threshold, °C	37.5 ± 0.2	38.0 ± 0.3*	38.1 ± 0.2**†	37.5 ± 0.2
slope, ΔSR/ΔT_{es}	0.88 ± 0.28	1.08 ± 0.21	1.13 ± 0.30	0.86 ± 0.23
r²	0.81 ± 0.05	0.90 ± 0.03	0.76 ± 0.05	0.87 ± 0.03

Table 12. Control of sweating during exercise in the heat.

	Follicular Phase	Luteal Phase	Progestin	Estradiol + Progestin
BW, kg	59.9 ± 2.3	59.6 ± 2.6	60.6 ± 2.9	60.3 ± 2.7
PV, ml	2538 ± 162	2448 ± 114*††	2533 ± 227	2773 ± 99
BV ml /kg BW	59.8 ± 2.9	58.8 ± 2.1	56.2 ± 3.8	58.6 ± 3.0
P_[E2], (pg/ml)	16.1 ± 2.8	80.6 ± 11.4	12.9 ± 4.4	20.9 ± 5.5
P_[P4], (ng/ml)	0.6 ± 0.1	12.7 ± 0.7	0.7 ± 0.1	1.0 ± 0.5
P_{Osm}, mOsm/kg H₂O	286 ± 1	280 ± 1*	284 ± 1	283 ± 1
S_[Na+], mEq/l	137.7 ± 0.4	137.0 ± 0.6	137.5 ± 0.6	137.2 ± 0.7
P_{Osm}-thirst slope, mm/mOsm	5.9 ± 0.9	7.0 ± 0.8	7.6 ± 0.9	6.3 ± 0.7
P_{Osm}-thirst x- intercept, mOsm	286 ± 1	283 ± 1*	286 ± 2	284 ± 2

Table 13. Subject characteristics and thirst responses during hypertonic saline infusion.

	Pre-HSI	End HSI	Recovery		
	0 min	120 min	180 min	210 min	240 min
Hct, %					
Follicular	36.8 ± 0.6	32.2 ± 0.8	33.3 ± 0.7	33.8 ± 0.8	33.5 ± 0.7
Luteal	37.7 ± 0.6*	33.2 ± 0.5*	34.2 ± 0.5*	34.2 ± 0.6*	34.4 ± 0.4*
OC P	37.3 ± 0.6	33.0 ± 0.5	33.6 ± 0.5	1.1 ± 0.6	33.5 ± 0.5
OC E + P	36.7 ± 0.6	31.7 ± 0.6	33.0 ± 0.5	33.1 ± 0.5	33.3 ± 0.7
Hb, g/dl					
Follicular	12.4 ± 0.3	12.0 ± 0.3	11.4 ± 0.3	11.2 ± 0.3	---
Luteal	11.9 ± 0.3*	11.4 ± 0.4*	11.7 ± 0.3*	11.6 ± 0.3*	---
OC P	12.5 ± 0.3	11.3 ± 0.3	11.5 ± 0.3	11.2 ± 0.2	---
OC E + P	12.3 ± 0.2	11.1 ± 0.2	11.4 ± 0.2	11.2 ± 0.2	---
PV, % change					
Follicular	---	21.0 ± 1.5	15.0 ± 1.1	16.0 ± 1.0	---
Luteal	---	18.9 ± 2.5	14.2 ± 1.3	15.4 ± 1.6	---
OC P	---	18.0 ± 1.5	14.8 ± 1.5	17.5 ± 1.2	---
OC E + P		18.7 ± 0.8	14.3 ± 0.6	17.1 ± 1.7	---
Thirst, mm					
Follicular	9 ± 3	74 ± 12	76 ± 12	20 ± 7	23 ± 7
Luteal	9 ± 3	97 ± 10	95 ± 10	15 ± 5	15 ± 4
OC P	9 ± 2	100 ± 5	105 ± 5	17 ± 4	18 ± 4
OC E + P	6 ± 2	82 ± 6	94 ± 9	18 ± 6	28 ± 8

Table 14. Blood and thirst responses at rest, and during hypertonic saline infusion and recovery

	Pre-HSI	End HSI	Recovery	
	0 min	120 min	180 min	240 min
U_v ml/min				
Follicular	3.4 ± 0.7	2.1 ± 0.3	2.2 ± 0.2	1.7 ± 0.2
Luteal	4.5 ± 0.7	1.9 ± 0.2	2.2 ± 0.2	2.1 ± 0.2
OC P	2.8 ± 0.8	1.7 ± 0.3	1.7 ± 0.1	1.4 ± 0.1
OC P + E	2.4 ± 0.8	1.7 ± 0.3	2.0 ± 0.3	1.5 ± 0.2
U_{osm}, mosmol/kgH₂O				
Follicular	355 ± 121	560 ± 42	687 ± 19	706 ± 23
Luteal	236 ± 63	498 ± 58	682 ± 14	627 ± 40
OC P	306 ± 74	622 ± 46	723 ± 22	731 ± 26
OC P + E	468 ± 111	703 ± 62	748 ± 41	770 ± 38
U_{osm}/P_{osom}				
Follicular	1.2 ± 0.4	1.9 ± 0.1	2.3 ± 0.1	2.5 ± 0.1
Luteal	0.8 ± 0.2	1.7 ± 0.2	2.3 ± 0.0	2.2 ± 0.1
OC P	1.0 ± 0.3	2.1 ± 0.2	2.4 ± 0.1	2.5 ± 0.1
OC P + E	1.6 ± 0.4	2.4 ± 0.2	2.2 ± 0.3	2.7 ± 0.1
CH₂O, ml/min				
Follicular	1.1 ± 0.6	-1.6 ± 0.2	-2.8 ± 0.2	-2.4 ± 0.3
Luteal	2.1 ± 0.7	-1.7 ± 0.2	-2.6 ± 0.3	-2.5 ± 0.2
OC P	0.8 ± 0.8	-1.6 ± 0.3	-2.5 ± 0.2	-2.2 ± 0.2
OC P + E	0.6 ± 0.8	-1.9 ± 0.3	-2.6 ± 0.4	-2.4 ± 0.3
C_{osm}				
Follicular	2.3 ± 0.2	3.7 ± 0.4	5.0 ± 0.5	4.0 ± 0.5
Luteal	2.3 ± 0.1	3.6 ± 0.3	4.9 ± 0.4	4.6 ± 0.3
OC P	2.1 ± 0.3	3.3 ± 0.6	4.2 ± 0.3	3.8 ± 0.3
OC P + E	1.8 ± 0.3	3.6 ± 0.6	4.4 ± 0.7	4.0 ± 0.5

Table 15. Renal osmoregulatory responses at rest, and during hypertonic saline infusion and recovery.

	Pre-HSI	End HSI	Recovery	
	0 min	120 min	180 min	240 min
GFR, ml/min				
Follicular	99 ± 13	107 ± 12	109 ± 8	99 ± 12
Luteal	110 ± 8	113 ± 8	104 ± 8	113 ± 11
OC P	129 ± 12	109 ± 16	93 ± 8	89 ± 11
OC P + E	107 ± 5	121 ± 4	123 ± 5	118 ± 6
FE_{Na+}, %				
Follicular	0.88 ± 0.12	2.43 ± 0.41	3.78 ± 0.77	2.93 ± 0.43
Luteal	1.02 ± 0.23	2.21 ± 0.25	3.77 ± 0.40	2.98 ± 0.33
OC P	0.49 ± 0.09	2.73 ± 0.38	3.04 ± 0.66	2.55 ± 0.49
OC P + E	0.58 ± 0.10	2.07 ± 0.46	2.63 ± 0.44	2.49 ± 0.46
U_{Na+}, mEq				
Follicular	7.7 ± 1.2	47.4 ± 8.9	30.8 ± 5.0	23.8 ± 4.4
Luteal	8.0 ± 1.4	42.3 ± 2.8	31.8 ± 1.7	26.8 ± 1.6
OC P	5.2 ± 1.0	39.2 ± 6.5	30.2 ± 9.3	26.4 ± 9.1
OC P + E	4.8 ± 1.1	42.8 ± 9.4	31.9 ± 7.7	27.3 ± 7.3
U_{K+}, mEq				
Follicular	2.3 ± 0.5	8.6 ± 1.8	7.2 ± 1.1	6.7 ± 0.8
Luteal	3.9 ± 1.4	7.5 ± 1.1	7.9 ± 1.1	7.3 ± 1.1
OC P	3.3 ± 0.8	11.6 ± 3.0	6.7 ± 1.0	6.5 ± 0.9
OC P + E	1.5 ± 0.2	8.5 ± 1.6	8.4 ± 1.9	7.8 ± 1.8
[Na⁺]_u/[K⁺]_u				
Follicular	4.0 ± 0.5	5.7 ± 0.7	4.3 ± 0.4	3.5 ± 0.4
Luteal	2.4 ± 0.5	5.8 ± 1.3	4.6 ± 0.9	3.3 ± 0.4
OC P	3.0 ± 0.8	6.1 ± 1.3	4.1 ± 1.0	3.1 ± 0.5
OC P + E	3.4 ± 0.6	5.6 ± 1.3	4.1 ± 0.6	3.3 ± 0.5

Table 16. Renal electrolyte excretion at rest, during hypertonic saline infusion and recovery.

	HSI		Recovery	
	Pre-	End-		
	0 min	120 min	180 min	240 min
HR, beats/min				
Follicular	73 ± 3	69 ± 2	68 ± 3	68 ± 3
Luteal	71 ± 2	72 ± 3	67 ± 2	71 ± 3
OC P	69 ± 2	71 ± 2	73 ± 3	75 ± 2
OC E+P	69 ± 3	68 ± 2	66 ± 2	70 ± 3
MAP, mm Hg				
Follicular	82 ± 2	83 ± 4	76 ± 4	78 ± 2
Luteal	80 ± 3	83 ± 4	80 ± 3	78 ± 3
OC P	78 ± 2	83 ± 2	79 ± 3	79 ± 3
OC E+P	76 ± 3	81 ± 4	80 ± 2	76 ± 3
SBP, mm Hg				
Follicular	112 ± 3	119 ± 5	112 ± 4	115 ± 3
Luteal	114 ± 4	119 ± 5	115 ± 5	115 ± 4
OC P	112 ± 4	116 ± 3	116 ± 5	114 ± 4
OC E+P	110 ± 4	119 ± 5	116 ± 3	112 ± 4
DBP, mm Hg				
Follicular	64 ± 2	64 ± 4	57 ± 5	59 ± 3
Luteal	63 ± 3	65 ± 3	63 ± 3	59 ± 3
OC P	60 ± 2	66 ± 2	59 ± 3	62 ± 2
OC E+P	59 ± 3	62 ± 3	63 ± 3	59 ± 3
PP, mm Hg				
Follicular	51 ± 3	55 ± 5	54 ± 6	56 ± 6
Luteal	51 ± 4	54 ± 4	53 ± 4	56 ± 3
OC P	51 ± 3	51 ± 2	59 ± 4	52 ± 3
OC E+P	51 ± 3	57 ± 3	53 ± 4	53 ± 3

Table 17. Cardiovascular responses at rest, and during hypertonic saline infusion and recovery.

	Women- Follicular Phase	Women- Luteal Phase	Men
Age (y)	29 ± 2	29 ± 2	24 ± 1
BW (kg)	59.2 ± 2.6	59.2 ± 2.6	75.5 ± 3.1
Height (cm)	164 ± 5	164 ± 5	175 ± 2
PV (ml)	2538 ± 162	2448 ± 114	3447 ± 410
BV (ml/kg)	59.8 ± 2.9	58.8 ± 2.1	75.3 ± 5.1
P _[E2] , (pg/ml)	16.1 ± 2.8	80.6 ± 11.4	--
P _[P4] , (ng/ml)	0.6 ± 0.1	12.7 ± 0.7	--
P _{Osm} , mOsm/kg H ₂ O	286 ± 1	280 ± 1 ^{*#}	289 ± 1
S _[Na+] , mEq/l	137.7 ± 0.4	137.0 ± 0.6 ^{*#}	138.8 ± 0.7
P _{Osm} -thirst slope, mm/mOsm	5.9 ± 0.9	7.0 ± 0.8	5.3 ± 1.3
P _{Osm} -thirst x-intercept, mOsm	286 ± 1	283 ± 1 [*]	285 ± 3

Table 18. Subject characteristics and thirst responses during hypertonic saline infusion in men and women.

	Pre-HSI	End HSI	Recovery		
	0 min	120 min	150 min	210 min	240 min
Hct, %					
Follicular	36.8 ± 0.6	32.2 ± 0.8	33.3 ± 0.7	33.8 ± 0.8	33.5 ± 0.7
Luteal	37.7 ± 0.6* [#]	33.2 ± 0.5* [#]	34.2 ± 0.5* [#]	34.2 ± 0.6* [#]	34.4 ± 0.4* [#]
Men	41.1 ± 0.4	36.1 ± 0.5	37.0 ± 0.5	37.6 ± 0.4	37.8 ± 0.5
Hb, g/dl					
Follicular	12.4 ± 0.3	12.0 ± 0.3	11.4 ± 0.3	11.2 ± 0.3	---
Luteal	11.9 ± 0.3* [#]	11.4 ± 0.4* [#]	11.7 ± 0.3* [#]	11.6 ± 0.3* [#]	---
Men	14.3 ± 0.3	12.8 ± 0.2	13.0 ± 0.3	13.2 ± 0.2	---
PV, % change					
Follicular	---	21.0 ± 1.5	15.0 ± 1.1	16.0 ± 1.0	---
Luteal	---	18.9 ± 2.5	14.2 ± 1.3	15.4 ± 1.6	---
Men	---	21.9 ± 1.6	18.7 ± 1.4	16.0 ± 1.6	---
Thirst, mm					
Follicular	9 ± 3	74 ± 12	76 ± 12	20 ± 7	23 ± 7
Luteal	9 ± 3	97 ± 10	95 ± 10	15 ± 5	15 ± 4
Men	21 ± 9	78 ± 12	87 ± 13	26 ± 11	24 ± 9

Table 19. Blood and thirst responses at rest, and during hypertonic saline infusion and recovery in men and women.

	Pre-HSI	End HSI	Recovery	
	0 min	120 min	180 min	240 min
U_v ml/min				
Follicular	3.4 ± 0.7	2.1 ± 0.3	2.2 ± 0.2	1.7 ± 0.2
Luteal	4.5 ± 0.7	1.9 ± 0.2	2.2 ± 0.2	2.1 ± 0.2
Men	3.9 ± 1.1	1.8 ± 0.2	2.1 ± 0.3	2.2 ± 0.2
U_{osm}, mosmol/kgH₂O				
Follicular	355 ± 121	560 ± 42	687 ± 19	706 ± 23
Luteal	236 ± 63	498 ± 58	682 ± 14	627 ± 40
Men	482 ± 121	629 ± 93	770 ± 39	712 ± 50
U_{osm}/P_{osom}				
Follicular	1.3 ± 0.4	1.9 ± 0.1	2.3 ± 0.1	2.5 ± 0.1
Luteal	0.8 ± 0.2	1.7 ± 0.2	2.3 ± 0.0	2.2 ± 0.1
Men	1.7 ± 0.4	2.1 ± 0.3	2.6 ± 0.1	2.4 ± 0.2
CH₂O, ml/min				
Follicular	1.1 ± 0.6	-1.6 ± 0.2	-2.8 ± 0.2	-2.4 ± 0.3
Luteal	2.1 ± 0.7	-1.7 ± 0.2	-2.6 ± 0.3	-2.5 ± 0.2
Men	0.7 ± 1.2	-1.5 ± 0.4	-3.2 ± 0.2	-3.0 ± 0.2
C_{osm}				
Follicular	2.3 ± 0.2	3.7 ± 0.4	5.0 ± 0.5	4.0 ± 0.5
Luteal	2.3 ± 0.1	3.6 ± 0.3	4.9 ± 0.4	4.6 ± 0.3
Men	3.2 ± 0.6	3.3 ± 0.3	5.3 ± 0.5	5.2 ± 0.3

Table 20. Renal osmoregulatory responses at rest, and during hypertonic saline infusion and recovery.

	Pre-HSI	End HSI	Recovery	
	0 min	120 min	180 min	240 min
GFR, ml/min				
Follicular	99 ± 13	107 ± 12	109 ± 8	99 ± 12
Luteal	110 ± 8	113 ± 8	104 ± 8	113 ± 11
Men	101 ± 7	112 ± 14	117 ± 12	115 ± 11
FE_{Na+}, %				
Follicular	0.88 ± 0.12	2.43 ± 0.41	3.78 ± 0.77	2.93 ± 0.43
Luteal	1.02 ± 0.23	2.21 ± 0.25	3.77 ± 0.40	2.98 ± 0.33
Men	0.89 ± 0.18	1.74 ± 0.19	2.69 ± 0.32	2.59 ± 0.25
U_{Na+}, mEq				
Follicular	7.7 ± 1.2	47.4 ± 8.9	30.8 ± 5.0	23.8 ± 4.4
Luteal	8.0 ± 1.4	42.3 ± 2.8	31.8 ± 1.7	26.8 ± 1.6
Men	8.4 ± 2.6	38.8 ± 6.4	31.5 ± 4.4	31.5 ± 3.8
U_{K+}, mEq				
Follicular	2.3 ± 0.5	8.6 ± 1.8	7.2 ± 1.1	6.7 ± 0.8
Luteal	3.9 ± 1.1	7.6 ± 1.1	7.9 ± 1.1	7.3 ± 1.1
Men	2.5 ± 0.7	8.1 ± 1.6	8.5 ± 1.2	8.8 ± 1.1
[Na⁺]_u/[K⁺]_u				
Follicular	4.0 ± 0.5	5.7 ± 0.7	4.3 ± 0.4	3.5 ± 0.4
Luteal	2.4 ± 0.5	5.8 ± 1.3	4.6 ± 0.9	3.3 ± 0.4
Men	3.1 ± 0.6	5.7 ± 1.8	4.0 ± 1.0	3.6 ± 0.5

Table 21. Renal electrolyte excretion at rest, during hypertonic saline infusion and recovery in men and women.

	HSI		Recovery	
	Pre-	End-		
	0 min	120 min	180 min	240 min
HR, beats/min				
Follicular	73 ± 3	69 ± 2	68 ± 3	68 ± 3
Luteal	71 ± 2	72 ± 3	67 ± 2	71 ± 3
Men	70 ± 3	63 ± 3	65 ± 4	61 ± 3
MAP, mm Hg				
Follicular	82 ± 2	83 ± 4	76 ± 4	78 ± 2
Luteal	80 ± 3	83 ± 4	80 ± 3	78 ± 3
Men[#]	91 ± 3*§	90 ± 3*§	87 ± 3*§	88 ± 4*§
SBP, mm Hg				
Follicular	112 ± 3	119 ± 5	112 ± 4	115 ± 3
Luteal	114 ± 4	119 ± 5	115 ± 5	115 ± 4
Men[#]	124 ± 4*§	132 ± 3*§	131 ± 3*§	132 ± 4*§
DBP, mm Hg				
Follicular	64 ± 2	64 ± 4	57 ± 5	59 ± 3
Luteal	63 ± 3	65 ± 3	63 ± 3	59 ± 3
Men[#]	75 ± 3*§	69 ± 3	75 ± 4*§	66 ± 4*§
PP, mm Hg				
Follicular	51 ± 3	55 ± 5	54 ± 6	56 ± 6
Luteal	51 ± 4	54 ± 4	53 ± 4	56 ± 3
Men	49 ± 4	64 ± 4	65 ± 4	66 ± 3

Table 22. Cardiovascular responses at rest, and during hypertonic saline infusion and recover

APPENDIX B
Figures 2-20, 22-27




Figure 2. Plasma osmolality at rest, dehydration and rehydration




Figure 3. Plasma renin activity at rest, dehydration and rehydration




Figure 4. Plasma aldosterone concentration at rest, dehydration and rehydration




Figure 5. Plasma atrial natriuretic peptide concentration at rest, dehydration and rehydration





Figure 6. Osmotic regulation of arginine vasopressin during dehydration.




Figure 7. Cumulative sodium loss







Figure 8. Body fluid balance





Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 22




Figure 23




Figure 24




Figure 25




Figure 26




Figure 27

Award Number: DAMD17-96-C-6093

Title: *Hormonal Contraception, Body Water Balance and Thermoregulation*

Nina Stachenfeld, Ph.D., Principal Investigator

Publications (3)

Physiological variability of fluid-regulation hormones in young women

NINA S. STACHENFELD,¹ LORETTA DiPIETRO,¹ CHERYL A. KOKOSZKA,¹
CELSE SILVA,⁴ DAVID L. KEEFE,⁴ AND ETHAN R. NADEL^{1,2,3}

¹The John B. Pierce Laboratory, Departments of ²Epidemiology and Public Health,
and ³Cellular and Molecular Physiology, Yale University School of Medicine, New Haven,
Connecticut 06519; and ⁴Women and Infants Hospital, Brown University School of Medicine,
Providence, Rhode Island 02905

Stachenfeld, Nina S., Loretta DiPietro, Cheryl A. Kokoszka, Celso Silva, David L. Keefe, and Ethan R. Nadel. Physiological variability of fluid-regulation hormones in young women. *J. Appl. Physiol.* 86(3): 1092–1096, 1999.—We tested the physiological reliability of plasma renin activity (PRA) and plasma concentrations of arginine vasopressin ($P_{[AVP]}$), aldosterone ($P_{[ALD]}$), and atrial natriuretic peptide ($P_{[ANP]}$) in the early follicular phase and midluteal phases over the course of two menstrual cycles ($n = 9$ women, ages 25 ± 1 yr). The reliability (Cronbach's $\alpha \geq 0.80$) of these hormones within a given phase of the cycle was tested 1) at rest, 2) after 2.5 h of dehydrating exercise, and 3) during a rehydration period. The mean hormone concentrations were similar within both the early follicular and midluteal phase tests; and the mean concentrations of $P_{[ALD]}$ and PRA for the three test conditions were significantly greater during the midluteal compared with the early follicular phase. Although Cronbach's α for resting and recovery $P_{[ANP]}$ were high (0.80 and 0.87, respectively), the resting and rehydration values for $P_{[AVP]}$, $P_{[ALD]}$, and PRA were variable between trials for the follicular (α from 0.49 to 0.55) and the luteal phase (α from 0.25 to 0.66). Physiological reliability was better after dehydration for $P_{[AVP]}$ and PRA but remained low for $P_{[ALD]}$. Although resting and recovery $P_{[AVP]}$, $P_{[ALD]}$, and PRA were not consistent within a given menstrual phase, the differences in the concentrations of these hormones between the different menstrual phases far exceeded the variability within the phases, indicating that the low within-phase reliability does not prevent the detection of menstrual phase-related differences in these hormonal variables.

aldosterone; renin; atrial natriuretic peptide; arginine vasopressin; estrogen; progesterone

THE BODY'S WATER- AND SODIUM-regulating hormones vary considerably over the course of the menstrual cycle (7–9, 14, 15, 18, 19). For example, during the midluteal phase of the menstrual cycle, plasma aldosterone concentration ($P_{[ALD]}$) and plasma renin activity (PRA) are greater at rest (9) and during exercise (14,

15) than in the follicular phase. In addition, resting plasma arginine vasopressin concentration ($P_{[AVP]}$) is higher (8) during the preovulatory and midluteal phases of the cycle when plasma estrogen concentration ($P_{[E_2]}$) is high. In lower animals, estrogen administration increases osmotic stimulation of AVP (1, 4, 5) and water retention (3), and both estrogen and progesterone exhibit important effects on sodium regulation and the sodium-regulation hormones (10–12, 21); this supports the hypothesis that the gonadal steroids have important modulatory effects on body fluid and electrolyte balance.

No studies exist that examine the physiological reliability of the fluid-regulating hormones within a given phase and over the course of two or more menstrual cycles. Reported plasma concentrations of these hormones across different menstrual cycles differ due to natural physiological variations, due to selection of an inappropriate day to conduct physiological testing, due to variations in water and/or sodium intake, or due to inaccurate hormone-analysis techniques. The purpose of this study was to eliminate variability caused by the latter three reasons to determine the natural physiological variability of the responses of fluid- and sodium-regulating hormones over two menstrual cycles. Accordingly, we tested women twice during the early follicular phase (when estrogen and progesterone are low) and twice during the midluteal phase of the menstrual cycle (when estrogen and progesterone are high).

METHODS

Study Design

Subjects were nine healthy, nonsmoking women (age, 25 ± 1 yr; range, 22–31 yr). To drive the fluid-regulation system, each woman participated in a series of dehydration experiments in which the study hormones were measured 1) at rest, 2) during dehydration, and 3) during rehydration in both the early follicular and the midluteal menstrual phases. The study design employed four dehydration experiments: two conducted in the early follicular phase (2–4 days after the beginning of menstrual bleeding) and two in the midluteal phase of the menstrual cycle (conducted 7–10 days after the luteinizing hormone peak), as determined individually by the use of ovulation-prediction kits (OvuQuick; Quidel, San Diego, CA). The tests were conducted during nonconsecutive men-

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

strual phases, 12–16 wk apart. To verify the phase of the menstrual cycle, plasma levels of 17β -estradiol and progesterone were assessed from a basal blood sample.

Dehydration Experiments

On the day of the dehydration test, volunteers arrived at the laboratory between 7:00 and 8:00 AM, after they had eaten only a prescribed low-fat breakfast (~300 kcal). The subjects refrained from alcohol and caffeine for 12 h before the experiment. Subjects were asked to drink 7 ml/kg body weight of tap water at home before arrival at the laboratory. On arrival at the laboratory, the subjects gave a baseline urine sample; they were weighed and then sat on the contour chair of a cycle ergometer in the test chamber [27°C , 30% relative humidity (RH)] for 60 min of control rest. During the control period, an indwelling catheter was placed in an arm vein. At the end of the control period, a 20-ml blood sample was drawn and urine was collected. Consistency of the pretest hydration state was assessed from the specific gravity of the basal urine sample (mean = 1.001), which did not differ across trials.

After the control period, the chamber temperature was increased to 36°C . The subjects then exercised at 50% maximal power output for 150 min, with 5-min rest periods every 25 min, during which time they were deprived of fluids. Blood samples (10–20 ml) were drawn and body weight was assessed at 60, 120, and 150 min during exercise. At the end of exercise, the chamber temperature was reduced to 27°C . After dehydration, subjects rested for 30 min in a contour chair, without access to fluids; after 30 min, they drank water ad libitum for 180 min. Blood samples (20 ml) were taken just before drinking (time 0) and at 30, 60, 120, and 180 min of rehydration. Urine was collected at the end of exercise and at hourly intervals during rehydration, and the urine samples were analyzed for volume and sodium excretion.

Blood samples. Subjects were semirecumbent during placement of the catheter (21 gauge) and were seated for 60 min before samples were taken to ensure a steady state in plasma volume and constituents. Free-flowing venous blood was obtained for the measurement of hematocrit (Hct), plasma osmolality (P_{Osm}), PRA, $P_{[\text{AVP}]}$, $P_{[\text{ALD}]}$, $P_{[\text{E}_2]}$, and plasma concentrations of atrial natriuretic peptide ($P_{[\text{ANP}]}$) and progesterone ($P_{[\text{P}_4]}$). An aliquot (0.5 ml) was removed for immediate assessment of Hct in triplicate by microhematocrit. Second and third aliquots were transferred to a heparinized tube and a tube without additive, and all other aliquots were placed in tubes that contained EDTA. The tubes were centrifuged, and the plasma taken off the heparinized sample was analyzed for aldosterone. $P_{[\text{E}_2]}$ and $P_{[\text{P}_4]}$ were measured by using serum from the tube without additive. The EDTA samples were analyzed for $P_{[\text{AVP}]}$, $P_{[\text{ANP}]}$, and PRA. All blood samples were analyzed for Hct, P_{Osm} , $P_{[\text{ALD}]}$, $P_{[\text{AVP}]}$, $P_{[\text{ANP}]}$, and PRA; only the basal blood samples were also analyzed for $P_{[\text{E}_2]}$ and $P_{[\text{P}_4]}$.

Blood Analysis

P_{Osm} was measured by freezing-point depression (Advanced Instruments 3DII); $P_{[\text{ALD}]}$, $P_{[\text{AVP}]}$, $P_{[\text{ANP}]}$, $P_{[\text{E}_2]}$, and $P_{[\text{P}_4]}$ were measured by radioimmunoassay. Intra- and interassay coefficients of variation for the midrange standards were, respectively, as follows: $P_{[\text{AVP}]}$ (4.52 pg/ml), 6.0 and 3.4% [Immuno Biological Laboratories (IBL), Hamburg, Germany]; PRA ($4.5 \text{ ng} \cdot \text{ml}^{-1} \text{ ANG} \cdot \text{h}^{-1}$), 2.3 and 2.9% (Diasorin, Stillwater, MN); $P_{[\text{ALD}]}$ (132 pg/ml), 3.4 and 3.6% (Diagnostic Products, Los Angeles, CA); $P_{[\text{ANP}]}$ (63.3 pg/ml), 5.1 and 5.2% (Diasorin); $P_{[\text{E}_2]}$ (64.3 pg/ml), 3.7 and 4.0% (Diagnostic Prod-

ucts); and $P_{[\text{P}_4]}$ (3.7 pg/ml), 2.1 and 2.5% (Diagnostic Products). The assay for AVP has a sensitivity of 0.8 pg/ml; this sensitivity is necessary to detect small, but important, changes in this hormone.

Statistical Analysis

Pearson's product-moment correlation on individual data was used to assess the slope and abscissal intercepts of the $P_{[\text{AVP}]}-P_{\text{Osm}}$ relationship during dehydration (6). The within-phase reliability of our most important dependent variables (fluid-regulating hormones and osmotic regulation of AVP, as measured at rest, dehydration, and rehydration) was determined with Cronbach's α , assuming a value ≥ 0.80 as an acceptable level of reliability (2). Areas under the curve (AUC; trapezoid method) were calculated during the rehydration period (starting 30 min postexercise) for PRA, $P_{[\text{ALD}]}$, and $P_{[\text{ANP}]}$, and their reliability was determined within a given menstrual cycle by using Cronbach's α . We used repeated measures ANOVA models, followed by Bonferroni's *t*-test to test differences in the dependent variables both within and between menstrual phases. Data were analyzed by using BMDP statistical software (BMDP Statistical Software, Los Angeles, CA) and were expressed as means \pm SE.

RESULTS

All subjects were tested during the first 5 days (4 ± 1 days) after the start of menstrual bleeding for early follicular-phase tests, and between 20 and 25 days (22 ± 2 days) for the midluteal-phase tests. Specifically, the subjects were tested between days 7 and 10 after the LH peak, and, therefore, ~6–9 days after ovulation.

Between-Phase Measurements

At rest, Hct, $P_{[\text{E}_2]}$, $P_{[\text{P}_4]}$, $P_{[\text{ALD}]}$, and PRA were higher, and P_{Osm} and $P_{[\text{ANP}]}$ were lower, in the luteal phase compared with the follicular phase ($P < 0.05$); however, there were no differences in body weight or $P_{[\text{AVP}]}$ (Tables 1 and 2). During dehydrating exercise, body water loss ($1.5 \pm 0.2 \text{ kg}$, or 2.3% of preexercise body weight) was comparable between the follicular and midluteal phases. Similarly, despite the baseline variability, $P_{[\text{AVP}]}$ and PRA responses to exercise (i.e., change from baseline) were similar between the two phases (Table 2). However, this was not the case for $P_{[\text{ALD}]}$, in which the exercise response was greater during the midluteal phase. Linear regression analysis of the individual subjects' data during dehydration indicated significant correlations between $P_{[\text{AVP}]}$ and P_{Osm} , with *r* values ranging from 0.82 to 0.98. The abscissal intercept of the linear $P_{[\text{AVP}]}-P_{\text{Osm}}$ relationship, or "theoretical osmotic threshold" for AVP release, was lower in the midluteal phase (278 ± 1 and $279 \pm 1 \text{ mosmol/kgH}_2\text{O}$; Table 1 and Fig. 1) compared with the follicular phase (282 ± 1 and $283 \pm 1 \text{ mosmol/kgH}_2\text{O}$; $P < 0.05$). The slopes of this relationship were unaffected by menstrual phase. During rehydration, the AUCs for $P_{[\text{ALD}]}$ and PRA were significantly greater in the luteal compared with the follicular phase.

Within-Phase Measurements

Early follicular phase. Within the follicular phase, there were no significant differences among the means

Table 1. *Subject characteristics in early follicular and midluteal phases of the menstrual cycle*

Characteristics	Follicular Phase	Luteal Phase
Body weight, kg		
Trial A	61.7 ± 3.6	61.3 ± 3.5
Trial B	61.5 ± 3.9	61.6 ± 3.7
Hematocrit, %		
Trial A	36.6 ± 0.8	36.8 ± 1.0*
Trial B	36.5 ± 0.7	37.9 ± 0.9*
P _[E₂] , pg/ml		
Trial A	26.9 ± 4.6	98.9 ± 16.6*
Trial B	20.7 ± 4.1	128.1 ± 20*
P _[P₄] , ng/ml		
Trial A	1.3 ± 0.4	8.7 ± 2.0*
Trial B	0.9 ± 0.4	9.8 ± 2.3*
P _{Osm} -P _[AVP] slope, pg·ml ⁻¹ ·mosmol ⁻¹		
Trial A	0.47 ± 0.11	0.51 ± 0.18
Trial B	0.49 ± 0.14	0.56 ± 0.17
P _{Osm} -P _[AVP] x-intercept, mosmol/kgH ₂ O		
Trial A	283 ± 2	279 ± 1*
Trial B	283 ± 1	279 ± 1*

Values are means ± SE; Trial A and Trial B are the first and second trials, respectively, within the specified menstrual phase. Preexercise body weight, hematocrit, and plasma concentrations of 17β-estradiol (P_[E₂]) and progesterone (P_[P₄]) in the early follicular and midluteal phases of the menstrual cycle. Slopes and abscissal intercepts are based on individual subjects' plasma arginine vasopressin concentration (P_[AVP])-plasma osmolality (P_{Osm}) relationship during dehydration in the early follicular and midluteal phases of the menstrual cycle. *Significant difference between follicular and luteal phases, $P < 0.05$.

of any of the variables during rest, dehydration, and rehydration. However, with the exception of P_[ANP], none of the resting values of the fluid-regulating hormones attained sufficiently high Cronbach's α to be considered reliable (Table 3). Reliability for P_[AVP] and PRA was better after dehydrating exercise, although reliability remained low for P_[ALD] ($\alpha = 0.66$) and remained high for P_[ANP] ($\alpha = 0.90$). During dehydration, both the slope and abscissal intercept of the P_{Osm}-P_[AVP] relationship were highly reliable within the follicular phase, attaining Cronbach's α of 0.96 and 0.90, respectively. Again, P_[AVP], P_[ALD], and PRA were not reliably reproduced during rehydration, whereas Cronbach's α for P_[ANP] was 0.93. P_[E₂] was highly reproducible within the follicular-phase tests, attaining Cronbach's α of 0.85, but P_[P₄] attained a Cronbach's α value of only 0.62 between tests in the follicular phase.

Midluteal phase. As in the follicular phase, there were no differences in mean hormonal concentrations at rest, after dehydration, or during rehydration within the midluteal phase. Again, resting values for P_[AVP], P_[ALD], and PRA were not highly reproducible between the two midluteal phase tests (Table 3). Reliability for P_[ANP] was greater, compared with the other fluid-regulating hormones, at rest and during exercise and rehydration. Despite high levels of reliability for osmotic regulation of AVP (Table 3), resting and rehydration levels of P_[AVP] were not consistently correlated within the luteal-phase tests. In contrast to the follicular phase, however, both P_[E₂] and P_[P₄] were highly

consistent between the two luteal-phase tests, yielding Cronbach's α values of 0.93 and 0.93, respectively.

DISCUSSION

We examined the within-phase physiological reliability of the fluid- and sodium-regulating hormone concentrations in the plasma over two nonconsecutive menstrual cycles (12–16 wk apart) during the early follicular and midluteal phases. P_[AVP], P_[ALD], and PRA varied within each of the different menstrual phases; however, there were no statistical differences among the means of any of these hormone concentrations. This indicates that the within-subject variability remains undetected when only the means are tested or reported. Nonetheless, our data indicate that between-phase differences in the hormone concentrations far exceed the variability within the phases, and, therefore, the low within-phase reliability does not prevent the detection of menstrual-phase-related changes in these variables. In contrast, P_[AVP], PRA, and P_[ANP] responses to dehydration were highly reliable within each menstrual phase; this indicates that hormonal responses to stress are

Table 2. *Fluid-regulation hormone concentrations at rest and during exercise and rehydration in early follicular and midluteal phases of menstrual cycle*

	Preexercise, 0 min	Exercise, 150 min	Rehydration, AUC
<i>Follicular phase</i>			
P _[ALD] , pg/ml			
Trial A	79 ± 12	275 ± 65	228 × 10 ² ± 37 × 10 ²
Trial B	96 ± 19	198 ± 47	166 × 10 ² ± 30 × 10 ²
PRA, ng·ml ANG ⁻¹ ·h ⁻¹			
Trial A	0.8 ± 0.2	3.9 ± 1.0	287 ± 60
Trial B	0.9 ± 0.2	3.4 ± 1.1	267 ± 62
P _[AVP] , pg/ml			
Trial A	1.3 ± 0.2	3.7 ± 0.8	399 ± 72
Trial B	1.2 ± 0.4	3.5 ± 0.8	374 ± 106
P _[ANP] , pg/ml			
Trial A	33.0 ± 3.9	88.1 ± 11.7	78 × 10 ² ± 8 × 10 ²
Trial B	38.0 ± 5.3	87.9 ± 12.1	76 × 10 ² ± 8 × 10 ²
<i>Luteal phase</i>			
P _[ALD] , pg/ml			
Trial A	157 ± 22*	388 ± 43*	330 × 10 ² ± 47 × 10 ² *
Trial B	155 ± 21*	500 ± 51*	460 × 10 ² ± 52 × 10 ² *
PRA, ng·ml ANG ⁻¹ ·h ⁻¹			
Trial A	1.8 ± 0.4*	6.1 ± 1.7*	471 ± 113*
Trial B	1.7 ± 0.2*	4.2 ± 0.9*	653 ± 121*
P _[AVP] , pg/ml			
Trial A	1.2 ± 0.2	3.2 ± 0.6	347 ± 79
Trial B	1.1 ± 0.3	3.7 ± 1.1	496 ± 125
P _[ANP] , pg/ml			
Trial A	49.6 ± 5.6	109.2 ± 14.5	94 × 10 ² ± 9 × 10 ²
Trial B	54.6 ± 9.2	114.8 ± 22.2	101 × 10 ² ± 14 × 10 ²

Values are means ± SE. Trials A and B are first and second trials, respectively, within specified menstrual phase. AUC, area under the curve (trapezoid). Plasma renin activity (PRA), P_[AVP], and plasma concentrations of aldosterone (P_[ALD]) and atrial natriuretic peptide (P_[ANP]) at rest, and in response to dehydrating exercise and 180 min of ad libitum rehydration in early follicular and midluteal phases of menstrual cycle. *Significant difference between follicular and luteal phases, $P < 0.05$.




Fig. 1. Mean plasma arginine vasopressin concentration ($P_{[AVP]}$) responses to increases in plasma osmolality (P_{Osm}) during dehydration in follicular and luteal phase tests. Trials A and B are the first and second trials, respectively, within the specified menstrual phases. Data are means \pm SE.

more consistent, despite the variability in baseline values.

Although there were no significant within-phase differences between the means of the sodium-regulating hormones, only $P_{[ANP]}$ values were consistently reliable during rest, exercise, and rehydration within either of the two phases. Resting $P_{[AVP]}$, $P_{[ALD]}$, and PRA were quite variable across the two trials within both the follicular and luteal menstrual phases. Indeed, this baseline variability exists even with careful control of predehydration water and sodium intake, posture, and timing of the experiments to coincide with specific events during the menstrual cycle (such as ovulation and menses). Resting or basal variations in $P_{[AVP]}$ may be exaggerated further by the fact that values were close to the lowest level of sensitivity of our assay technique (i.e., 0.8 pg/ml). Also, because the rehydration was ad libitum, hydration-recovery rates may have been different among the test days. Therefore, although

Table 3. Cronbach's α for reliability within 2 follicular and 2 luteal phase tests

	Cronbach's α	
	Follicular phase	Luteal phase
Resting $P_{[AVP]}$	0.49	0.25
Exercise $P_{[AVP]}$	0.81*	0.98*
Rehydration $P_{[AVP]}$	0.58	0.96*
$P_{[AVP]}-P_{Osm}$ slope	0.96*	0.81*
$P_{[AVP]}-P_{Osm}$ intercept	0.90*	0.86*
Resting $P_{[ANP]}$	0.80*	0.80*
Exercise $P_{[ANP]}$	0.90*	0.87*
Rehydration $P_{[ANP]}$	0.93*	0.80*
Resting PRA	0.49	0.51
Exercise PRA	0.72	0.89*
Rehydration PRA	0.67	0.95*
Resting $P_{[ALD]}$	0.55	0.66
Exercise $P_{[ALD]}$	0.66	0.82*
Rehydration $P_{[ALD]}$	0.64	0.76
Resting $P_{[E_2]}$	0.85*	0.93*
Resting $P_{[P_4]}$	0.62	0.92*

* Cronbach's $\alpha \geq 0.80$ was considered reliable.

total fluid intake was similar over the four tests, changes in drinking patterns or drinking rates may substantially affect AVP release at a given blood sampling point (17) and, consequently, affect our ability to observe repeatable $P_{[AVP]}$.

In any case, despite the low within-phase reliability of $P_{[AVP]}$ at rest and during rehydration, osmotic regulation of $P_{[AVP]}$ (i.e., slopes and intercepts) during dehydration was highly reproducible. This indicates that, although individual values may vary, the regulation of this hormone in response to environmental stress (e.g., exercise) remains constant. This is an important finding, because small shifts in the regulation of AVP lead to large changes in renal water retention (13). Moreover, although a number of studies have demonstrated changes in osmotic regulation of $P_{[AVP]}$ over the course of a single menstrual cycle (18, 19), the menstrual-phase effects on the P_{Osm} threshold for AVP release are only $\sim 5-6$ mosmol/kgH₂O, making essential a precise and consistent measurement of the P_{Osm} intercept within a given menstrual phase.

Interestingly, the shifts in osmotic regulation of AVP and the fluid regulation hormones over the course of the menstrual cycle do not seem to impact overall body fluid and sodium retention. Despite the shift in osmotic AVP regulation, fluid loss during exercise was similar in both menstrual phases. In the luteal phase, a progesterone-induced inhibition of aldosterone-dependent sodium reabsorption at distal sites in the nephron causes transient natriuresis (12). This natriuresis is followed by a compensatory stimulation of the renin-aldosterone system (9, 16, 20), resulting in a slight attenuation of sodium excretion during the luteal phase (7.2 ± 1.4 vs. 11.5 ± 2.0 meq). Nonetheless, overall water and sodium balance appear unaffected by the shifts in either progesterone or the sodium regulation hormones (9). This leads us to speculate that estrogen and progesterone have their primary impact on body water regulation through changes in body water and sodium distribution rather than through retention.

We also tested the reliability of the female sex hormones 17 β -estradiol and progesterone. $P_{[E_2]}$ was highly reproducible between the two trials in both the follicular and midluteal phases. $P_{[P_4]}$, although reproducible during the luteal phase, was somewhat variable between the two trials in the follicular phase. $P_{[P_4]}$ is normally low during the follicular phase of the menstrual cycle, so even small variations lead to large error values and may thus exaggerate the variability of $P_{[P_4]}$ during the follicular phase. Nonetheless, despite the low reliability, $P_{[P_4]}$ values were consistent and low enough to indicate the subjects were in the follicular phase of the menstrual cycle.

The variability in the fluid-regulating hormones was not substantial enough either to create significant statistical differences in means between trials within the same menstrual phase or to obscure the large differences in these hormone concentrations between menstrual phases. Nonetheless, these findings suggest that there is a natural variability in these hormone

responses, which may be undetected when only grouped mean values are presented.

We gratefully acknowledge the technical support of Tamara S. Morocco, John R. Stofan, and Richard Wemple, and the cooperation of the volunteer subjects. We also thank Lou A. Stephenson for contributions to the research design.

This work is supported by the US Army Medical Research and Materiel Command under contract No. DAMD17-96-C-6093. The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy, or decision unless so designated by other documentation.

In conduct of research where humans are the subjects, the investigators adhered to the policies regarding the protection of human subjects as prescribed by 45 CFR 46 and 32 CFR 219 (Protection of Human Subjects).

Address for reprint requests and other correspondence: N. S. Stachenfeld, The John B. Pierce Laboratory, 290 Congress Ave., New Haven, CT 06519 (E-mail: nstach@jbpiere.org).

Received 18 September 1998; accepted in final form 23 November 1998.

REFERENCES

- Barron, W. M., J. Schreiber, and M. D. Lindheimer. Effect of ovarian sex steroids on osmoregulation and vasopressin secretion in the rat. *Am. J. Physiol.* 250 (*Endocrinol. Metab.* 13): E352-E361, 1986.
- BMDP. *BMDP Statistical Software Manual* (7th ed.). Los Angeles, CA: BMDP Statistical Software, Inc., 1992.
- Carlberg, K. A., M. J. Fregley, and M. Fahey. Effects of chronic estrogen treatment on water exchange in rats. *Am. J. Physiol.* 247 (*Endocrinol. Metab.* 10): E101-E110, 1984.
- Crofton, J. T., P. G. Baer, L. Share, and D. P. Brooks. Vasopressin release in male and female rats: effects of gonadectomy and treatment with gonadal steroid hormones. *Endocrinology* 117: 1195-1200, 1985.
- Crowley, R. S., and J. A. Amico. Gonadal steroid modulation of oxytocin and vasopressin gene expression in the hypothalamus of the osmotically stimulated rat. *Endocrinology* 133: 2711-2718, 1993.
- Davison, J. M., E. A. Gilmore, J. Durr, G. L. Robertson, and M. D. Lindheimer. Altered osmotic thresholds for vasopressin secretion and thirst in human pregnancy. *Am. J. Physiol.* 246 (*Renal Fluid Electrolyte Physiol.* 15): F105-F109, 1984.
- De Souza, M., C. Maresch, M. Maguire, and W. Kraemer. Menstrual cycle status and plasma vasopressin, renin activity, and aldosterone exercise responses. *J. Appl. Physiol.* 67: 736-743, 1989.
- Forsling, M. L., M. Akerlund, and P. Stromberg. Variations in plasma concentrations of vasopressin during the menstrual cycle. *J. Endocrinol.* 89: 263-266, 1981.
- Michelakis, A. M., H. Yoshida, and J. C. Dormois. Plasma renin activity and plasma aldosterone during the normal menstrual cycle. *Am. J. Obstet. Gynecol.* 123: 724-726, 1975.
- Mulay, S., S. D'Sylva, and D. R. Varma. Inhibition of the aldosterone-suppressant activity of atrial natriuretic factor by progesterone and pregnancy in rats. *Life Sci.* 52: 1121-1128, 1993.
- Mulay, S., S. Omer, P. Vaillancourt, S. D'Sylva, A. Singh, and D. R. Varma. Hormonal modulation of atrial natriuretic factor receptors and effects on adrenal glomerulosa cells of female rats. *Life Sci.* 55: 169-176, 1994.
- Myles, K., and J. W. Funder. Progesterone binding to mineralocorticoid receptors: in vitro and vivo studies. *Am. J. Physiol.* 270 (*Endocrinol. Metab.* 33): E601-E607, 1996.
- Schrier, R. W., and T. Berl. Nonosmolar factors affecting renal water excretion. *N. Engl. J. Med.* 292: 141-145, 1975.
- Stephenson, L. A., and M. A. Kolka. Menstrual cycle phase and time of day alter reference signal controlling arm blood flow and sweating. *Am. J. Physiol.* 249 (*Regulatory Integrative Comp. Physiol.* 18): R186-R191, 1985.
- Stephenson, L. A., M. A. Kolka, R. Francesconi, and R. R. Gonzalez. Circadian variations in plasma renin activity, catecholamines and aldosterone during exercise in women. *Eur. J. Appl. Physiol.* 58: 756-764, 1989.
- Sundsfjord, J. A. Plasma renin activity and aldosterone excretion during prolonged progesterone administration. *Acta Endocrinol.* 67: 486-490, 1971.
- Takamata, A., G. W. Mack, C. M. Gillen, A. C. Jozsi, and E. R. Nadel. Osmoregulatory modulation of thermal sweating in humans: reflex effects of drinking. *Am. J. Physiol.* 268 (*Regulatory Integrative Comp. Physiol.* 37): R414-R422, 1995.
- Trigoso, W. F., J. M. Wesly, D. L. Meranda, and Y. Shenker. Vasopressin and atrial natriuretic peptide hormone responses to hypertonic saline infusion during the follicular and luteal phases of the menstrual cycle. *Hum. Reprod.* 11: 2392-2395, 1996.
- Vokes, T. J., N. M. Weiss, J. Schreiber, M. B. Gaskill, and G. L. Robertson. Osmoregulation of thirst and vasopressin during normal menstrual cycle. *Am. J. Physiol.* 254 (*Regulatory Integrative Comp. Physiol.* 23): R641-R647, 1988.
- Weinberger, M. H., N. J. Kramer, C. E. Grim, and L. P. Petersen. The effect of posture and saline loading on plasma renin activity and aldosterone concentration in pregnant, non-pregnant and estrogen-treated women. *J. Clin. Endocrinol. Metab.* 44: 69-77, 1977.
- Zhang, Y., K. Novak, and S. Kaufman. Atrial natriuretic factor release during pregnancy in rats. *J. Physiol. (Lond.)* 488: 509-514, 1995.

Estrogen modifies the temperature effects of progesterone

NINA S. STACHENFELD,¹ CELSO SILVA,² AND DAVID L. KEEFE²

¹The John B. Pierce Laboratory and Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06519; and ²Women and Infants Hospital, Brown University School of Medicine, Providence, Rhode Island 02905

Stachenfeld, Nina S., Celso Silva, and David L. Keefe. Estrogen modifies the temperature effects of progesterone. *J Appl Physiol* 88: 1643–1649, 2000.—To test the hypothesis that progestin-mediated increases in resting core temperature and the core temperature threshold for sweating onset are counteracted by estrogen, we studied eight women (24 ± 2 yr) at 27°C rest, during 20 min of passive heating (35°C), and during 40 min of exercise at 35°C. Subjects were tested four times, during the early follicular and midluteal menstrual phases, after 4 wk of combined estradiol-norethindrone (progestin) oral contraceptive administration (OC E+P), and after 4 wk of progestin-only oral contraceptive administration (OC P). The order of the OC P and OC E+P were randomized. Baseline esophageal temperature (T_{es}) at 27°C was higher ($P < 0.05$) in the luteal phase ($37.08 \pm 0.21^\circ\text{C}$) and in OC P ($37.60 \pm 0.31^\circ\text{C}$) but not during OC E+P ($37.04 \pm 0.23^\circ\text{C}$) compared with the follicular phase ($36.66 \pm 0.21^\circ\text{C}$). T_{es} remained above follicular phase levels throughout passive heating and exercise during OC P, whereas T_{es} in the luteal phase was greater than in the follicular phase throughout exercise ($P < 0.05$). The T_{es} threshold for sweating was also greater in the luteal phase ($38.02 \pm 0.28^\circ\text{C}$) and OC P ($38.07 \pm 0.17^\circ\text{C}$) compared with the follicular phase ($37.32 \pm 0.11^\circ\text{C}$) and OC E+P ($37.46 \pm 0.18^\circ\text{C}$). Progestin administration raised the T_{es} threshold for sweating during OC P, but this effect was not present when estrogen was administered with progestin, suggesting that estrogen modifies progestin-related changes in temperature regulation. These data are also consistent with previous findings that estrogen lowers the thermoregulatory operating point.

progestin; thermoregulation; menstrual cycle; exercise

RESTING CORE BODY TEMPERATURE (18, 31) and the temperature thresholds for sweating (31) and vasodilation (17, 31) during exercise are greater during the midluteal phase and in women taking oral contraceptives (OC) (7) compared with the follicular phase of the menstrual cycle. The core temperature increases are concomitant with the progesterone peak in the midluteal phase (18), do not occur in anovulatory cycles (26), and consistently occur with progesterone administration in animals (24). In contrast, the regulated body temperature in women is at its lowest during the late

follicular phase coincident with the cyclic estrogen surge (33), and estrogen treatment in postmenopausal women reduces resting body temperature and core temperature thresholds for sweating and vasodilation during exercise (34). Taken together, the available evidence suggests that high blood progesterone levels are responsible for a greater core temperature and that estrogen alone reduces regulated body temperature in women.

The mechanism by which estrogen and progesterone affect the regulated body temperature has not been established in humans. Sex steroids most likely impact thermoregulation through action in the brain to change the regulated hypothalamic temperature. Studies in animals have shown that estrogen and progesterone can act directly on specific sex steroid-binding neurons in the preoptic/anterior hypothalamus (21, 27). Conversely, estrogen and progesterone may also act on the thermoregulatory system indirectly through cytokines (4) or regulators that regulate fluid balance (30). Finally, estrogen could exert its effect on temperature regulation through locally mediated peripheral effects, such as on blood vessels to relax the vascular smooth muscle and to inhibit vasoconstrictor tone (16, 20), although chronic estrogen administration, with and without progesterone, does not alter resting or maximal skin blood flow in postmenopausal women (3).

The synthetic progestins and estrogens in oral contraceptives could potentially impact the thermoregulatory system in the same manner as the endogenous hormones. Based on thermoregulatory changes in the midfollicular and midluteal phases of the menstrual cycle, we would predict that the progestin component of the pill would override the estrogen component to increase the hypothalamic set-point temperature and, consequently, the regulated body temperature. In support of this hypothesis, chronic combined (estrogen + progesterone) OC administration induced an upward shift in regulated body temperature during rest (22°C) (25), passive heating (6, 8), and exercise (14, 25), and the progestin treatment eliminated the temperature-lowering effect of estrogen during combined hormone therapy in postmenopausal women (2).

Despite the progress in characterizing the effects of estrogen and progesterone on temperature regulation, much remains to be elucidated. For example, the effects of progesterone administration alone on resting and

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

exercise core temperatures in young women have not been determined nor has it been established to what extent estrogen modifies the progesterone effects. Estrogen can act on progesterone receptors in the reproductive system (28), so it may have similar effects on the preoptic area and anterior hypothalamus to affect temperature regulation. Most previous investigators studying oral contraceptive effects on the regulated body temperature in young women report chronic effects of therapy in a cross-sectional design (25) or in a within-subject design that uses the subjects' week off from the pill as a control (6–8). These comparisons are limited because they do not allow for within-subject analysis in the first instance and do not account for the variable tissue washout rates of synthetic progestins and estrogens in oral contraceptives in the second instance.

To determine progesterone effects on the body temperature regulation system, and the potential modifying influence of estrogen on those effects, we administered progestin (norethindrone)-only (OC P) and combined (ethinyl estradiol and norethindrone; OC E+P) oral contraceptives to young women in a randomized, crossover design. We then evaluated how each treatment affected the regulated body temperature by assessing resting core temperature and thermal responses to passive heating (35°C) and exercise in the heat (35°C). We hypothesized that progestin administration would increase resting core temperature and increase the core temperature threshold for onset of sweating, and these responses would be counteracted by estrogen administration with progesterone during combined oral contraceptive administration. Plasma volume adjustments to both OC treatments were also determined to assess the contribution of changes in blood volume to changes in temperature.

METHODS

Study Design

Subjects were nine healthy, nonsmoking women (age 24 ± 2 yr, range 19–28 yr) with no contraindications to oral contraceptive use. All subjects were interviewed about their medical history, underwent medical and gynecological examinations, and provided written confirmation of a negative Papanicolaou smear within 1 yr of being admitted to the study. During the month (early follicular phase) preceding the first heat stress experiment, resting plasma volume was determined with Evans blue dye dilution (see *Blood Volume*, below), and peak oxygen consumption ($\dot{V}O_{2\text{peak}}$) was determined from an incremental recumbent cycle ergometer test with the use of an automated metabolic cart (Sensor Medics, Yorba Linda, CA).

Each woman participated in four experiments: two baseline heat stress tests and one heat stress test while taking each type of oral contraceptive (two total). Estrogen and progesterone vary across the menstrual cycle, so the study design employed a heat stress test conducted in the early follicular phase, 2–4 days after the beginning of menstrual bleeding (low estrogen and progesterone), and one conducted in the midluteal phase, 7–9 days after the luteinizing hormone peak (high estrogen and progesterone), determined

individually by the use of ovulation prediction kits (Ovu-Quick, Quidel, San Diego, CA). After completing the baseline heat stress tests, the subjects again performed heat stress protocols after 4 wk of either continuous combined (estrogen-progestin, OC E+P) or progestin-only (OC P) oral contraceptive treatment (random assignment). After a 4-wk washout period, the subjects crossed over to the other pill treatment.

During OC E+P, subjects received 0.035 mg of ethinyl estradiol and 1 mg of norethindrone daily. During OC P treatment, subjects received 1 mg/day of norethindrone. To verify phase of the menstrual cycle, plasma levels of estrogen and progesterone were assessed from the preexercise blood sample before the temperature regulation protocol was undertaken.

Heat Stress Tests

Volunteers arrived at the laboratory between 7:00 and 8:00 AM after having eaten only a prescribed low-fat breakfast (~300 kcal). The subjects refrained from alcohol and caffeine for 12 h before the experiment. Blood volumes were not manipulated before any of the experiments, although subjects prehydrated by drinking 7 ml/kg body wt of tap water at home before arrival at the laboratory. On arriving at the laboratory, each subject gave a baseline urine sample, was weighed to the nearest 10 g on a beam balance, and was instrumented for the measurement of cardiac output (see following paragraphs). The subject then sat on the contour chair of a semirecumbent cycle ergometer in the test chamber (27°C, 30% relative humidity). During the control period, the subject was instrumented for the measurement of esophageal (T_{es}) and skin (T_{sk}) temperatures, sweat rate, and blood pressure. An indwelling catheter (21-gauge) was inserted into an arm vein for blood sampling, and a heparin block (20 U/ml) maintained catheter patency. Subjects were semirecumbent during placement of the catheter and were seated for 45 min before sampling to ensure a steady state in plasma volume and constituents. Resting blood pressure (Colin Medical Instruments, Komaki, Japan), heart rate, and cardiac stroke volume (see *Measurements*) were recorded at the end of the 45-min control period. At the end of the control period, a blood sample (12 ml) was drawn. Hydration state was assessed from the specific gravity of the baseline urine sample (mean = 1.002 ± 0.001).

After the control measurements, the chamber temperature was increased to 35°C and the subject sat quietly for 20 min of passive heating. Measurements were made of arterial blood pressure every 10 min, of cardiac output at 15 min, and of T_{es} and mean T_{sk} continuously. At the end of the passive heating, another blood sample (12 ml) was drawn.

Immediately after passive heating, the subjects exercised on a recumbent bicycle at 60% of their individual $\dot{V}O_{2\text{peak}}$ for 40 min. The subjects exercised with a fan positioned directly in front of the bike, with a fan speed of 1.6 m/s to promote continuous evaporative sweating (1). Blood pressure was measured every 10 min, T_{es} and mean T_{sk} were monitored continuously, and cardiac output estimates were obtained at 15 and 35 min during exercise. Sweating rate was also determined continuously throughout exercise. Blood samples were drawn at 10, 20, and 40 min of exercise.

Measurements

Body core temperature (T_{es}) was measured continuously from an esophageal thermocouple at the level of the left atrium. T_{sk} was measured on the forehead, chest, upper arm, lateral flank, thigh, and calf. T_{es} and T_{sk} were collected at a rate of 5 data points per second. Data were stored in a

computer through an analog-to-digital converter system (ACRO 931, Daisylab, National Instruments, Austin, TX) as a mean value of every 30 s. Mean T_{sk} was calculated from the following equation, which takes into consideration surface area (15) and the thermosensitivity of each skin area (23)

$$T_{sk} = 0.10 T_{ch} + 0.21 T_{fh} + 0.28 T_{ab} + 0.18 T_{ua} + 0.15 T_{th} + 0.18 T_{ca}$$

where subscripts refer to mean skin (sk), chest (ch), forehead (fh), abdomen (ab), upper arm (ua), thigh (th), and calf (ca) values. An automatic dew-point sensor enclosed in a ventilated Plexiglas capsule was placed on the forearm and secured with surgical glue to determine sweating rate (12). Cardiac stroke volume was measured noninvasively by impedance cardiography (Minnesota Impedance Cardiograph, Model 304B), with two silver tape electrodes placed around the neck and two around the torso. The distance between the inner tapes was measured and made identical for all four experiments. Cardiac stroke volume was calculated by using the equation of Kubicek et al. (19) and was averaged (ensemble averaging) over 25 s.

All blood samples were analyzed for hematocrit (Hct), the concentrations of Hb ([Hb]) and total protein ([TP]), plasma osmolality (Posm), and serum concentrations of sodium and potassium. The control blood samples were also analyzed for 17β -estradiol ($P_{[E2]}$) and progesterone ($P_{[P4]}$) concentrations.

Blood and Urine Analysis

From each blood sample, an aliquot (1 ml) was removed for immediate assessment of Hct, [Hb], and [TP] in triplicate by microhematocrit, cyanomethemoglobin, and refractometry respectively. A second aliquot was transferred to a heparinized tube, and a third aliquot was placed into a tube without anticoagulant for the determination of serum concentrations of sodium and potassium. All other aliquots were placed in chilled tubes containing EDTA. The samples containing EDTA were analyzed for $P_{[E2]}$ and $P_{[P4]}$ and were centrifuged, frozen immediately, and stored at -80°C until analysis. All urine samples were analyzed for volume, osmolality, and sodium and potassium.

Serum and urine sodium and potassium were measured by flame photometry (Instrumentation Laboratory, Model 943). Posm and urine osmolality were assessed by freezing point depression (Advanced Instruments 3DII). Plasma concentrations of $P_{[E2]}$ and $P_{[P4]}$ were measured by RIA. Intra- and inter-assay coefficients of variation for the midrange standard for $P_{[E2]}$ (58 ± 4 pg/ml) were 15% and 4% (Diagnostic Products, Los Angeles, CA) and for $P_{[P4]}$ (1.7 pg/ml) were 14% and 6% (Diagnostic Products).

Blood Volume

Absolute blood volume was measured by dilution of a known amount of Evans blue dye dilution. This technique involves injection of an accurately determined volume of dye (by weight, because the specific density is 1.0) into an arm vein and taking blood samples for determination of dilution after complete mixing (10, 20, and 30 min). Plasma volume was determined from the product of the concentration and volume of dye injected divided by the concentration in plasma after mixing, taking into account 1.5% lost from the circulation within the first 10 min. Blood volume was calculated from plasma volume and Hct corrected for peripheral sampling (13).

Changes in plasma volume (PV) were estimated from changes in Hct and [Hb] from the control (preexercise) sample according to the equation

% Δ PV

$$= 100[(\text{Hb}_b)/(\text{Hb}_a)][(1 - \text{Hct}_a \cdot 10^{-2})]/[(1 - \text{Hct}_b \cdot 10^{-2})] - 100$$

in which subscripts a and b denote measurements at time a and control, respectively. We used this equation to calculate both changes from baseline during exercise within a given experimental day as well as changes between each experimental day vs. the follicular phase. This equation has been demonstrated to be reliable and valid under stressful conditions (13), and red cell mass does not change over the menstrual cycle (10).

Electrolyte losses in urine were calculated by multiplying the volume of water loss in each fluid by the concentration of the electrolyte within the fluid. Total body sweat loss was calculated from the change in body weight during exercise.

Statistics

We used the 30-s averages to determine individual T_{es} thresholds for the onset of sweating. Each subject's sweating rate was plotted as a function of T_{es} during exercise, and the T_{es} threshold for sweating (i.e., the T_{es} above which the effector response is greater than that of baseline) was determined by two independent investigators. The average estimate was used for analysis, and the estimates had an interrater reliability of 0.95. For other analyses, before statistical treatment, the independent variable (time) was partitioned into 5-min bins. Within each subject, the dependent variables were averaged for every other bin, so that each averaged time period was separated by a 5-min partition. We used repeated-measures ANOVA models, followed by Bonferroni's *t*-test, to test differences in T_{es} , sweating rate, and the T_{es} sweating threshold and slopes due to menstrual phase or oral contraceptive treatment (9). On the basis of an alpha level of 0.05 and a sample size of 8, our beta level (power) was >0.80 for detecting effect sizes of 0.28°C . Data were analyzed with BMDP statistical software (BMDP Statistical Software, Los Angeles, CA) and expressed as means \pm SE.

RESULTS

Subject Characteristics

One subject did not have a large luteal phase progesterone peak, so her data were excluded from further analysis. Therefore, all statistical analyses were performed on the remaining eight subjects and only their data are presented. On the pretesting orientation day, the subjects weighed 53.0 ± 3.1 kg, were 162 ± 3 cm tall, their plasma and blood volumes were 2642 ± 258 ml and 74.3 ± 6.6 ml/kg, respectively, and their $\dot{V}O_{2\text{peak}}$ was 34.8 ± 2.1 ml/kg on the recumbent bicycle ergometer. Plasma levels of 17β -estradiol and progesterone were consistent with expected values during the early follicular and midluteal phases of the menstrual cycle and were suppressed during oral contraceptive treatment (Table 1).

Preexercise. During thermoneutral rest, T_{es} was greater during OC P compared with the follicular phase and OC E+P and was also greater during the luteal compared with the follicular phase (Table 1, $P < 0.05$). Mean T_{sk} was not affected by menstrual phase or oral

Table 1. Baseline subject characteristics and responses to passive heating and 40 min of exercise in the heat

	Follicular	Luteal	OC P	OC E + P
BW, kg	53.8 ± 3.3	53.2 ± 3.0	53.3 ± 2.9	52.1 ± 3.1
P _[E2] , pg/ml	23.5 ± 4.6	85.4 ± 21.9	31.3 ± 10.0	10.0 ± 2.9
P _[P4] , ng/ml	0.7 ± 0.1	12.0 ± 1.8	0.6 ± 0.1	0.7 ± 0.1
Hct, %	38.3 ± 0.7	39.3 ± 0.5*	38.9 ± 0.5	37.8 ± 0.7
[Hb], g/dl	13.1 ± 0.3†	13.4 ± 0.2†	13.1 ± 0.2†	12.3 ± 0.3
Posm, mosmol/kg	284 ± 1	283 ± 1	285 ± 1	282 ± 1*
S _[Na+] , meq/l	137.8 ± 0.8	137.4 ± 0.5	138.0 ± 0.7	136.8 ± 0.9
P _{[P4]/P_[E2]}	30.1 ± 3.8	166.0 ± 56.1		
T _{es} , °C at 27°C	36.68 ± 0.21	37.08 ± 0.21*	37.60 ± 0.31*	37.04 ± 0.23
T _{sk} , °C at 27°C	31.27 ± 0.38	31.68 ± 0.16	31.76 ± 0.19	31.82 ± 0.27
T _{es} , °C at 35°C preexercise	36.71 ± 0.17	37.20 ± 0.24*	37.65 ± 0.24*†	36.74 ± 0.14
T _{sk} , °C at 35°C preexercise	35.08 ± 0.29	35.04 ± 0.14	35.21 ± 0.15	35.45 ± 0.20
T _{es} , °C at 35°C 40 min of exercise	37.88 ± 0.17	38.32 ± 0.27*†	38.73 ± 0.34*†	37.75 ± 0.21
T _{sk} , °C at 35°C 40 min of exercise	34.82 ± 0.26	34.99 ± 0.41	34.60 ± 0.07	35.25 ± 0.21

Values are means ± SE. Subject characteristics were measured at 27°C and after passive heating (35°C) and exercise in the heat (35°C). Preexercise body weight (BW), plasma concentrations of endogenous 17β-estradiol (P_[E2]) and progesterone (P_[P4]), hematocrit (Hct), blood hemoglobin concentration ([Hb]), plasma osmolality (Posm), and serum sodium concentration (S_[Na+]) are shown. Esophageal (T_{es}) and skin (T_{sk}) temperatures in the early follicular and midluteal phases of the menstrual cycle and during administration of combined (estradiol + progestin, OC E + P) and (progestin only, OC P) oral contraceptive pills are also shown at rest and after 40 min of exercise at 35°C. *Difference from follicular. †Difference from OC E + P. Differences were considered statistically significant at $P < 0.05$.

contraceptive treatment. Based on Hct and [Hb] changes, combined OC treatment (OC E + P) increased plasma volume by $\sim 7.3 \pm 3.4\%$ (190 ml, $P < 0.05$) relative to the follicular phase. However, there were no differences in plasma volume in the luteal phase (approximately $-3.8 \pm 2.2\%$, -115 ml) or OC P treatment (approximately -0.7 ± 1.8 ml, -36 ml) compared with the follicular phase. Posm and serum sodium concentration were reduced before exercise during OC E + P relative to the follicular phase (Table 1, $P < 0.05$). Heart rate, stroke volume, cardiac output, and blood

pressure were unaffected by menstrual phase or oral contraceptive treatment before exercise (Table 2).

Passive heating. At the end of 20 min of passive heating, T_{es} during OC P was still greater relative to the follicular phase and OC E + P, but there were no differences between the menstrual phases (Fig. 1). Blood Hct and [Hb], Posm, and serum sodium concentration during OC E + P remained below the other trials during passive heating (data are not shown). Passive heating did not increase heart rate, cardiac output, or blood pressure under any of the four conditions (Table 2).

Exercise responses. Exercise increased T_{es} during all four trials and remained greatest during OC P (Fig. 2, $P < 0.05$). Exercise sweating rate was similar across all trials (Fig. 2), but the T_{es} threshold for sweating onset was greater during the luteal phase and OC E + P relative to the follicular phase (Table 3, $P < 0.05$). As with the other time periods, Posm and serum sodium concentration were reduced during OC E + P relative to the other trials (data not shown). Heart rate, stroke volume, cardiac output, and blood pressure increased similarly across trials during exercise (Table 2). Urine sodium losses during the rest, passive heating, and exercise periods were similar across all trials (74.9 ± 22.1 , 64.6 ± 17.4 , 107.4 ± 29.4 , and 73.2 ± 15.5 mEq for follicular and luteal phases, OC E + P and OC P, respectively).

DISCUSSION

Our major findings are that unopposed progestin administration increased the regulated body temperature as both core temperature and the core temperature threshold for sweating increased and that estrogen administered with progestin reversed these thermoregulatory changes. These effects are likely due to differences in the direct or indirect actions of oral contraceptives on the central nervous system (CNS). Our data support earlier findings that these tempera-

Table 2. Cardiovascular responses to passive heat and exercise

	Rest (27°C)	Rest (35°C)	Exercise 35°C (20 min)	Exercise 35°C (40 min)
Heart rate, bpm				
Follicular	67 ± 3	69 ± 3	132 ± 8	140 ± 8
Luteal	67 ± 3	69 ± 4	127 ± 7	137 ± 7
OC P	66 ± 3	68 ± 3	131 ± 6	141 ± 7
OC E + P	64 ± 4	67 ± 4	126 ± 10	135 ± 9
Stroke volume, ml				
Follicular	81 ± 8	80 ± 7	98 ± 10	99 ± 10
Luteal	88 ± 8	88 ± 7	111 ± 11	111 ± 10
OC P	87 ± 6	87 ± 6	113 ± 10	110 ± 11
OC E + P	99 ± 7	95 ± 8	112 ± 8	115 ± 15
Cardiac output, l/min				
Follicular	5.3 ± 0.4	5.5 ± 0.4	12.9 ± 1.1	13.6 ± 1.2
Luteal	5.8 ± 0.5	6.0 ± 0.3	13.9 ± 1.2	14.9 ± 1.4
OC P	5.8 ± 0.4	6.0 ± 0.3	14.4 ± 0.9	15.2 ± 1.4
OC E + P	6.4 ± 0.5	6.2 ± 0.5	13.6 ± 1.0	15.1 ± 1.4
Mean arterial pressure, mmHg				
Follicular	80 ± 4	81 ± 4	90 ± 4	92 ± 5
Luteal	80 ± 3	78 ± 3	92 ± 4	90 ± 5
OC P	78 ± 2	76 ± 2	88 ± 2	89 ± 2
OC E + P	77 ± 2	78 ± 2	93 ± 5	96 ± 5

Values are means ± SE. Heart rate, stroke volume, cardiac output, and mean arterial pressure values were measured at rest (27°C) and in response to 20 min of passive heating (35°C) and 40 min of exercise (35°C) in the follicular and luteal menstrual phases.




Fig. 1. Esophageal temperature (T_{es}) during 20-min rest at 27°C and during 20-min passive heating at 35°C. *Different from follicular phase. #Different from combined estrogen-progestin oral contraceptive administration (OC E+P). Differences considered significant at $P < 0.05$. OC P, progestin-only oral contraceptive administration.

ture effects are independent of peripheral influences on temperature regulation such as body fluid balance (3). This within-subject report addressed potential modulating effects of estrogen on the pronounced progesterone-related increase in regulated body temperature in humans (18, 26), and the results are consistent with previous findings that estrogen lowers the thermoregulatory operating point (33).

Charkoudian and Johnson (7) recently demonstrated that the core temperature threshold for active cutaneous vasodilation during passive heating was increased in women taking oral contraceptives containing estrogen and progestin compared with their responses after ~5 days of not taking the pill, a result consistent with earlier findings of increased core temperature threshold for initiation of cutaneous vasodilation during exercise in the luteal phase (18, 31). Postmenopausal women taking combined progestin and estrogen did not exhibit the same reduction in the T_{es} threshold for vasodilation or sweating seen in women taking only estrogen during exercise (2), suggesting that progestin reverses some of the estrogen-related thermoregulatory effects. On the other hand, Chang et al. (5) did not demonstrate a reduction in core temperature after 3 days of estrogen administration to young women in their early follicular phase, perhaps because 3 days of estrogen administration is not long enough to elicit

temperature changes or because another hormone, such as FSH, facilitates hypothalamic neuronal adaptation to estradiol. Nonetheless, these reports indicate a disparity between chronic and acute effects of exogenous estrogens and progestins on temperature regulation.

Our data support earlier findings that chronic estrogen with progestin administration does not alter the T_{es} threshold for thermoregulatory effector activation (2). However, our data conflict with other reports in which chronic administration of combined estrogen and progesterone to young women was associated with greater oral temperature responses to passive heating (6–8). The contrast in our findings may be due to the longer length of time between tests in our study (12–16 wk) compared with the earlier studies (5–7 days). In addition, these earlier studies tested women taking chronic oral contraceptives and compared them with the 5–7 days in the cycle off the pills, whereas we provided an acute treatment to women not taking birth control pills. Either one of these factors may have introduced greater variability into our data and thus type II error.

Our primary hypothesis, that estrogen reverses progestin-related increases in core temperature and thermoregulatory effector response activation, is supported by our data. Estrogen administered along with progestin reduced baseline T_{es} by 0.58°C and the exercise T_{es}




Fig. 2. T_{es} and arm sweat rate (SR) during 40 min of semirecumbent cycle exercise in the heat (35°C). *Different from follicular phase. †Different from luteal phase. #Different from OC E+P. Differences considered significant at $P < 0.05$.

Table 3. *Temperature regulatory responses during 60% VO_{2peak} exercise at 35°C*

	Follicular	Luteal	OC P	OC E + P
T_{ss} threshold, °C	37.32 ± 0.11	38.02 ± 0.28*	38.07 ± 0.17*†	37.46 ± 0.18
Slope, $\Delta SR/\Delta T_{ss}$	0.88 ± 0.28	1.08 ± 0.21	1.13 ± 0.30	0.86 ± 0.23
r^2	0.81 ± 0.05	0.90 ± 0.03	0.76 ± 0.05	0.87 ± 0.03

Values are means ± SE. Thermoregulation measured during exercise. T_{ss} for sweating was measured during 40 min of exercise (35°C) in the early follicular and midluteal phases of the menstrual cycle and during administration OC E + P and OC P. *Difference from follicular. †Difference from OC E + P. Differences were considered statistically significant at $P < 0.05$.

threshold for sweating by 0.68°C compared with progestin-only administration, indicating a profound modifying role for estrogen on the progesterone-induced core temperature increase. We suspect that the actions of these hormones occur via direct effects in the preoptic/anterior hypothalamus, the primary temperature regulation area of the brain. Both estrogen and progesterone readily cross the blood-brain barrier and may modulate thermoregulation via action in the CNS, and sex steroid receptors have important effects on thermosensitive neurons in the brains of animals (24, 27). Progesterone inhibits warm-sensitive neuron activity, thus inhibiting heat-loss mechanisms and increasing body temperature (24). Conversely, estrogen inhibits cold and stimulates warm-sensitive neurons (27), and should therefore inhibit heat-retaining mechanisms, excite heat loss mechanisms, and thus cause a decrease in the regulated body temperature. Although we did not test CNS mechanisms for the temperature effects, sex steroids are unlikely to act via a secondary mediator or pathway, such as cytokines (4) or heat shock proteins. These indirect mechanisms have been essentially ruled out as possible mediators in recent investigations in which neither interleukin-1 β nor interleukin-6 was elevated during OC E+P administration to young women (25), the temperature responses were unaffected by PG inhibition with ibuprofen (6), and heat-shock proteins were unchanged during heating in young women given estrogen (5).

Although direct actions within the CNS are the primary mechanism by which progesterone and estrogen exert their effects on the temperature regulation systems, the regulation of body temperature in humans also interacts with systems that regulate the volume and osmotic pressure of the extracellular fluid (22). Blood volume expansion improves the efficiency of cardiovascular and thermoregulatory responses during physical activity. When blood volume is expanded, cardiac stroke volume increases, resulting in elevated cardiac output and improved ability to deliver blood to muscle and skin simultaneously, where heat transfer takes place. During the menstrual cycle (32) and during short-term estrogen administration (29, 34), high estrogen levels in the blood are associated with plasma volume expansion. In this investigation, plasma volume appeared lowest during the midluteal phase of the menstrual cycle coinciding with the highest core temperature and delayed sweating onset during exercise. However, although OC E+P was associated with a large increase in plasma volume compared with the follicular phase, there were no differences in the thermo-

regulatory responses during exercise and no increase in stroke volume associated with OC E+P. Finally, although plasma volume was greater during OC E+P compared with OC P, again, stroke volume did not increase with OC E+P, suggesting that these plasma volume increases had little impact on heat loss mechanisms (11).

Finally, our findings are limited by our inability to measure exogenous progestins and their metabolites, so plasma progesterone does not reflect the true levels of progestins during oral contraceptive administration. Therefore, we recognize that comparison of the different pill preparations is tenuous because the relative potency of synthetic estrogens and progestins found in oral contraceptives on the temperature regulation system is unknown. Furthermore, synthetic estrogens and progestins are metabolized at different rates among individual women so we are limited in our ability to predict the level of these hormones actually acting on tissue simply by knowing the quantity of the hormone administered.

We found that oral contraceptive pills containing estrogen with progestin did not produce the thermoregulatory effects of oral contraceptive pills that contained only progestin. This estrogen-related reversal of the thermoregulatory actions of progestin is most likely due to specific effects on thermosensitive neurons in the CNS. These results confirm earlier findings that estrogen lowers the thermoregulatory operating point (33). Our findings differed from previous findings in young women taking chronic oral contraceptives in that we did not find that oral contraceptives containing both estrogen and progestin significantly increased core temperature at baseline or after passive heating (6–8). Finally, although estimated plasma volume was lower during administration of progestin alone compared with combined estrogen and progestin administration, exercise stroke volume was unchanged, supporting earlier findings that plasma volume change is not a major contributor to altered temperature regulation during oral contraceptive administration (2).

We gratefully acknowledge the technical support of Cheryl A. Kokoszka, Danielle Day, and Tamara S. Morocco and the cooperation of the volunteer subjects. We also thank Lou A. Stephenson for contributions to the research design and the writing of this manuscript.

This work is supported by the U.S. Army Medical Research and Materiel Command under contract DAMD17-96-C-6093. The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy, or decision unless so designated by other documentation.

In conduct of research where humans are the subjects, the investigators adhered to the policies regarding the protection of human subjects as prescribed by 45 CFR 46 and 32 CFR 219 (Protection of Human Subjects).

Address for reprint requests and other correspondence: N. S. Stachenfeld, The John B. Pierce Laboratory, 290 Congress Ave., New Haven, CT 06519 (E-mail: nstach@jbpiere.org).

Received 11 November 1999; accepted in final form 11 January 2000.

REFERENCES

- Adams WC, Mack GW, Langhans GW, and Nadel ER. Effects of varied air velocity on sweating and evaporative rates during exercise. *J Appl Physiol* 73: 2668–2674, 1992.
- Brooks EM, Morgan AL, Pierzga JM, Wladkowski SL, Gorman JT, Derr JA, and Kenney WL. Chronic hormone replacement therapy alters thermoregulatory and vasomotor function in postmenopausal women. *J Appl Physiol* 83: 477–484, 1997.
- Brooks-Asplund EM and Kenney WL. Chronic hormone replacement therapy does not alter resting or maximal skin blood flow. *J Appl Physiol* 85: 505–510, 1998.
- Cannon JG and Dinarello CA. Increased plasma interleukin-1 activity in women after ovulation. *Science* 227: 1247–1249, 1985.
- Chang RT, Lambert GP, Moseley PL, Chapler FK, and Gisolfi CV. Effect of estrogen supplementation on exercise thermoregulation on premenopausal women. *J Appl Physiol* 85: 2082–2088, 1998.
- Charkoudian N and Johnson J. Altered reflex control of cutaneous circulation by female sex steroids in independent of prostaglandins. *Am J Physiol Heart Circ Physiol* 276: H1634–H1640, 1999.
- Charkoudian N and Johnson JM. Modification of active cutaneous vasodilation by oral contraceptive hormones. *J Appl Physiol* 83: 2012–2018, 1997.
- Charkoudian N and Johnson JM. Reflex control of cutaneous vasoconstrictor system is reset by exogenous female reproductive hormones. *J Appl Physiol* 87: 381–385, 1999.
- Colton T. *Statistics in Medicine*. Boston, MA: Little, Brown, 1974.
- Fortney SM, Turner C, Steinmann L, Driscoll T, and Alfrey C. Blood volume responses of men and women to bed rest. *J Clin Pharmacol* 34: 434–9, 1994.
- Fortney SM, Wenger CB, Bove JR, and Nadel ER. Effects of plasma volume on forearm venous and cardiac stroke volumes during exercise. *J Appl Physiol* 55: 884–890, 1983.
- Graichen H, Rascati R, and Gonzalez RR. Automated dew-point temperature sensor. *J Appl Physiol* 52: 1658–1660, 1982.
- Greenleaf JE, Convertino VA, and Mangseth GR. Plasma volume during stress in man: osmolality and red cell volume. *J Appl Physiol* 47: 1031–1038, 1979.
- Gruzca R, Pekkarinen H, Titov EK, Kononoff A, and Hanninen O. Influence of the menstrual cycle and oral contraceptives on thermoregulatory responses to exercise in young women. *Eur J Appl Physiol* 67: 279–285, 1993.
- Hardy JD. Heat transfer. In: *Physiology of Heat Regulation and Science of Clothing*, edited by Newburgh LH. Philadelphia, PA: Saunders, 1949, p. 78–108.
- Hayashi T, Yamada K, Esaki T, Kuzuya M, Satake S, Ishikawa T, Hidaka H, and Iguchi A. Estrogen increases endothelial nitric oxide by a receptor-mediated system. *Biochem Biophys Res Commun* 214: 847–855, 1995.
- Hirata K, Nagasaka T, Hirashita M, Takahata T, and Nuriomura T. Effects of human menstrual cycle on thermoregulatory vasodilation during exercise. *Eur J Appl Physiol* 54: 559–565, 1986.
- Kolka M and Stephenson L. Control of sweating during the human menstrual cycle. *Eur J Appl Physiol* 58: 890–895, 1989.
- Kubicek WG, Karnegis JN, Patterson RP, Witsoe DA, and Mattson RH. Development and evaluation of an impedance cardiac output system. *Aerospace Med* 37: 1208–1212, 1966.
- Lehtovirta P. Peripheral haemodynamic effects of combined oestrogen/progestogen oral contraceptives. *J Obstet Gynecol Neonatal Nurs* 81: 526–534, 1974.
- McEwen BS. Neural gonadal steroid actions. *Science* 211: 1303–1311, 1981.
- Morimoto T. Thermoregulation and body fluids: role of blood volume and central venous pressure. *Jpn J Physiol* 40: 165–179, 1990.
- Nadel ER, Mitchell JW, and Stolwijk JAJ. Differential thermal sensitivity in the human skin. *Pflügers Arch* 340: 71–76, 1973.
- Nakayama T, Suzuki M, and Ishizuka N. Action of progesterone on thermosensitive neurons. *Nature* 258: 80, 1975.
- Rogers SM and Baker MA. Thermoregulation during exercise in women who are taking oral contraceptives. *Eur J Appl Physiol* 75: 34–38, 1997.
- Rubenstein BB. Estimation of ovarian activity by the consecutive-day study of basal body temperature and basal metabolic rate. *Endocrinology* 22: 41–44, 1938.
- Silva NL and Boulant JA. Effects of testosterone, estradiol, and temperature on neurons in preoptic tissue slices. *Am J Physiol Regulatory Integrative Comp Physiol* 250: R625–R632, 1986.
- Speroff L, Glass RH, and Kase NG. The Breast. In: *Clinical Gynecologic Endocrinology and Infertility*. Baltimore, MD: Williams & Wilkins, 1989, p. 305–305.
- Stachenfeld NS, DiPietro L, Palter SF, and Nadel ER. Estrogen influences osmotic secretion of AVP and body water balance in postmenopausal women. *Am J Physiol Regulatory Integrative Comp Physiol* 274: R187–R195, 1998.
- Stachenfeld NS, Silva CS, Keefe DL, Kokoszka CA, and Nadel ER. Effects of oral contraceptives on body fluid regulation. *J Appl Physiol* 87: 1016–1025, 1999.
- Stephenson LA and Kolka MA. Menstrual cycle phase and time of day alter reference signal controlling arm blood flow and sweating. *Am J Physiol Regulatory Integrative Comp Physiol* 249: R186–R191, 1985.
- Stephenson LA and Kolka MA. Plasma volume during heat stress and exercise in women. *Eur J Appl Physiol* 57: 373–381, 1988.
- Stephenson LA and Kolka MA. Esophageal temperature threshold for sweating decreases before ovulation in premenopausal women. *J Appl Physiol* 86: 22–28, 1999.
- Tankersley CG, Nicholas WC, Deaver DR, Mikita D, and Kenney WL. Estrogen replacement therapy in middle-aged women: thermoregulatory responses to exercise in the heat. *J Appl Physiol* 73: 1238–1245, 1992.

Effects of oral contraceptives on body fluid regulation

NINA S. STACHENFELD, CELSO SILVA, DAVID L. KEEFE,
CHERYL A. KOKOSZKA, AND ETHAN R. NADEL†

*The John B. Pierce Laboratory, Department of Epidemiology and Public Health,
and Department of Cellular and Molecular Physiology, Yale University School
of Medicine, New Haven, Connecticut 06519; and Women and Infants Hospital,
Brown University School of Medicine, Providence, Rhode Island 02905*

Stachenfeld, Nina S., Celso Silva, David L. Keefe, Cheryl A. Kokoszka, and Ethan R. Nadel. Effects of oral contraceptives on body fluid regulation. *J. Appl. Physiol.* 87(3): 1016–1025, 1999.—To test the hypothesis that estrogen reduces the operating point for osmoregulation of arginine vasopressin (AVP), thirst, and body water balance, we studied nine women (25 ± 1 yr) during 150 min of dehydrating exercise followed by 180 min of ad libitum rehydration. Subjects were tested six different times, during the early-follicular (twice) and midluteal (twice) menstrual phases and after 4 wk of combined [estradiol-norethindrone (progestin), OC E + P] and 4 wk of norethindrone (progestin only, OC P) oral contraceptive administration, in a randomized crossover design. Basal plasma osmolality (P_{osm}) was lower in the luteal phase (281 ± 1 mosmol/kgH₂O, combined means, $P < 0.05$), OC E + P (281 ± 1 mosmol/kgH₂O, $P < 0.05$), and OC P (282 ± 1 mosmol/kgH₂O, $P < 0.05$) than in the follicular phase (286 ± 1 mosmol/kgH₂O, combined means). High plasma estradiol concentration lowered the P_{osm} threshold for AVP release during the luteal phase and during OC E + P [α -intercepts, 282 ± 2 , 278 ± 2 , 276 ± 2 , and 280 ± 2 mosmol/kgH₂O, for follicular, luteal (combined means), OC E + P, and OC P, respectively; $P < 0.05$, luteal phase and OC E + P vs. follicular phase] during exercise dehydration, and 17 β -estradiol administration lowered the P_{osm} threshold for thirst stimulation [α -intercepts, 280 ± 2 , 279 ± 2 , 276 ± 2 , and 280 ± 2 mosmol/kgH₂O for follicular, luteal, OC E + P, and OC P, respectively; $P < 0.05$, OC E + P vs. follicular phase], without affecting body fluid balance. When plasma 17 β -estradiol concentration was high, P_{osm} was low throughout rest, exercise, and rehydration, but plasma arginine vasopressin concentration, thirst, and body fluid retention were unchanged, indicating a lowering of the osmotic operating point for body fluid regulation.

estrogen; progesterone; rehydration; osmolality; arginine vasopressin

ESTROGEN ADMINISTRATION can lead to significant body fluid retention (19) and, in very high doses, hypertension (14). Although the mechanism underlying the estrogen-mediated body fluid retention is unclear, a number of studies have demonstrated that the osmotic thirst and arginine vasopressin (AVP) responses to hypertonicity occur earlier with elevations in estrogen and progesterone, such as during the luteal phase of

the menstrual cycle (18, 26, 27) and during pregnancy (8). Using hypertonic saline infusion followed by water loading, Vokes et al. (27) demonstrated a downward resetting of the osmoreceptors during the luteal phase. In addition, we recently demonstrated a reduction in the osmotic threshold for AVP release during hypertonic saline infusion in postmenopausal women who were taking estrogen (19), and the greater AVP response was associated with fluid retention.

Although it seems clear that elevations in estrogen, with and without elevations in progesterone, alter osmotic regulation of AVP (18, 26, 27) and thirst sensitivity (8, 27), the specific estrogen effects on body fluid regulation after body water loss are not known. Addressing the question of estrogen effects during dehydration as opposed to hypertonic saline infusion is important, because hypertonic saline infusion increases plasma osmolality (P_{osm}) and volume (PV), whereas dehydration increases P_{osm} while it reduces total body water and PV. The AVP- P_{osm} and thirst- P_{osm} relationships are shifted with differing volume status (15), so an evaluation of the fluid regulation systems while PV is reduced and the body is actively retaining fluid is necessary to fully understand the effects of estrogen on these systems. These differences in PV status during hypertonic saline infusion and dehydration may exaggerate AVP and thirst responses to osmotic stimulation during dehydration but may also have particular relevance during subsequent rehydration, inasmuch as they could alter the compartmentalization of ingested fluid. Alterations in the compartmentalization of ingested fluid have important implications for physical performance, because changes in body water storage will influence fluid maintenance during exertion and fluid restoration during recovery from exertion in environmentally stressful conditions.

Therefore, to determine estrogen effects on the body water regulation system, we administered oral contraceptives to young women and then evaluated their responses to progressive, exercise-induced dehydration and a subsequent rehydration period. Combined oral contraceptive agents deliver pharmacological levels of estrogens that exhibit 6–10 times the estrogenic activity provided by endogenous, circulating estrogens. In contrast, progestin-only pills contain no estrogen, and the unopposed progestin tends to downregulate estrogen receptors. Thus these two oral contraceptive preparations differ significantly in their estrogenic activity, providing the appropriate conditions in which to isolate estrogen effects on body fluid regulation. We hypoth-

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

†Deceased

esized that oral contraceptive pills containing estrogen would reduce the threshold for osmotic AVP and thirst increases to progressive, exercise-induced dehydration to a greater degree than a progestin-only pill. In addition, we hypothesized that fluid intake and renal water retention would also be increased and lead to greater water retention during combined oral contraceptive treatment. Finally, consideration of the PV and arterial pressure control of Na^+ excretion is essential for a complete evaluation of body fluid regulation, so we also determined the effects of our oral contraceptive regimen on Na^+ regulation and the Na^+ -regulating hormones.

METHODS

Study design. Subjects were nine healthy, nonsmoking women (age 25 ± 1 yr, range 22–31 yr) with no contraindications to oral contraceptive use. All subjects were interviewed about their medical history, had medical and gynecological examinations, and provided written confirmation of a negative Papanicolaou smear within 1 yr of being admitted to the study. During the month (early-follicular phase) preceding the first dehydration experiment, resting PV was determined with Evans blue dye dilution (see below) and peak O_2 consumption was determined from an incremental cycle ergometer test with use of an automated metabolic cart (Sensor Medics, Yorba Linda, CA).

Each woman participated in two series of experiments (Fig. 1), each consisting of two baseline dehydration tests (4 total) and one dehydration test while taking each type of oral contraceptive (2 total). Estrogen and progesterone vary across the menstrual cycle, so the study design employed two dehydration baseline studies conducted in the early-follicular phase, 2–4 days after the beginning of menstrual bleeding (low estrogen and progesterone), one for each pill treatment, and two conducted in the midluteal phase, 7–9 days after the luteinizing hormone peak (high estrogen and progesterone), determined individually by the use of ovulation prediction kits (OvuQuick, Quidel, San Diego, CA). After completing the first baseline dehydration tests, the subjects again performed dehydration protocols after 4 wk of continuous combined (estrogen-progestin, OC E + P) or progestin-only oral contraceptive treatment (random assignment, double blind, OC P). After completing the first dehydration testing series and after a 4-wk "washout" period, the subjects crossed over to the other pill treatment.

During OC E + P treatment, subjects received 0.035 mg of ethinyl estradiol and 1 mg of the progestin norethindrone daily. During OC P treatment, subjects received 1 mg/day of the progestin norethindrone. To verify phase of the menstrual cycle and compliance to the pill regimen, plasma levels of estrogen and progesterone were assessed from the preexercise blood sample before the dehydration protocol was undertaken.

Dehydration experiments. Volunteers arrived at the laboratory between 7 and 8 AM, after having eaten only a prescribed low-fat breakfast (~300 kcal). The subjects refrained from alcohol and caffeine for 12 h before the experiment. Blood volumes were not manipulated before any of the experiments, although subjects prehydrated by drinking 7 ml/kg body wt of tap water at home before arrival at the laboratory. On arriving at the laboratory, each subject gave a baseline urine sample, was weighed to the nearest 10 g on a beam balance, and then sat on the contour chair of a semirecumbent cycle ergometer in the test chamber (27°C, 30% relative humidity) for 60 min of control rest. During the control period, an indwelling catheter (21 gauge) was inserted into an arm vein, and electrodes and a blood pressure cuff were placed. Subjects were semirecumbent during placement of the catheter and were seated for 60 min before sampling to ensure a steady state in PV and constituents. Resting blood pressure (Colin Medical Instruments, Komaki, Japan) and heart rate (electrocardiogram) were recorded at the end of the 60-min control period. At the end of the control period, a blood sample (20 ml) was drawn and urine was collected. Hydration state was assessed from the specific gravity of the preexercise urine sample (mean = 1.002 ± 0.001).

After the control period the chamber temperature was increased to 36°C and the subjects began pedaling at an intensity corresponding to 50% maximal power output. The exercise duration was 150 min, with 5-min rest periods every 25 min, during which time they received no fluids. Blood samples (10–20 ml) were drawn and body weight was measured immediately before the rest periods at 60, 120, and 150 min during exercise. On the basis of previous experience in our laboratory, we expected a weight loss of 2.0–2.5% of preexercise body weight. To accurately determine weight loss, we previously determined the saturated weight of the shorts and a jog-bra worn during exercise (0.250 kg) and subtracted this weight from the final exercise weight. Heart rate was monitored throughout exercise to ensure subject safety. A urine sample was collected at the end of exercise, and then the chamber temperature was reduced to 27°C for the 3.5-h recovery period.




Fig. 1. Time line for sex hormone administration.

For sweat collection during exercise, sealed absorbent patches (Pacific Biometrics, Seattle, WA) were placed on the thigh, forearm, chest, back, and forehead for 20- to 25-min periods. The sweat patch consisted of 4.7×3.1 -cm filter paper, sealed and affixed to the skin with Tegaderm. The skin areas used for the patch were cleaned with deionized water before placement of the patch and wiped with a clean dry towel. Local sweat rate was determined by each patch weight increase (to 0.0001 g) from the dry weight per minute on the skin. After sweat was collected and the sweat patch was weighed, the sweat-soaked patches were transferred to plastic screw-capped bottles. The fluid in the patches was collected by centrifugation with use of nylon Microfuge centrifuge filter tubes and analyzed for Na^+ and K^+ concentrations.

After dehydration, each subject rested for 30 min in a contour chair without access to fluids to allow the body fluid compartments to stabilize, then drank water ad libitum for 180 min. Blood was sampled just before drinking (time 0, 10 ml) and at 15 (10 ml), 30, 60, 120, and 180 min of rehydration (20 ml each sample). Urine samples were collected and body weight was measured every 60 min of rehydration. The total blood drawn during each experiment was ~ 180 ml, which is too small to have any independent effect on any of the measured variables.

All blood samples were analyzed for hematocrit (Hct), concentrations of Hb ([Hb]) and total protein ([TP]), P_{osm} , plasma concentrations of creatinine, glucose, urea, and AVP (P_{AVP}), and serum concentrations of Na^+ ($S_{[\text{Na}^+]}$) and K^+ ($S_{[\text{K}^+]}$). Plasma renin activity (PRA) and concentrations of aldosterone (P_{ald}) and atrial natriuretic peptide (P_{ANP}) were analyzed from the control sample, from samples taken at the end of exercise, and from samples taken at 0, 60, 120, and 180 min of rehydration. The control blood samples were also analyzed for 17β -estradiol (P_{E_2}) and progesterone (P_{P_4}).

Blood and urine analysis. An aliquot (1 ml) was removed for immediate assessment of Hct, [Hb], and [TP] in triplicate by microhematocrit, cyanomethemoglobin, and refractometry, respectively. A second aliquot was transferred to a heparinized tube, and a third aliquot was placed into a tube without anticoagulant for the determination of $S_{[\text{Na}^+]}$ and $S_{[\text{K}^+]}$. All other aliquots were placed in chilled tubes containing EDTA. The tubes were immediately centrifuged at 4°C , and the plasma taken off the heparinized sample was analyzed for creatinine and aldosterone. The samples containing EDTA were analyzed for P_{AVP} , P_{ANP} , and PRA. These centrifuged samples were frozen immediately and stored at -80°C until analysis. All urine samples were analyzed for volume, osmolality, and creatinine concentration.

Plasma, sweat, and urine Na^+ and K^+ were measured by flame photometry (model 943, Instrumentation Laboratory). P_{osm} and urine osmolality were assessed by freezing-point depression (model 3DII, Advanced Instruments). Plasma and urine creatinine, plasma glucose, and urea concentrations were determined by colorimetric assay (Sigma Diagnostic Products). P_{AVP} , P_{ald} , P_{ANP} , P_{E_2} , P_{P_4} , and PRA were measured by RIA. Intra- and interassay coefficients of variation for the midrange standard were as follows: 6.0 and 3.4% (Immuno Biological Laboratories, Hamburg, Germany) for P_{AVP} (4.52 pg/ml), 3.4 and 3.6% (Diagnostic Products, Los Angeles, CA) for P_{ald} (132 pg/ml), 5.1 and 5.2% (Diasorin, Stillwater, MN) for P_{ANP} (63.3 pg/ml), 3.7 and 4.0% (Diagnostic Products) for P_{E_2} (64.3 pg/ml), 2.1 and 2.5% (Diagnostic Products) for P_{P_4} (3.7 pg/ml), and 2.3 and 2.9% (Diasorin) for PRA (4.5 ng·ml $\text{ANG}^{-1}\cdot\text{h}^{-1}$). The assay for AVP has a sensitivity of 0.8 pg/ml, which is necessary to detect small, but important, changes in this hormone.

Blood volume. Absolute blood volume was measured by dilution of a known amount of Evans blue dye. This technique involves injection of an accurately determined volume of dye (by weight, since the specific density is 1.0) into an arm vein and taking blood samples for determination of dilution after complete mixing (10, 20, and 30 min). PV was determined from the product of the concentration and volume of dye injected divided by the concentration in plasma after mixing, with 1.5% lost from the circulation within the first 10 min taken into account. Blood volume was calculated from PV and Hct concentration corrected for peripheral sampling (9).

Thirst ratings. We assessed thirst perception by asking the subject to make a mark on a line rating scale in response to the question, "How thirsty do you feel now?" The line is 175 mm long and is marked "not at all" on one end and "extremely thirsty" at the 125-mm point. We told subjects that they could mark beyond the "extremely thirsty" point if they wished and they could even have extended the line if they felt it was necessary. This method was developed by Marks et al. (11) and has been used with great success in the evaluation of several sensory systems. We have found an extraordinarily good relationship between the perception of thirst and P_{osm} during hypertonic saline infusion and dehydration in young subjects (20, 25).

Calculations. Total water loss due to dehydration was determined from body weight loss during exercise. Net fluid gain during rehydration was calculated by subtracting total urine loss from water intake, with the assumption that respiratory and sweat losses were negligible in the 27°C recovery condition. Changes in PV were estimated from changes in Hct and [Hb] from the control (preexercise) sample according to the equation

$$\% \Delta \text{PV} = 100[(\text{Hb}_b)/(\text{Hb}_a)] \cdot [(1 - \text{Hct}_a \cdot 10^{-2})]/[(1 - \text{Hct}_b \cdot 10^{-2})] - 100$$

in which subscripts *a* and *b* denote measurements at time *a* and control, respectively.

Fractional excretions of water ($\text{FE}_{\text{H}_2\text{O}}$) and Na^+ (FE_{Na^+}) were calculated from the following equations

$$\text{FE}_{\text{H}_2\text{O}} = (U_v/\text{GFR}) \cdot 100$$

$$\text{FE}_{\text{Na}^+} = (U_v \cdot U_{[\text{Na}^+]}/\text{GFR} \cdot [\text{Na}^+]_f) \cdot 100$$

$$[\text{Na}^+]_f = \text{the Donnan factor for cations } (0.95) \cdot S_{[\text{Na}^+]}$$

in which the subscript *f* is glomerular filtrate, U_v is urine flow rate, $U_{[\text{Na}^+]}$ is Na^+ concentration in urine, and $S_{[\text{Na}^+]}$ is $S_{[\text{Na}^+]}$ in protein-free solution (meq/kg H_2O). Glomerular filtration rate (GFR) was estimated from creatinine clearance.

Electrolyte losses in sweat and urine during dehydration were calculated by multiplying the volume of water loss in each fluid by the concentration of the electrolyte within the fluid. Whole body sweat electrolyte concentration was calculated from sweat rate, local electrolyte concentration, and body surface area using the following equation (24)

$$[\text{E}]_m = (0.07[\text{E}]_{\text{th}}\text{SR}_{\text{th}} + 0.36[\text{E}]_{\text{tr}}\text{SR}_{\text{tr}} + 0.13[\text{E}]_{\text{fa}}\text{SR}_{\text{fa}} + 0.32[\text{E}]_{\text{th}}\text{SR}_{\text{th}}/0.07\text{SR}_{\text{th}} + 0.36\text{SR}_{\text{tr}} + 0.13\text{SR}_{\text{fa}} + 0.32\text{SR}_{\text{th}})$$

where the subscripts *m*, *th*, *tr*, *fa*, and *th* are whole body mean, forehead, trunk, forearm, and thigh, respectively, $[\text{E}]$ is electrolyte concentration (Na^+ or K^+ , meq/l), SR is local sweat rate ($\text{mg} \cdot \text{min}^{-1} \cdot \text{cm}^{-2}$), and the constants 0.07, 0.36, 0.13, and 0.32 represent the percent distribution of body surface in the head, trunk, arms, and legs, respectively. Total electrolyte

loss from sweat was calculated by multiplying $[E]_m$ by total body sweat loss, calculated from the change in body weight during exercise. Electrolyte losses during rehydration were calculated by multiplying the volume of water loss by the concentration of electrolytes in the urine.

Statistics. Separate repeated-measures ANOVA models were performed to test differences in the dependent variables due to menstrual phase and OC E + P or OC P administration. Bonferroni's *t*-test was used to correct for multiple comparisons where appropriate. Pearson's product moment correlation was used to assess the relationship of $P_{[AVP]}$ as a function of P_{osm} on individual data during exercise, and the abscissal intercepts defined the "theoretical osmotic threshold" for AVP release (8). We used repeated-measures ANOVA models, followed by Bonferroni's *t*-test, to test differences in the abscissal intercepts and slopes due to menstrual phase or oral contraceptive treatment (4, 8). On the basis of an α -level of 0.05 and a sample size of 8, our β -level (power) was ≥ 0.80 for detecting effect sizes of 2.0 pg/ml, 0.67 ml/min, 2.0 ng·ml $ANG^{-1} \cdot h^{-1}$, 40 pg/ml, 10 pg/ml, and 3.0 meq for $P_{[AVP]}$, renal free water clearance, PRA, $P_{[ald]}$, $P_{[ANP]}$, and renal Na^+ excretion, respectively (4, 7, 8, 28). Data were analyzed using BMDP statistical software (BMDP Statistical Software, Los Angeles, CA) and expressed as means \pm SE.

RESULTS

Combined oral contraceptive administration caused severe nausea in one woman, and she did not complete dehydration testing while on this pill, so all her control data for OC E + P have also been excluded. This analysis compares the dehydration test responses of nine women on OC P with their two control tests and eight women on OC E + P with their control tests.

Subject characteristics. The subjects were 25 ± 1 yr (range 20–34 yr), weighed 62.5 ± 3.6 kg, and were 164 ± 3 cm tall. Their mean blood volume was 66.4 ± 2.0 ml/kg, mean PV was $2,780 \pm 124$ ml, and mean peak O_2 consumption was 30.6 ± 2.4 ml·kg $^{-1}$ ·min $^{-1}$.

Baseline (preexercise). Preexercise body weight was similar for both phases of the menstrual cycle and oral contraceptive administration (Table 1). The $P_{[E_2]}$ and $P_{[P_4]}$ values in Table 1 demonstrate that the subjects were

tested in the early-follicular and midluteal phases of the menstrual cycle during both trials. Finally, oral contraceptive administration suppressed the endogenous production of 17β -estradiol and progesterone (Table 1).

Preexercise P_{osm} was lower in the luteal phase and after 1 mo of OC E + P and OC P than in the follicular phase (Fig. 2; $P < 0.05$), although $P_{[AVP]}$ and thirst were unaffected by phase of the menstrual cycle or by oral contraceptive administration (Table 2). Plasma glucose and urea concentrations were unaffected by menstrual phase or either oral contraceptive pill, but $S_{[Na^+]}$ was lower [138 ± 0.5 , 136 ± 0.4 , 136.2 ± 0.6 , and 136.6 ± 0.3 meq/l for follicular and luteal phases (combined means), OC E + P, and OC P, respectively], suggesting that the lower P_{osm} (in the luteal phase and with oral contraceptives) was a function of lower $S_{[Na^+]}$. Changes in Hct and [Hb] indicated an estimated (calculated) contraction of PV compared with the follicular phase (Table 1). There was no effect of menstrual phase or oral contraceptive treatment on plasma protein concentration (6.7, 6.8, 6.7, and 6.8 g/l for follicular and luteal phases, OC E + P, and OC P, respectively). Preexercise PRA was greater in both luteal phase tests than in the follicular phase tests and during OC E + P, and $P_{[ald]}$ was increased in the luteal phase tests compared with the follicular phase tests (Table 3; $P < 0.05$). In contrast, $P_{[ANP]}$ was greater at baseline in the follicular phase tests than in the luteal phase and during OC P, and $P_{[ANP]}$ was greater during OC E + P than in the luteal phase test (Table 3; $P < 0.05$). Preexercise U_v , urine osmolality, GFR, and renal electrolyte excretion were similar within subjects before each exercise test.


Preexercise heart rate and blood pressure were similar at baseline and dehydration within the follicular and luteal phase tests, so the combined mean of the two series is given for the baseline values and for the dehydration tests. Baseline heart rate and mean blood pressure were unaffected by menstrual phase, averaging 78 ± 4 beats/min and 85 ± 2 mmHg during the

Table 1. Subject characteristics and changes in osmotic AVP and thirst regulation

	Follicular Phase (n = 8)	Midluteal Phase (n = 8)	OC E + P (n = 8)	Follicular Phase (n = 9)	Midluteal Phase (n = 9)	OC P (n = 9)
Body wt, kg	61.4 \pm 4.1	61.8 \pm 4.1	61.6 \pm 3.8	60.7 \pm 3.7	61.1 \pm 3.4	60.0 \pm 3.5
PV, ml	2780 \pm 124					
$P_{[E_2]}$, pg/ml	27.3 \pm 5.6 (12.3–40.8)	105.1 \pm 26.2 (63.6–189.6)	<12.0	26.1 \pm 6.7 (13.1–36.2)	146.7 \pm 38.3 (61.1–222.0)	25.1 \pm 5.3 (6.4–26.7)
$P_{[P_4]}$, ng/ml	1.3 \pm 0.6 (0.3–2.2)	8.7 \pm 3.1 (5.2–19.1)	<0.02	0.49 \pm 1.0 (0.4–0.8)	9.8 \pm 2.2 (5.2–18.3)	<0.02
P_{osm} - $P_{[AVP]}$ slope, pg·ml $^{-1}$ ·mosmol $^{-1}$	0.47 \pm 0.11	0.51 \pm 0.18	0.49 \pm 0.12	0.49 \pm 0.14	0.55 \pm 0.17	0.46 \pm 0.14
P_{osm} - $P_{[AVP]}$ x-intercept, mosmol/kg H $_2$ O	282 \pm 1	278 \pm 1*	276 \pm 2†	283 \pm 1	279 \pm 1*	280 \pm 2
P_{osm} -thirst slope, mm/mosmol	13.7 \pm 3.5	14.0 \pm 2.7	13.3 \pm 3.7	12.8 \pm 1.7	12.9 \pm 2.9	13.7 \pm 2.1
P_{osm} -thirst x-intercept, mm	280 \pm 3	278 \pm 2	276 \pm 2†	280 \pm 1	279 \pm 2	280 \pm 2
PV change, %		-8.4 \pm 2.5	3.2 \pm 2.1		-7.5 \pm 2.7	-2.3 \pm 2.5

Values are means \pm SE; ranges are in parentheses. Resting plasma volume (PV) was measured on a separate day in the follicular phase. Preexercise body weight and plasma concentrations of endogenous 17β -estradiol ($P_{[E_2]}$) and progesterone ($P_{[P_4]}$) were measured in early-follicular and midluteal phases and during administration of combined [estradiol + progestin (norethindrone), OC E + P] and progestin (norethindrone)-only (OC P) oral contraceptive pills. Slopes and abscissal intercepts of individual subject's plasma arginine vasopressin concentration ($P_{[AVP]}$)-plasma osmolality (P_{osm}) and thirst- P_{osm} relationships during dehydration in early-follicular and midluteal phases and OC E + P and OC P are shown. Percent change in PV relative to the follicular phase was estimated from changes in preexercise hematocrit and Hb. * $P < 0.05$, follicular vs. midluteal phase; † $P < 0.05$, follicular phase vs. OC E + P.

Fig. 2. Plasma osmolality (P_{osm}) at rest and in response to dehydrating exercise and 180 min of ad libitum rehydration in follicular and luteal phases and during combined estradiol-progestin (norethindrone, OC E + P, $n = 8$) and progestin (norethindrone)-only oral contraception administration (OC P, $n = 9$). * $P < 0.05$, follicular vs. luteal phase. # $P < 0.05$, follicular phase vs. OC E + P. § $P < 0.05$, follicular phase vs. OC P. Values are means \pm SE.



follicular phase and 78 ± 5 beats/min and 82 ± 2 mmHg during the luteal phase. These cardiovascular variables were also unchanged by oral contraceptive treatment, averaging 78 ± 3 beats/min and 83 ± 1 mmHg and 81 ± 2 beats/min and 81 ± 2 mmHg during OC E + P and OC P, respectively.

Exercise responses. The subjects lost similar body weight (and percent body weight) at the end of 150 min of exercise during the follicular (1.4 ± 0.1 kg, 2.3%) and luteal (1.4 ± 0.1 kg, 2.2%) phase tests and during OC E + P (1.3 ± 0.2 kg, 2.3%). The same was true for the follicular (1.4 ± 0.1 kg, 2.3%) and luteal (1.4 ± 0.1 kg, 2.4%) phase tests compared with OC P (1.3 ± 0.1 kg, 2.2%). Heart rate increased to similar levels during dehydrating exercise in the follicular (145 ± 6 beats/min) and luteal (141 ± 5 beats/min) phase tests and during the OC P test (141 ± 7 beats/min), but this increase was attenuated during the OC E + P test (135 ± 6 beats/min, $P < 0.05$). Mean blood pressure did not change during dehydration in any of the experimental conditions.

Exercise increased P_{osm} and P_{AVP} and decreased PV similarly during the follicular and luteal phases and during OC E + P and OC P (Fig. 2, Table 2). Linear regression analysis of the individual subjects' data during dehydration indicated significant correlations between P_{AVP} and P_{osm} (mean $r = 0.88 \pm 0.03$). The abscissal intercepts of the linear $P_{\text{AVP}}-P_{\text{osm}}$ relationship, or "theoretical osmotic threshold" for AVP release, was significantly lower in the midluteal phase and with OC E + P than in the follicular phase (Table 1, $P < 0.05$). The slopes of this relationship, however, were unaffected by menstrual phase or oral contraceptive use. Figure 3 shows the downward shift in the linear $P_{\text{AVP}}-P_{\text{osm}}$ relationships during dehydrating exercise when P_{E_2} and P_{P_4} were increased in the luteal phase and during OC E + P. The data in Table 2 indicate that thirst increased similarly during dehydration in all conditions. Linear regression analysis of the individual subjects' P_{osm} and thirst responses indicated significant correlations (mean $r = 0.90 \pm 0.03$). Osmotic thirst

Table 2. Plasma AVP concentrations, subjective thirst responses, and PV changes

	Preexercise (0 min)	End Exercise (150 min)	Rehydration			
			0 min	60 min	120 min	180 min
$P_{[AVP]}$, pg/ml			<i>OC E + P</i>			
Follicular	1.3 ± 0.2	4.0 ± 0.8	3.3 ± 0.9	1.7 ± 0.4	1.6 ± 0.3	1.6 ± 0.3
Luteal	1.2 ± 0.2	3.8 ± 0.7	3.0 ± 0.7	1.5 ± 0.4	1.3 ± 0.3	1.5 ± 0.4
OC E + P	1.6 ± 0.3	3.1 ± 0.4	3.1 ± 0.4	2.7 ± 0.7	1.9 ± 0.4	2.3 ± 0.4
Thirst, mm						
Follicular	18 ± 9	101 ± 10	100 ± 10	21 ± 8	24 ± 11	13 ± 5
Luteal	29 ± 11	111 ± 11	97 ± 12	12 ± 5	23 ± 8	7 ± 3
OC E + P	29 ± 10	94 ± 13	101 ± 12	19 ± 6	22 ± 8	17 ± 6
PV, % change						
Follicular		-8.6 ± 1.3	-2.6 ± 1.6	1.3 ± 1.6	1.2 ± 1.7	2.5 ± 1.8
Luteal		-9.5 ± 2.6	-3.3 ± 2.0	0.2 ± 1.4	0.7 ± 1.6	0.5 ± 1.5
OC E + P		-7.9 ± 1.2	-0.5 ± 1.2	1.9 ± 1.3	3.6 ± 1.0	5.1 ± 1.7
$P_{[AVP]}$, pg/ml			<i>OC P</i>			
Follicular	1.2 ± 0.4	3.7 ± 1.0	2.5 ± 0.5	1.8 ± 0.6	1.8 ± 0.6	1.6 ± 0.4
Luteal	1.1 ± 0.3	4.8 ± 1.4	2.3 ± 0.6	2.0 ± 0.5	1.9 ± 0.6	1.9 ± 0.6
OC P	1.0 ± 0.2	4.0 ± 1.2	2.7 ± 0.7	1.8 ± 0.7	2.2 ± 0.7	1.5 ± 0.4
Thirst, mm						
Follicular	20 ± 5	97 ± 12	90 ± 12	17 ± 6	12 ± 4	9 ± 4
Luteal	28 ± 9	97 ± 6	98 ± 11	31 ± 10	21 ± 6	25 ± 10
OC P	24 ± 8	97 ± 9	108 ± 6	19 ± 9	19 ± 9	18 ± 9
PV, % change						
Follicular		-7.5 ± 1.2	0.0 ± 1.4	2.3 ± 1.1	3.1 ± 1.1	5.0 ± 0.7
Luteal		-7.4 ± 1.0	0.1 ± 1.1	3.2 ± 0.1	0.8 ± 1.2	1.6 ± 1.1
OC P		-6.5 ± 1.0	0.4 ± 0.9	4.7 ± 1.4	4.5 ± 1.3	5.2 ± 1.6

Values are means ± SE. Anginine vasopressin plasma concentration ($P_{[AVP]}$), cognitive thirst ratings, and plasma volume (PV) (estimated percent change from preexercise value) were measured at rest and in response to dehydrating exercise and 180 min of ad libitum rehydration in follicular and luteal phases and during OC E + P ($n = 8$) and OC P ($n = 9$).

stimulation was unaffected by menstrual phase, but OC E + P led to a fall in the abscissal intercept of this relationship (Table 1).

PRA, $P_{[ald]}$, and $P_{[ANP]}$ increased during exercise in all conditions, with luteal phase values for $P_{[ald]}$ remaining

above the follicular phase, OC E + P, and OC P (Table 3; $P < 0.05$). Sweat Na^+ loss was greatest during exercise in the follicular phase tests (56.3 ± 7.0 and 59.4 ± 9.2 meq, $P < 0.05$) but was similar between the luteal phase tests (45.2 ± 9.1 and 46.5 ± 7.8 meq) compared

Table 3. Plasma concentrations of Na^+ -regulating hormones

	Preexercise (0 min)	End Exercise (150 min)	Rehydration			
			0 min	60 min	120 min	180 min
PRA, ng·ml $ANG^{-1} \cdot h^{-1}$			<i>OC E + P</i>			
Follicular	0.7 ± 0.1 ^a	3.4 ± 1.2 ^a	1.5 ± 0.4 ^a	0.9 ± 0.2 ^{a,b}	0.8 ± 0.1 ^{a,b}	0.8 ± 0.2 ^{a,b}
Luteal	1.5 ± 0.3 ^c	6.5 ± 2.2 ^c	3.1 ± 0.8	2.0 ± 0.5	1.9 ± 0.5	1.7 ± 0.5
OC E + P	1.1 ± 0.2	3.6 ± 0.8	2.4 ± 0.6	2.0 ± 0.6	2.2 ± 0.7	1.5 ± 0.3
$P_{[ald]}$, pg/ml						
Follicular	72 ± 12 ^a	247 ± 67 ^a	131 ± 27 ^a	94 ± 19 ^a	73 ± 14 ^a	56 ± 11 ^a
Luteal	168 ± 20	405 ± 45 ^c	240 ± 38 ^c	155 ± 27	122 ± 22	123 ± 22 ^c
OC E + P	131 ± 32	235 ± 26	104 ± 17	98 ± 17	87 ± 16	58 ± 11
$P_{[ANP]}$, pg/ml						
Follicular	52.9 ± 6.8 ^a	111.5 ± 14.8 ^a	69.1 ± 9.2 ^a	39.7 ± 5.0	36.3 ± 4.4	33.3 ± 5.2
Luteal	33.0 ± 5.1 ^c	91.8 ± 13.0 ^c	56.1 ± 9.8	31.9 ± 3.7	30.6 ± 3.8	33.7 ± 5.7
OC E + P	45.8 ± 4.5	113.0 ± 17.5	56.4 ± 5.4	42.2 ± 6.4	40.8 ± 5.8	41.1 ± 4.7
PRA, ng·ml $ANG^{-1} \cdot h^{-1}$			<i>OC P</i>			
Follicular	0.8 ± 0.2 ^a	3.2 ± 1.2 ^a	1.4 ± 0.4 ^a	1.0 ± 0.2 ^a	0.9 ± 0.2 ^a	0.8 ± 0.2 ^a
Luteal	1.7 ± 0.3	7.0 ± 1.6	4.3 ± 1.0	2.8 ± 0.2	2.7 ± 0.5	2.0 ± 0.4
OC P	1.2 ± 0.2	4.0 ± 1.0	2.6 ± 0.7	1.7 ± 0.4	1.5 ± 0.3	1.4 ± 0.2
$P_{[ald]}$, pg/ml						
Follicular	88 ± 19 ^a	184 ± 41 ^a	98 ± 28 ^a	75 ± 15 ^a	57 ± 12 ^a	38 ± 7 ^a
Luteal	162 ± 22	500 ± 47 ^d	343 ± 57 ^d	220 ± 31 ^d	171 ± 24 ^d	131 ± 18 ^d
OC P	123 ± 40	285 ± 41	169 ± 44	114 ± 32	78 ± 20	77 ± 22
$P_{[ANP]}$, pg/ml						
Follicular	55.8 ± 10.3 ^{a,e}	117.6 ± 25.0 ^{a,e}	61.4 ± 8.8 ^{a,e}	42.7 ± 5.7	40.0 ± 4.3	39.2 ± 4.1
Luteal	37.8 ± 6.0	86.3 ± 13.6	50.7 ± 8.0	31.2 ± 3.0	29.6 ± 2.3	29.6 ± 3.0
OC P	38.9 ± 2.8	86.9 ± 12.1	41.3 ± 3.2	36.7 ± 2.0	33.8 ± 2.3	34.2 ± 2.5

Values are means ± SE. Plasma renin activity (PRA) and plasma aldosterone ($P_{[ald]}$) and atrial natriuretic peptide concentrations ($P_{[ANP]}$) were measured at rest and in response to dehydrating exercise and 180 min of ad libitum rehydration in the follicular and luteal phases and during OC E + P ($n = 8$) and OC P ($n = 9$). ^a $P < 0.05$, follicular vs. luteal phase; ^b $P < 0.05$, follicular phase vs. OC E + P; ^c $P < 0.05$, luteal phase vs. OC E + P; ^d $P < 0.05$, luteal phase vs. OC P; ^e $P < 0.05$, follicular phase vs. OC P.




Fig. 3. Mean plasma arginine vasopressin concentration (P_{AVPI}) responses to increases in P_{Osm} during dehydration in follicular and luteal phases and during OC E + P ($n = 8$) and OC P ($n = 9$). Values are means \pm SE.

with the OC E + P (47.1 ± 10.7 meq) or OC P (46.7 ± 8.8 meq) tests. Sweat K^+ loss was unaffected by menstrual phase or oral contraception administration. Renal Na^+ excretion increased during exercise in all conditions, and this increase was greatest during the follicular phase tests [12.2 ± 2.6 , 8.0 ± 1.8 , 7.4 ± 1.6 , and 8.5 ± 3.3 meq for follicular and luteal phases (combined means), OC E + P, and OC P, respectively, $P < 0.05$].

Rehydration. Ad libitum fluid intake was similar by the end of the 180 min of rehydration on all six experimental test days. At 180 min of ad libitum drinking, subjects had restored 41 ± 5 and $40 \pm 10\%$ (follicular phase), 42 ± 7 and $39 \pm 6\%$ (luteal phase), $38 \pm 11\%$ (OC E + P), and $39 \pm 7\%$ (OC P) of body weight that was lost during dehydration. P_{Osm} was higher throughout the rehydration period in the follicular phase than in the luteal phase, OC E + P, and OC P tests (Fig. 2; $P < 0.05$), although P_{AVPI} was similar

during all rehydration tests. For the entire rehydration period, PRA was lower during the follicular phase tests than during the luteal phase tests, and $P_{[ald]}$ was significantly greater in the luteal phase tests than in the follicular phase and the OC P test (Table 3, $P < 0.05$).

During rehydration, neither renal function nor electrolyte excretion was affected by menstrual phase or oral contraceptive administration, and overall fluid balance (i.e., fluid intake - urine output) was unaffected by either phase of the menstrual cycle or oral contraceptive administration (Fig. 4). Heart rate recovered to similar levels during rehydration in the follicular (75 ± 4 beats/min) and luteal (79 ± 4 beats/min) phase tests and during the OC E + P (78 ± 4 beats/min) and OC P (83 ± 4 beats/min) tests. Mean blood pressure remained unchanged throughout rehydration (78 ± 2 , 79 ± 4 , 77 ± 2 , and 79 ± 2 mmHg for follicular and luteal phases, OC E + P, and OC P, respectively).

DISCUSSION

Our major finding was that administration of oral contraceptive pills containing estrogen increased osmotically induced AVP and thirst stimulation during dehydration in young, healthy women, although there were no changes in body fluid regulation during dehydration or subsequent ad libitum rehydration. These findings indicate that the shift in osmotic regulation of AVP and thirst represents a shift in body water regulation to a lower P_{Osm} operating point. These data extend to young women our earlier findings in postmenopausal women, in whom estrogen administration reduced the P_{Osm} threshold for AVP release during hypertonicity (19), although with an important difference. In postmenopausal women, 17β -estradiol administration reduced the P_{Osm} threshold for AVP release during hypertonicity but also increased water retention and, therefore, did not indicate a shift in the operating point for body fluid regulation. In contrast, estradiol administration to the young women in our present investigation reduced P_{Osm} but did not affect P_{AVPI} , thirst ratings, or body water loss. After dehydration the subjects restored body water to the reduced, preexercise levels of P_{Osm} during ad libitum rehydration, indicating a shift in the operating point for body fluid volume and composition with increased blood levels of estrogen. During dehydrating exercise, Na^+ excretion was lower during the luteal phase and OC E + P and OC P than during the follicular phase. However, although $P_{[ald]}$ and PRA were greater at rest and during rehydration in the luteal phase, neither the estrogen nor the progestin (norethindrone) in oral contraceptives stimulated the renin-angiotensin-aldosterone system or increased Na^+ retention or blood pressure.

Vokes et al. (27) used hypertonic saline infusion and water loading to stimulate and suppress the osmoreceptors, respectively, and demonstrated a resetting of osmoreceptor thresholds for AVP and thirst in the luteal phase of the menstrual cycle. Our findings support those of Vokes et al. and others (18, 26), indicating that AVP secretion persists at lower P_{Osm}




Fig. 4. Body fluid balance after dehydrating exercise and during 180 min of ad libitum rehydration in the follicular and luteal phases and during OC E + P ($n = 8$) and OC P ($n = 9$). * $P < 0.05$, follicular phase vs. OC E + P. † $P < 0.05$, luteal phase vs. OC E + P. Values are means \pm SE.

during the luteal phase, thus causing a reduction in renal free water excretion and maintenance of this lower plasma tonicity. Estrogen and progesterone are elevated in the midluteal phase, so these studies did not determine whether the changes in osmoregulation were due to estrogen or progesterone effects. The data in our investigation extend these earlier findings and suggest that the shift in osmoregulation is due to the estrogen component of the oral contraceptive pill, because this shift did not occur during administration of progestin (norethindrone) only, which not only contains no estradiol, but downregulates estrogen receptors (17). Furthermore, progestin does not have a strong impact on estrogenic activity when administered with estradiol because of weak binding of progestins to estrogen receptors (17).

Estrogen readily crosses the blood-brain barrier and can likely modulate osmotic AVP and thirst regulation via its action within the central nervous system. Studies in lower animals have demonstrated that estrogen

acts directly on estrogen-binding neurons in the hypothalamus (1, 2, 5, 16), thereby affecting synthesis and release of AVP. Estradiol receptors have been identified in the nuclei of neurophysin- and AVP-producing cells in the mouse supraoptic nucleus (16), and osmotic stimulation of vasopressinergic neuronal activity is upregulated by estrogen in the supraoptic nucleus of brain slices of ovariectomized rats (2). Estrogen may also modulate hypothalamic AVP release indirectly through catecholaminergic (10) and/or angiotensinergic (23) neurons, which bind estrogen and project to the paraventricular and supraoptic nuclei. Using [3 H]estradiol, Heritage et al. (10) identified estradiol-binding sites in the nuclei of catecholamine neuronal systems, as well as the presence of catecholamine nerve terminals surrounding estradiol target sites in the paraventricular and supraoptic nuclei. Crowley et al. (6) noted parallel changes in brain norepinephrine and AVP in normally cycling rats and that ovarian steroids modulated norepinephrine turnover in the paraventricular

nucleus, indicating that estrogen may act on the osmoregulatory system through catecholamines. There also is evidence for cholinergic and angiotensinergic innervation of vasopressinergic cells in the paraventricular and supraoptic nuclei, both of which are modulated by sex steroids (23).

Conversely, peripheral mechanisms for the estrogen effect on osmotic stimulation of AVP are unlikely to play a role in the response. For example, PV reduction, such as that during the midluteal phase, could have contributed to the lower P_{osm} threshold for AVP release, because PV is a potent AVP stimulus. However, this mechanism seems unlikely, because there was no change in PV during OC E + P relative to the follicular phase. In addition, the luteal phase PV contraction was not associated with a great enough fall in PV (<10%) to stimulate AVP (15). ANP has also been shown to suppress the osmotically induced rise in AVP (3), but the follicular phase and OC E + P were associated with greater $P_{[ANP]}$, although with different osmotic AVP response.

Blood volume and arterial pressure also play important roles in body fluid regulation, primarily by modulating Na^+ excretion. Previously, oral contraceptives containing high doses of estrogen (2 mg/day) led to hypertension and greater plasma angiotensinogen levels, although with only small elevations in plasma renin or aldosterone levels (14). The estrogen dose in our study did not increase blood pressure or cause consistent elevations in PRA and aldosterone, and norethindrone (the progestin in OC P), a progestational derivative of testosterone without antimineralocorticoid properties, also had no effect on PV. Nonetheless, our data confirm earlier findings demonstrating PV contraction during the midluteal phase of the menstrual cycle during rest, exercise, and heat exposure (21, 22), as well as large elevations in the sodium-regulating hormones (12). During the luteal phase a progesterone-mediated inhibition of aldosterone-dependent Na^+ reabsorption at distal sites in the nephron produces a transient natriuresis (13) and a compensatory stimulation of the renin-aldosterone system (12). The renin and aldosterone stimulation is a component of a system evolved to maintain blood pressure and plasma water and Na^+ content during the luteal phase progesterone peak, although clearly this system is not involved during OC E + P or OC P administration.

We found that oral contraceptive pills containing estradiol led to a lower osmotic operating point for body fluid regulation, similar to that found during the luteal phase. These data suggest that estradiol has the primary effects on body fluid regulation during oral contraceptive administration and indicate that the progestins in oral contraceptives do not have a major effect on osmotic regulation of AVP and thirst. However, more research is needed to determine possible effects of elevations in endogenous progesterone on osmoregulation and the other components of body fluid regulation, such as fluid distribution and Na^+ regulation.

We gratefully acknowledge the technical support of Tamara S. Morocco, John R. Stofan, and Richard Wemple and the cooperation of

the volunteer subjects. We also thank Lou A. Stephenson for contributions to the research design and the writing of the manuscript.

This work is supported by the US Army Medical Research and Materiel Command under Contract DAMD17-96-C-6093. The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy, or decision unless so designated by other documentation.

In conduct of research where humans are the subjects, the investigators adhered to the policies regarding the protection of human subjects as prescribed by 45 CFR 46 and 32 CFR 219 (Protection of Human Subjects).

Address for reprint requests and other correspondence: N. S. Stachenfeld, The John B. Pierce Laboratory, 290 Congress Ave., New Haven, CT 06519 (E-mail: nstach@jbpierce.org).

Received 25 January 1999; accepted in final form 29 April 1999.

REFERENCES

1. Akashi, T., and Y. Sakuma. Estrogen-induced modulation of hypothalamic osmoregulation in female rats. *Am. J. Physiol.* 258 (Regulatory Integrative Comp. Physiol. 27): R924–R929, 1990.
2. Barron, W. M., J. Schreiber, and M. D. Lindheimer. Effect of ovarian sex steroids on osmoregulation and vasopressin secretion in the rat. *Am. J. Physiol.* 250 (Endocrinol. Metab. 13): E352–E361, 1986.
3. Clark, B. A., D. Elahi, L. Fish, M. McAloon-Dyke, K. Davis, K. L. Minaker, and F. H. Epstein. Atrial natriuretic peptide suppresses osmostimulated vasopressin release in young and elderly humans. *Am. J. Physiol.* 261 (Endocrinol. Metab. 24): E252–E256, 1991.
4. Colton, T. *Statistics in Medicine*. Boston, MA: Little, Brown, 1974.
5. Crowley, R. S., and J. A. Amico. Gonadal steroid modulation of oxytocin and vasopressin gene expression in the hypothalamus of the osmotically stimulated rat. *Endocrinology* 133: 2711–2718, 1993.
6. Crowley, W. R., T. L. O'Donohue, J. M. George, and D. M. Jacobowitz. Changes in pituitary oxytocin and vasopressin during the estrous cycle and after ovarian hormones: evidence for mediation by norepinephrine. *Life Sci.* 23: 2579–2586, 1978.
7. Davidson, B. J., C. D. Rea, and G. J. Valenzuela. Atrial natriuretic peptide, plasma renin activity and aldosterone in women on estrogen therapy and with premenstrual syndrome. *Fertil. Steril.* 50: 743–746, 1988.
8. Davison, J. M., E. A. Gilmore, J. Durr, G. L. Robertson, and M. D. Lindheimer. Altered osmotic thresholds for vasopressin secretion and thirst in human pregnancy. *Am. J. Physiol.* 246 (Renal Fluid Electrolyte Physiol. 15): F105–F109, 1984.
9. Greenleaf, J. E., V. A. Convertino, and G. R. Mangseth. Plasma volume during stress in man: osmolality and red cell volume. *J. Appl. Physiol.* 47: 1031–1038, 1979.
10. Heritage, A. S., W. E. Stumpf, M. Sar, and L. D. Grant. Brainstem catecholamine neurons are target sites for sex steroid hormones. *Science* 207: 1377–1379, 1980.
11. Marks, L. E., J. C. Stevens, L. M. Bartoshuk, J. F. Geny, B. Rifkin, and V. K. Stone. Magnitude-matching: the measurement of taste and smell. *Chem. Senses* 13: 66–87, 1988.
12. Michelakis, A. M., H. Yoshida, and J. C. Dormois. Plasma renin activity and plasma aldosterone during the normal menstrual cycle. *Am. J. Obstet. Gynecol.* 123: 724–726, 1975.
13. Myles, K., and J. W. Funder. Progesterone binding to mineralocorticoid receptors: in vitro and vivo studies. *Am. J. Physiol.* 270 (Endocrinol. Metab. 33): E601–E607, 1996.
14. Oelkers, W. K. H. Effects of estrogen and progestogens on the renin-aldosterone system and blood pressure. *Steroids* 61: 166–171, 1996.
15. Robertson, G. L., and S. Athar. The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man. *J. Clin. Endocrinol. Metab.* 42: 613–620, 1976.
16. Sar, M., and W. E. Stumpf. Simultaneous localization of [3 H]estradiol and neurophysin I or arginine vasopressin in hypothalamic neurons demonstrated by a combined technique of dry-mount autoradiography and immunohistochemistry. *Neurosci. Lett.* 17: 179–184, 1980.

17. **Speroff, L., R. H. Glass, and N. G. Kase.** Steriod contraception. In: *Clinical Gynecological Endocrinology and Infertility*. Baltimore, MD: Williams & Wilkins, 1989, p. 461-498.
18. **Spruce, B. A., P. H. Baylis, J. Burd, and M. J. Watson.** Variation in osmoregulation of arginine vasopressin during the human menstrual cycle. *Clin. Endocrinol. (Oxf.)* 22: 37-42, 1985.
19. **Stachenfeld, N. S., L. DiPietro, S. F. Palter, and E. R. Nadel.** Estrogen influences osmotic secretion of AVP and body water balance in postmenopausal women. *Am. J. Physiol.* 274 (*Regulatory Integrative Comp. Physiol.* 43): R187-R195, 1998.
20. **Stachenfeld, N. S., G. W. Mack, A. Takamata, L. DiPietro, and E. R. Nadel.** Thirst and fluid regulatory responses to hypertonicity in older adults. *Am. J. Physiol.* 271 (*Regulatory Integrative Comp. Physiol.* 40): R757-R765, 1996.
21. **Stephenson, L. A., and M. A. Kolka.** Plasma volume during heat stress and exercise in women. *Eur. J. Appl. Physiol.* 57: 373-381, 1988.
22. **Stephenson, L. A., M. A. Kolka, R. Francesconi, and R. R. Gonzalez.** Circadian variations in plasma renin activity, catecholamines and aldosterone during exercise in women. *Eur. J. Appl. Physiol.* 58: 756-764, 1989.
23. **Stone, J. D., J. T. Crofton, and L. Share.** Sex differences in central adrenergic control of vasopressin release. *Am. J. Physiol.* 257 (*Regulatory Integrative Comp. Physiol.* 26): R1040-R1045, 1989.
24. **Takamata, A., G. W. Mack, C. M. Gillen, and E. R. Nadel.** Sodium appetite, thirst and body fluid regulation in humans during rehydration without sodium replacement. *Am. J. Physiol.* 266 (*Regulatory Integrative Comp. Physiol.* 35): R1493-R1502, 1994.
25. **Takamata, A., G. W. Mack, N. S. Stachenfeld, and E. R. Nadel.** Body temperature modification of osmotically induced vasopressin secretion and thirst in humans. *Am. J. Physiol.* 269 (*Regulatory Integrative Comp. Physiol.* 38): R874-R880, 1995.
26. **Trigoso, W. F., J. M. Wesly, D. L. Meranda, and Y. Shenker.** Vasopressin and atrial natriuretic peptide hormone responses to hypertonic saline infusion during the follicular and luteal phases of the menstrual cycle. *Hum. Reprod.* 11: 2392-2395, 1996.
27. **Vokes, T. J., N. M. Weiss, J. Schreiber, M. B. Gaskill, and G. L. Robertson.** Osmoregulation of thirst and vasopressin during normal menstrual cycle. *Am. J. Physiol.* 254 (*Regulatory Integrative Comp. Physiol.* 23): R641-R647, 1988.
28. **Watanabe, H., D. C. Lau, H. L. Guyn, and N. L. Wong.** Effect of progesterone therapy on arginine vasopressin and atrial natriuretic factor in premenstrual syndrome. *Clin. Invest. Med.* 20: 211-223, 1997.

